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CHAPTER 1 
General Introduction 

Introduction 
GENERAL INTRODUCTION 
History 
Chronic Fatigue Syndrome (CFS) is not a new medical condition, but in the past 
fifteen years it has been the object of renewed interest. In 1869, neurologist George Beard 
used the term neurasthenia to describe a condition of 'nervous exhaustion, characterized 
by undue fatigue on slightest exertion, both physical and mental, with which are 
associated symptoms of abnormal functioning, mainly referable to disorders of the 
vegetative nervous system' [1]. Beard acknowledged the need to distinguish neurasthenia 
from anaemia and other recognizable causes of exhaustion and stated that the diagnosis is 
obtained partly by positive symptoms, and partly by exclusion. 
Somewhat later, Da Costa described a syndrome of fatigue, breathlessness, 
palpitations, dizziness and chest pain among soldiers during the American Civil War. 
Headache, digestive disturbances, and difficulty in sleeping were other common 
symptoms. Most often the syndrome was precipitated by a febrile illnesses or 
gastroenteritis, while occasionally severe exertion was the proximate cause. During the 
first decades of the 20th century, Da Costa's syndrome was known as the effort 
syndrome, neurocirculatory asthenia, and the autonomic imbalance syndrome [1]. 
In the middle of this century (from 1934 to 1958), several outbreaks of fatiguing 
illnesses were reported [2]. These outbreaks were variously called Icelandic disease, 
Akureyri disease, Royal Free disease, atypical poliomyelitis, epidemic neurasthenia, and 
so on. Two episodes have particularly attracted attention: the epidemic at the Los Angeles 
County Hospital in 1934, and the outbreak in the Royal Free Hospital in London in 1955. 
Bearing in mind the fear for a new poliovirus epidemic and the predominance of 
neurological symptoms in these case clusters (although usually mild), the syndrome has 
also been called benign myalgic encephalomyelitis (ME). This term emphasizes the lack 
of mortality, muscular pain, presumed parenchymal damage to the nervous system, and 
presumed inflammatory disorder. Similarities were noted with poliomyelitis, although 
none of the patients displayed residual flaccid paralysis, and tendon reflexes remained 
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unaffected. In 1970, McEvedy and Beard reexamined the case notes from the Royal Free 
epidemic and other similar outbreaks. They concluded that there were strong arguments 
for mass hysteria in many of these outbreaks [3, 4]. Since the 1970s, there has been a 
shift from outbreaks to sporadic cases of chronic fatigue. Because both the outbreaks and 
the majority of the sporadic cases appeared to follow an acute, probably viral infection, 
the term postviral fatigue syndrome emerged. 
Renewed interest in patients with chronic persistent fatigue began in the 1980s, with 
the emergence of the chronic Epstein-Barr virus syndrome [5-7]. Symptoms included 
persistent fatigue, sleep disturbances, headache, myalgia, depression, impaired memory, 
confusion, inability to concentrate, lymphadenopathy, and sore throat. Although 
serological findings were thought to be consistent with reactivation of EBV, this might 
also represent an epiphenomenon. Later studies did not find differences in antibody levels 
to EBV between fatigued patients and non-fatigued healthy controls [8-11]. 
It is unclear whether the sporadic cases of CFS we see nowadays are similar to those 
described by Beard and da Costa, or even to the epidemic cases. 
Clinical presentation 
Chronic fatigue syndrome (CFS) is a clinically defined illness characterized by severe 
disabling fatigue of definite onset (not lifelong), lasting for more than 6 months, and for 
which no explanation has been found. Usually the fatigue is accompanied by a variety of 
non-specific symptoms, such as myalgia, impairment of memory, and difficulties in 
concentration [12-14]. Up to 80% of the patients report a sudden onset of symptoms after 
a 'flulike' illness. Physical examination and standard laboratory testing is generally 
unremarkable. The illness affects mostly women between 30 and 45 years. In the 
literature, the prevalence of CFS in population based studies is estimated to be 0.3-2.7 
per 1000 [15-17]. A recent questionnaire among general practitioners in the Netherlands 
revealed a calculated prevalence of 1.2 per 1000 [18]. 
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Hypotheses on the etiology of CFS 
A number of somatic and psychological hypotheses have been proposed as possible 
explanations for the cause of CFS [19, 20]. Since many of the cases were reported to 
follow an acute febrile illness, one of the hypotheses is that CFS is the result of a 
persistent infection that leads to continuous immune activation with production of pro-
inflammatory cytokines, which could explain a number of symptoms [21-24]. Many 
organisms have been linked to the syndrome of chronic fatigue (see table 1). The list of 
micro-organisms has been growing ever since. So far, none has proved to be the 
responsible agent [25-27]. 
It seems reasonable to question whether the host response to these antigens may be 
disturbed, thereby resulting in chronic symptoms. Studies of humoral immunity and 
cellular immunity revealed subtle immunological dysfunction [28-33]. Some parameters 
reflect impaired function while others suggest hyperreactivity. However, these 
immunological findings do not fully explain the symptomatology of CFS, nor do they 
correlate with changes in symptoms over time. 
Table 1. Microbial agents and fatigue syndromes 
Organism or disease implicated Year 
Brucella species 1934 
(Atypical) poliovirus 1954 
Epstein-Barr virus 1982 
Cytomegalovirus 1984 
Varicella zoster virus 1984 
Toxoplasma gondii 1985 
Borrelia burgdorferi 1987 
Enteroviruses 1988 
Human herpesvirus type 6 1988 
Candida albicans 1989 
Retroviruses 1991 
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As many patients report myalgia, many studies have been reported on muscle 
metabolism, histopathology, and physiology [34-41]. Although a wide range of 
histopathological changes in muscle biopsies from patients with CFS have been described, 
they are not consistent, may occur in healthy subjects, or may reflect secondary changes 
due to physical inactivity. The results of exercise testing are compatible with physical 
deconditioning [40, 41]. However, the perception of fatigue by patients with CFS seems 
to be increased. 
Recently an abnormality of the hypothalamic-hypopituitary-adrenal axis has been 
found in patients with CFS [42]. The data are consistent with the hypothesis that 
diminished secretion of corticotropin-releasing hormone by the hypothalamus leads to 
diminished secretion of corticotropin (adrenocorticotropic hormone) by the pituitary and, 
thereby, to diminished production of Cortisol by the adrenal glands. Whether disturbances 
of the hypothalamic-pituitary-adrenal axis play a role in the pathogenesis of CFS remains 
to be established. Further studies are needed to elucidate this issue. 
Psychological factors may play a role in the development of the symptoms, or at least 
in perpetuation of the symptoms, by means of a complex interaction with somatic factors. 
Three main hypotheses have been proposed with regard to the possible role of 
psychological factors in perpetuating the complaints. In the first avoidance of physical 
activity is central (the inactivity hypothesis), in the second depression, and in the third the 
role of attributions to a somatic cause [43]. In the inactivity hypothesis, it is assumed that 
the patient remains inactive after an acute infection. As a consequence his physical 
condition deteriorates. Thus, complaints such as fatigue and myalgia will occur at a lower 
level of exertion. The patient will try to prevent the complaints by avoiding physical 
exercise. Then, the vicious circle is established. 
Although there are many differences between patients with CFS and patients with a 
clinical depression, patients with CFS often have elevated scores on depression 
questionnaires. These elevated depression scores can also be found among patients with 
chronic physical complaints and may very well be the result of CFS [44, 45]. Depression 
could also play a role in the maintenance of the complaints. As early as 1961, Imboden 
and his associates demonstrated that patients with elevated depression scores showed 
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delayed convalescence from an infection [46]. The mechanism of this interaction is not 
fully understood, but it is conceivable that both somatic and psychological processes are 
involved. Factors such as depression and stress can influence the immune system, thereby 
rendering the individual more vulnerable to an infection [47-49]. Depression can lead to 
immunological and endocrine aberrations, while depressed patients also exhibit marked 
physical inactivity, which lends support to the inactivity hypothesis. 
Patients with CFS tend to attribute their complaints to somatic causes. They are 
convinced that the complaints have a physical cause and often show a strong resistance to 
psychological interpretations of the complaints [39, 50-52]. Attributing the complaints to a 
somatic cause which cannot be found enhances the feelings of helplessness and may lead 
to avoidance of physical exercise, or aggravate depressive feelings. This may mean that a 
depression is left untreated and allowed to exert its perpetuating influence on the 
complaints. It is obvious that as far as depression is related to CFS it will be in a 
complex manner, involving both somatic and psychological processes. 
Outline of the thesis 
During the late 80's, the Department of General Internal Medicine received an 
increasing number of referrals of patients with CFS. This became the starting point of our 
research on this clinical problem. The studies outlined in this thesis comprehend clinical, 
microbiological and immunological aspects of CFS. The studies were performed in self-
referred patients with CFS and matched healthy non-fatigued control subjects. We tried to 
find answers to the following questions: 
1] Which instruments can be used to measure different aspects of the subjective 
complaints of CFS? 
2] Do the laboratory data correlate with clinical symptoms and psychological 
parameters? Can laboratory tests be used as a diagnostic tool in CFS? 
3] Is there evidence for a persistent infection in patients with CFS? 
4] Is there evidence for immune activation or immune dysfunction in patients with CFS? 
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In chapter 2 an overview is given of the somatic and psychological hypotheses that 
had been proposed in the literature as possible explanation for the etiology of CFS at the 
start of our studies. The first question contains the problem of assessment of CFS. 
Chapter 3 elaborates particularly on the instruments used to assess fatigue severity, 
depression, and psychological well-being. The importance of dimensional assessment of 
CFS is stressed. 
The second question about laboratory abnormalities is addressed in chapter 4, in 
which the relation between severity of complaints, laboratory data and the psychological 
parameters fatigue severity, depression and functional impairment was investigated in 
patients with CFS compared to a well-matched control group. 
The hypotheses of persistent infection in CFS was studied in detail for enteroviruses, 
Epstein-Barr vims and Yersinia enterocolitica. An ELISA was developed for the detection 
of enteroviral antibodies (chapter 5). Persistence of enteroviruses in patients with CFS 
was studied by means of enterovirus-specific serological testing, VP-1 antigen testing on 
serum samples, PCR and viral culture of stool samples (chapter 6). The specific role for 
Epstein-Barr virus and Yersinia enterocolitica infection in CFS was investigated in chapter 
7 and 8 respectively. 
Studies on the immunological aspects of CFS, especially lymphocyte subsets, 
apoptosis and cytokines are described in chapter 9. Attempts were made to correlate 
immunologic abnormalities with fatigue severity, functional impairment, and 
psychological well-being. 
Finally, chapter 10 contains a summary and general discussion of the studies in this 
thesis. 
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Somatic hypotheses in CFS 
Introduction 
In the past few years, publications about the chronic fatigue syndrome (CFS) have 
appeared with increasing frequency in international literature. The syndrome is characterized 
by long-standing unexplained fatigue which has led to a serious decrease in the level of 
achievement. The majority of patients are females between 20 and 50 years old, often women 
from the higher social classes. The prevalence of CFS is estimated to be 0.1-1.0% [1-3]. In 
many countries patient organizations have already been established. The Dutch society (the 
Myalgie Encephalomyelitis or ME Foundation) now (1991) has 3600 members. 
The cause and the pathogenesis of this syndrome are as yet still unknown. In addition 
to sporadic cases, outbreaks or epidemic manifestations have also been described, although 
it is not known whether they are of the same etiology and pathogenesis. Since it is not clear 
whether one syndrome or multiple syndromes are involved, it would be better to refer to 
'chronic fatigue e causa ignota'. For simplicity's sake, however, we shall use the term 
'chronic fatigue syndrome' in this article. In literature one can find a wide variety of other 
terms: Akureyri disease, chronic fatigue and immune dysfunction syndrome (CFIDS), chronic 
Epstein-Barr virus syndrome, chronic mononucleosis, Iceland Disease, myalgic encephalo-
myelitis, neuromyasthenia, postviral fatigue syndrome, 'Royal Free' disease, and yuppie flu. 
For the history of CFS, the reader is referred to the literature [4, 5]. Various 
publications have also appeared in Dutch medical journals [6-9]. Dutch studies are, however, 
lacking. Various definitions of the term 'chronic fatigue' were used by the different authors, 
which affects the comparability of these studies. Many investigators used the definition of 
Holmes et al., 'persistent or relapsing debilitating fatigue, severe enough to reduce or impair 
daily activity below 50% of the premorbid activity level for a period of least 6 months, and 
for which no explanation could be found after prior examinations' [10]. The diagnosis CFS 
is established by means of exclusion (Table 1). 
This condition represents a difficult medical problem which - due to the lack of a 
solution - is commonly considered to be of little importance by the medical profession. Many 
physicians are sceptical about the existence of such a syndrome, especially because 
examination does not reveal any abnormalities [6, 11]. The conclusion that the doctor found 
23 
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Table 1. Criteria for the diagnosis of the chronic fatigue syndrome, according to Holmes et al. 
[10]· 
Major criteria 
1. New onset of persistent or relapsing, debilitating fatigue or easy fatigability that does 
not resolve with bed rest and is severe enough to reduce average daily activity by at 
least 50% of the premorbid activity level for a period of at least 6 months. 
2. Other clinical conditions that may cause similar symptoms must be excluded. These 
conditions include: malignancy, autoimmune disease, infection (occult abscess, 
endocarditis, Lyme disease, tuberculosis, fungal infections, helminthic infestation, 
toxoplasmosis, amebiasis, giardiasis, HIV infection), chronic inflammatory diseases 
(sarcoidosis, Wegener granulomatosis, chronic hepatitis), endocrine diseases (diabetes, 
hypothyroidism, Addison disease, Cushing syndrome), psychiatric diseases (endogenous 
depression, hysteria, anxiety neurosis, schizophrenia, etc.), alcoholism, drug 
dependency or abuse, intoxication (chemical solvents, pesticides, heavy metals), chronic 
cardiac, pulmonary, hepatic, gastrointestinal, renal or hematologic disease. 
Minor symptom criteria 
1. Mild fever (37.5° - 38.6°C orally) or chills 
2. Sore throat 
3. Painful posterior cervical, anterior cervical, or axillary lymph nodes 
4. Unexplained generalized muscle weakness 
5. Muscle discomfort or myalgia 
6. Prolonged (at least 24 hours) generalized fatigue following previously well-tolerated 
exercise 
7. New generalized headaches (different from headaches in the premorbid phase) 
8. Migratory arthralgia without joint swelling or redness 
9. Neuropsychologic symptoms (photophobia, transient visual scotoma, forgetfulness, 
excessive irritability, confusion, difficulty thinking, inability to concentrate, depression) 
10. Sleep disturbance (insomnia or hypersomnia) 
11. Acute or subacute onset of the symptoms (within several hours to days). 
Physical examination criteria 
1. Low-grade fever (37.6° - 38.6°C orally or 37.8° - 38.8 °C rectally) 
2. Nonexudative pharyngitis 
3. Palpable or tender anterior cervical, posterior cervical, or axillary lymph nodes 
(<2 cm in diameter). 
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'nothing' is, however, not accepted by the patient and certainly is not considered to be a 
solution for the problem of fatigue. The patient is convinced that the cause of his complaints 
is somatic. The fact that a satisfactory physical explanation of these complaints cannot be 
found is frustrating for both the patient and the examining physician. It leads to expensive, 
repetitive and unsuccessful diagnostics performed by the physician; for the patient it leads 
to repeated and continuously disappointing consultations with physicians from the regular as 
well as the alternative medical circuits. In this respect, a major problem is the fact that 
fatigue in itself is so difficult to measure. Furthermore, the prolonged presence of the 
complaints causes severe problems as far as daily functioning is concerned. In this article, 
the pattern of complaints, hypotheses on somatic causes, pathogenesis, and therapeutic 
aspects are described. The psychological aspects are discussed by Vercoulen et al. elsewhere 
in this journal. 
The pattern of complaints 
Definition of this syndrome is exceedingly difficult because of the lack of an objective 
instrument which can measure chronic fatigue. The same also applies for the frequently 
recorded accompanying phenomena. American clinical investigators of the Centers for 
Disease Control have drawn up a number of criteria (see Table 1) [10]. For establishment 
of the diagnosis, two of the major and 6-8 of the minor criteria are required. These criteria 
are of necessity somewhat arbitrary in nature. In addition, the required number of criteria 
is so large that we have found that a fairly sizeable proportion of the patients with severe 
chronic fatigue in our practice do not meet the criteria. On the other hand, these criteria do 
improve the comparability of the patient groups to be investigated. In addition, the criteria 
give a good impression of the various manifestations of CFS. It is clear that these can vary 
markedly. Depending on these manifestations, the patient will be referred to an internist, a 
neurologist, a reumatologist or a psychiatrist. 
CFS exhibits a striking number of similarities with a disease known in rheumatology as 
fibromyalgia [12-14]. Fibromyalgia or fibrositis is a form of non-articular rheumatism, which 
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is characterized by diffuse muscular and joint pain and is often accompanied by general 
fatigue, chronic headaches, depression, pallesthesia, and sleep disturbances. Painful pressure 
points are also characteristic. Like CFS, this condition affects predominantly women between 
20 and SO years of age. Laboratory studies reveal as a rule only mild abnormalities or none 
at all. Single fibre electromyography demonstrates abnormalities which are also found in 
patients with CFS. 
Hypotheses on the cause and pathogenesis 
The factors which play a role in the development of the complaints are to a large extent 
still unknown. In the literature a number of hypotheses have been proposed on somatic as 
well as psychologic factors which could play a role in the development and the perpetuation 
of CFS. In a large number of cases the complaints appear to have started subsequent to an 
acute infectious disease; this applies for the sporadic cases as well as the outbreaks. This has 
resulted in the hypothesis that there is a persistent infection together with an abnormal 
reaction of the immune system. In addition, for a group of selected patients abnormalities of 
the muscles were described. This could mean that these complaints indeed have an organic 
substrate. 
Possible cause. A number of micro-organisms has been indicated as the possible 
causative agent of the syndrome (Table 2)[6, 7, 15-33]. The references given in this table 
refer to studies of varying quality with conflicting results. The patient groups studied are as 
a rule poorly defined and are not mutually comparable. 
Attention has focused in particular on two viruses: the Epstein-Barr virus (EBV) and 
enteroviruses. EBV, a virus which infects more than 90% of the population, persists after 
the primary infection mainly in B-lymphocytes and the salivary glands. The fact that 
antibodies against the 'early antigen' (EA) of this virus are continuously demonstrated in 
patients with CFS, eventually together with a lack of antibodies against the nuclear antigen 
(EBNA), is considered proof of active viral multiplication in these patients [11, 15, 16]. 
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Table 2. Possible causative agents of the chronic fatigue syndrome. 
Micro-organisms 
Epstein-Barr virus [6, 7, 15-22] 
varicella zoster virus [21, 23] 
cytomegalovirus [18, 20, 21, 24] 
human herpes virus type 6 [22, 25] 
enterovirus [22, 26-28] 
retroviruses [22, 29] 
Borrelia burgdorferi [24, 30] 
Toxoplasma gondii [17] 
Candida albicans [31-33] 
Similar publications have also appeared in this journal [7-9]. In later studies, however, the 
presence of this serological pattern could not be confirmed; it could only be demonstrated 
in a small number of cases, but also healthy patients exhibited high anti-EA titers [17, 18]. 
Enteroviruses are also universal micro-organisms but they do not as a rule cause 
persistent infections. British investigators contended that enterovirus persists in patients with 
CFS; they believed that they had identified the somatic component of the disease [26]. This 
finding first encountered considerable scepticism since enteroviruses were actually not 
considered to be persistent viruses until several years ago (see also the article of Galama et 
al. elsewhere in this journal). Investigators have since demonstrated enterovirus RNA in 
muscle biopsies by means of hybridization techniques. In 24% of a group of patients with 
CFS selected on the basis of myalgia and muscle weakness, persistent enteroviruses were 
found in faeces and in muscle biopsies [26, 27]. In addition, viral antigens of enterovirus 
(VP-1) were demonstrated in serum in about 60% of the patients; moreover, a high 
percentage also exhibited IgM antibodies against enteroviruses. Epstein-Barr virus DNA was 
found in the muscle biopsies of more than 10% of this same group but not in the muscle 
biopsies of controls. The two viruses were never demonstrated in one and the same patient 
[27]. These results were reported by one group of investigators whereby the inclusion criteria 
for the patient group is poorly defined and the controls are not satisfactorily described. These 
observations therefore are in urgent need of confirmation. 
The significance of the other persistent micro-organisms listed in Table 2 is not yet clear. 
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A clear-cut association with CFS has not been demonstrated for any of them. In ortho-
molecular medicine (a form of alternative medicine) the hypothesis, based on Crook's book, 
that colonizing Candida species are the causative agent has caused quite a commotion [31]; 
the line of thought behind this theory, however, does not hold. Treatment with nystatin and 
complicated diets are prescribed. Scientific evidence of the efficacy of this approach is, 
however, lacking (see also the article of Berkhof et al. elsewhere in this journal)[32, 33]. 
As far as non-microbiological causes are concerned, significance has been attributed 
- especially by lay journalists - to the influence of intoxication by for example pesticides and 
amalgam. There is, however, no proof that the removal of amalgam from the teeth has a 
therapeutic effect [34]. 
On the grounds of information which is circulated among patients with CFS, many 
believe that they suffer from hypoglycaemia. Recently, a study was described of CFS patients 
who believed that they suffered from postprandial hypoglycaemia. However, during 
symptomatic periods normal blood glucose values were demonstrated [35]. We too have 
found that the blood glucose values for patients with CFS are consistently normal. 
Abnormal immune response. Although there is no proof, the available data point in the 
direction of an abnormal host reaction to certain persisting micro-organisms as a factor for 
the development of CFS. The immunological findings for CFS reported in the literature are, 
however, fairly contradictory [36]. IgG subclass deficiencies as well as normal IgG levels 
[37-39], increased as well as normal concentrations of circulating interleukin-2 [40, 41], and 
normal serum concentrations of interferon but an increased level of 2'-5'-oligoadenylate 
synthetase (a cellular enzyme that is induced specifically by interferon) have been described 
[42-45]. Decreased and normal numbers of CD4 cells (helper/inducer Τ cells) and CD8 cells 
(cytotoxic/suppresser Τ cells) have been reported [46-49]. The most consistent finding was 
probably the decreased cytotoxic capacity of natural killer (NK cells, lymphocytic cells with 
large granules which are able to lyse tumour cells and cells infected with viruses without 
prior sensibilization). The number of NK cells in patients with CFS can be normal or even 
increased but their function is clearly depressed [50]. There is, however, no clear relationship 
between the immunological abnormalities found and the severity of the clinical pattern. 
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An elevated cytokine production could possibly explain the fatigue and general malaise 
[40]. These phenomena are also encountered in patients who have been treated with 
interferon. The immunological abnormalities which are related in the literature to chronic 
fatigue cannot be demonstrated with any consistency. 
Abnormalities in the muscles. In a considerable percentage of patients with CFS, Epstein-
Barr virus DNA or enterovirus RNA has been demonstrated in muscle biopsies. In addition, 
single fibre electromyography has revealed abnormalities which are consistent with disturbed 
conduction across the muscle membrane [51, 52]. Decreased use of the muscles can, 
however, also lead to retarded conduction through the muscle fibres [51]. 
By means of nuclear magnetic resonance (NMR) spectroscopy early excessive acidosis 
was demonstrated in one patient with CFS [53]. According to some investigators patients 
with CFS have a decreased tolerance for exercise [54, 55]. At present, it is not known 
whether the cause is central (lack of psychological motivation) or peripheral (in muscle). 
Histologically one study showed a relative increase in type-2 fibres with atrophy of these 
fibres [56], which according to sceptics can be explained by inactivity. At the ultrastructural 
level, abnormal mitochondria and fat inclusions have been observed [56]. Confirmation of 
these observations is, however, lacking. 
It is not clear how frequent the abnormalities described above occur, nor whether the 
abnormalities found are a cause or a consequence of the complaints. 
Abnormalities of the central nervous system. Recently, studies of a group of patients with 
CFS investigated with single photon emission computerized tomography (SPECT) revealed 
abnormalities in more than 70% of cases; these abnormalities were suggestive of cortical 
hypoperfusion, especially in the temporal region [57]. This finding obviously needs 
confirmation. Other investigators have reported subtle abnormalities along the hypothalamus-
pituitary-adrenal axis [56]. They could be related to the depression and sleep disturbances 
experienced by a number of patients with CFS. 
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Therapeutical aspects 
There is as yet no specific therapy for CFS. Acyclovir, which is active against chronic 
EBV infections, was found to be ineffective in a controlled study [58]. In a placebo-
controlled study treatment with high doses of intramuscular immunoglobulin was effective 
in some cases [59]. In two recent studies the effect of high doses of intravenously 
administered IgG was assessed [60, 61]; although the immunological values improved in both 
studies, clinical improvement was seen only in one study in a small number of patients. In 
the other study no clinical improvement was observed. The group treated with Immunglobulin 
also suffered obvious side-effects. For the time being it appears that such an expensive 
therapy cannot be justified. 
It has also been reported that fish oil yields favourable results. Controlled studies with 
other medications (transfer factor, ampligen, calcium blockers) are still in progress. 
The possibilities of psychological treatment and therapy with antidepressant agents are 
discussed in the article by Vercoulen et al. 
Discussion 
The diagnosis of CFS can only be established by excluding a number of accepted causes 
of fatigue. For this purpose Homes et al. established a number of criteria [10]. There is, 
however, a lack of agreement about some of the exclusion criteria. In addition, the criteria 
for accompanying characteristics have not yet been validated. We must conclude that a good 
definition of CFS is not yet available. As a result, studies of CFS suffer a disadvantage: 
because the definitions of patient groups vary, the results of the studies cannot be compared 
mutually. This could explain the many conflicting findings. 
Among the various possible causes of CFS, a special role is attributed to the infectious 
diseases. The arguments for this are: 
- the complaints often begin after a flu-like disease; 
- the occurrence of outbreaks of CFS; 
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- the symptoms of night sweating, mild fever, and lymphadenopathy. 
Since most infections are considered to be accepted causes of fatigue, CFS must be 
attributable to special forms of infection. For instance, it might be an as yet unknown 
manifestation of the common infections. Whether EBV can play a causal role within the 
framework of this hypothesis is not yet clear. Serological studies at present do not provide 
the answer. Studies of the degree of viral multiplication performed by means of culture and 
in situ hybridization on muscle tissue can provide better insight. Few such studies have as 
yet been performed. 
The role of enteroviruses should also be investigated. Persistence is not a general 
characteristic of enteroviruses and could be indicative of a special form of the infection. It 
is striking that a high percentage of patients exhibit viral antigens (VP-1) in the circulation, 
according to reports from English investigators. It is not known how specific this VP-1 test 
is. In addition, these scientists studied a group of patients selected on the basis of muscle 
complaints. This means that these results probably do not apply for the total group of CFS 
patients. 
On the one hand, subtle immunological abnormalities can form the basis for persistence 
of the virus. On the other hand, the continuous defence against a persisting infection can lead 
to an increased activity of the immune system, accompanied by the production of cytokines 
which in themselves could form the explanation for the fatigue. The central position of the 
immune system becomes even more apparent when one realizes that there is a close 
relationship between the immune apparatus, the central nervous system and the neuro-
endocrine system. Lymphocytes are able to produce adrenocorticotropic hormone-like 
(ACTH-like) substances after a viral infection. In addition, lymphocytes have receptors for 
a number of neuropeptides and the mitogenic reaction of lymphocytes is inhibited by stress 
[62-64]. Depression too can give rise to a number of immunological and endocrinological 
changes [65]. They could represent the connection with the psychological hypotheses. An 
integrated investigation of the psychological and somatological findings therefore appears to 
be essential. The fact that immunological studies have as yet yielded few consistent results 
is presumably a question of methodology. It is therefore also recommended that the 
immunological studies be repeated under standard conditions. Studies of the muscles revealed 
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subtle abnormalities. It is not clear how frequently these abnormalities occur nor whether 
they are a cause or a consequence of the complaints. It is striking that according to Stokes 
et al. the muscular strength and the fatigability of the muscles are normal in CFS [55]. We 
too have found that patients with CFS do not exhibit muscular atrophy despite the prolonged 
inactivity. This is indicative of a central (i.e. motivation) rather than a peripheral (in the 
muscles) cause. 
A specific therapy is at present not available. In his approach to the patient the physician 
must exhibit a positive attitude and understanding of the patient. Attempts to soothe the 
patient ('luckily we found nothing') are counterproductive. At Nijmegen Academic Hospital 
an investigation has been started to gain more insight into the pathogenesis of CFS. Both the 
somatological and the psychological aspects will be taken into consideration. 
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Psychological hypotheses in CFS 
Introduction 
In the article of Swanink et al. elsewhere in this journal the somatic aspects of the 
chronic fatigue syndrome (CFS) are described. Patients with CFS report not only various 
somatic complaints but also psychological complaints. Most of these patients experience 
memory and concentration disturbances. Often, they also feel depressed. As a rule, these 
complaints have a marked influence on their daily life: many can only work on a part-time 
basis or not at all and they often also suffer various social and physical limitations. 
Specific studies of the role of psychological factors in chronic fatigue have only been 
undertaken in the past few years. Earlier studies were orientated almost entirely toward 
somatic aspects. Of the studies which focus specifically on psychological factors, more than 
half have been published in the recent past. From these investigations, it is clear that in one 
way or another there is an important relationship between psychological factors and chronic 
fatigue. In this article a survey of these factors is presented. For this purpose we shall first 
consider studies which focused on general functioning, the role of personality factors and the 
significance of psychological diagnoses. Subsequently several psychological hypotheses on 
etiological factors and factors which cause the complaints to persist will be presented. 
Finally possible approaches to treatment are discussed. 
Consequences of the complaints for daily functioning 
Fatigue is a complaint which is difficult to quantify. Partly for this reason, it is very 
difficult to assess the magnitude of the influence of the complaint on daily functioning. In 
only one investigation, the influence of the complaint on daily functioning was investigated 
in a standardized manner [1]. This study consisted of 1159 patients who had visited the 
general practitioner because of physically unexplained fatigue of more than 1 month duration. 
From the scores of the 'sickness impact profile' [2], an instrument which measures the 
influence of disease in 12 areas of psychosocial and physical functioning, it appeared that 
these patients experienced many more problems in the fields of household work, occupation, 
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social contacts, and recreation than people without complaints [1]. We have found that many 
of our patients with chronic fatigue are declared partially or totally disabled and draw 
sickness benefits; moreover their social contacts become less frequent, recreational activities 
such as sports and hobbies decrease and jobs in and around the home are scarsely done. 
Many patients report that colleagues, friends and (to a lesser extent) family do not take their 
complaints seriously, especially if a somatic explanation cannot be found. The patient often 
has the feeling that he has to defend himself against the belief that he is shamming. 
Other complaints experienced by patients with CFS are of a neuropsychological nature. 
This type of complaint involves the cognitive processes such as language, memory, 
concentration and the capacity to abstract. The majority of the patients complain of 
forgetfulness and concentration problems [3, 4]; they cannot follow the news on television, 
cannot remember why they went into a particular room, find it difficult to reach a decision 
and cannot pay attention to a conversation, especially if several people are taking part. Still, 
it is not easy to reproduce these complaints in the laboratory situation with the help of 
standardized neuropsychological tests. Some investigators report indeed demonstrable 
concentration and memory disturbances among their patients [4-7] but their results have not 
always been confirmed [8, 9]. The explanation for these contradictions lies presumably in 
the diversity of the measurement methods used and the differences in inclusion criteria. 
Another unanswered question is what causes the eventual neuropsychological disorders: 
are they the direct result of, for example, a viral disease or are they only the consequences 
of the fatigue? 
Despite the discrepancies in the neuropsychologic investigations it remains a fact that the 
complaints of patients with CFS can have severe consequences for their daily functioning. 
It continues to be worthwhile to collect new data in this field. 
Personality factors 
Is it possible to distinguish a specific personality profile for patients with CFS which 
might predispose to the development of CFS? Stricklin et al. found the following personality 
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profile for patients with CFS: Socially withdrawn, depression, tension, stress, physical 
discomfort, low self-esteem and feeling of helplessness [10]. In another study, the patients 
were characterized as being more sensitive, less sociable, more pessimistic and more 
inhibited than individuals without complaints [1]. Both of these studies were however 
retrospective in nature. It is therefore likely that the characteristics mentioned are not in fact 
premorbid personality characteristics but are instead a consequence of the prolonged 
complaints. There are therefore insufficient indications for personality characteristics which 
can be called typical of or predisposing to CFS. 
Psychiatric diagnoses 
A relatively large number of investigations has focused on the psychiatric diagnostics for 
patients with CFS. The percentage patients for whom a psychiatric diagnosis has been 
established varies between 60 and 80% [1, 3, 11-14]. The diagnoses include somatization 
disorders, anxiety disorders and mood disorders, specifically depression. Can the complaints 
of patients with CFS be considered as a manifestation of a psychiatric disorder? 
Somatization disorder, which also includes 'hysteria', although this term is no longer in 
use, is defined in DSM-III-R as 'prolonged presence of multiple somatic symptoms for which 
a physical basis cannot be demonstrated'. For this diagnosis, at least 13 out of a list of 35 
symptoms, varying from gastrointestinal complaints, complaints of pain and cardiopulmonary 
complaints to conversion or pseudoneurological complaints, must be present. Fatigue is not 
one of the criteria. This means that the diagnosis of a somatization disorder can only be 
established for patients with CFS and a large number of accompanying complaints. 
The prevalence of the diagnosis somatization disorder among patients with CFS is about 
15% [14, 16]. Although this percentage is considerably higher than that reported for the 
healthy population (the prevalence for the latter lies between 0.2 and 2.0%)[15], it is 
comparable to the prevalence found for somatization disorder for other patient groups, such 
as women who have undergone a hysterectomy, patients with the irritable bowel syndrome 
and patients with chronic pain [17]. Both the low percentage and the fairly arbitrary manner 
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in which it is diagnosed indicate that somatization disorder cannot explain CFS. 
The anxiety disorders experienced by patients with CFS are mainly social phobia (2%) 
and panic disorder (7-8%) [3, 14, 16]. It has been reported that 36% of patients with CFS 
have at some time experienced an episode which can be diagnosed as an anxiety disorder 
[18]. This percentage did not differ significantly from that found for a group of healthy 
controls (25%). 
Some investigators believe that in a number of cases the complaints of patients with CFS 
are a manifestation of depression [19, 20]. This is based on the following arguments and 
findings: in more than half of the cases of CFS, depression - according to the strict definition 
- has been diagnosed [3, 11, 13, 14, 18]; the symptoms of the patients with CFS are to a 
large extent identical to the symptoms of depression [11]; fatigue or a lack of energy is even 
one of the DSM-III-R criteria for depression [15]. Among patients with CFS who also have 
been found to suffer from depression, there is a marked relationship between the onset of the 
complaints of fatigue and the onset of the depression [21]. In another investigation, the 
premorbid prevalence of depression was reported to be higher than that found for the normal 
population (50% versus 12.5%)[22]. There are, however, also arguments which make it less 
likely that CFS is a manifestation of depression. Firstly, agreement in symptoms between the 
two disorders does not automatically imply that the two disorders are identical. Depression 
and dementia, for example, also exhibit a marked similarity in symptoms [22]. Moreover, 
the higher premorbid prevalence of depression could not be confirmed in another study [3]. 
Finally differences have been found between patients with CFS and a control group of 
depressed patients: the degree of neurosis as well as the severity of the depression was 
considerably lower among patients with CFS than the depressed controls [3]. With respect 
to the severity, it was noted that in CFS there is an elevated depression score rather than a 
clinical depression [8]. 
The conclusion for the time being is that psychiatric diagnoses do not sufficiently explain 
the complaints of chronic fatigue. In view of the fact that a certain degree of depression is 
encountered among many patients with CFS, it is likely that depression plays a role in CFS 
in one way or another. 
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Psychological hypotheses 
In the literature presently available there are indications that psychological factors play 
a role in the development as well as - and probably predominantly - in the perpetuation of 
the complaints. Here a complex interaction with physical factors is involved. 
ТЫ role of stress in the development of CFS. At the time of the development of CFS 
stressful 'life events' can play a role. It has been reported that patients with CFS experience 
more stressful life events or subjective stress before the development of the complaints than 
healthy controls [8, 10, 21]. Stress and depression could have a negative influence on the 
immunological capacities of an organism [23-25], and in this way the defence against 
infections could be diminished [26, 27]. A subsequent infection could be the start of CFS. 
The problem with this explanation is that it is so non-specific with respect to the development 
of CFS. For other physical complaints too it has been reported that the patients had 
experienced more stressful life events before the development of the disease than healthy 
controls. 
As far as perpetuation of the CFS complaints is concerned, there are 3 hypotheses. In 
the first, physical inactivity is central, in the second depression and in the third the role of 
attributions. 
The inactivity hypothesis. This cognitive-behavioural hypothesis assigns the key role to 
the avoidance of physical activity which ensures that the complaints of fatigue are maintained 
[28, 29]. It is assumed that the patient is inactive during an acute infection; as a result his 
physical condition deteriorates. Complaints such as fatigue and myalgia subsequently occur 
at lower levels of exertion. The patient can 'learn' that physical exercise will call up 
complaints of fatigue and myalgia; thus, he will try to prevent these complaints by avoiding 
physical exercise. As a result his physical condition deteriorates further and a vicious circle 
is established. 
A relationship between inactivity and fatigue has indeed been demonstrated [1, 21]. The 
question now is: does inactivity lead to the persistence of complaints or does persistence of 
43 
Chapter 2b 
the complaints lead to inactivity. Support for the first possibility (and therefore for the 
inactivity hypothesis) is a study which demonstrated that physical training of patients with 
CFS led to an increase in the exercise capacity and a decrease in complaints [30]. Others 
have also reported an acquired response of avoidance [31]; they found no abnormalities of 
the muscular system but suspect that there is a decreased tolerance for the consequences of 
exercise. In other investigations abnormalities of the muscular system were seen but the 
question remains whether the abnormalities are a consequence of being inactive or the 
inactivity is a consequence of the abnormalities (see also the article by Swanink et al. 
elsewhere in this journal). It is clear that the last word has not yet been spoken in this 
respect. 
The influence of depression. As mentioned above there are too many differences between 
patients with CFS and patients with a clinical depression to be able to state that chronic 
complaints of fatigue must be considered a manifestation of depression. Nevertheless patients 
with CFS often have elevated scores on depression questionnaires, as do other patients with 
physical complaints [32]. The presence of a depression or, more accurately, the fact that the 
depression score is elevated must probably be considered a consequence of CFS which is 
directly related to a viral infection [33] or a psychologic reaction to the chronic complaints 
[3, 33]. In a number of publications it has been reported that many patients were very active 
before the development of the complaints and that they set very high standards for themselves 
[27, 34]. The feeling that they are now capable of little or nothing could be very frustrating 
and might lead to a reaction of depression. 
Depression as a result of chronic fatigue could also play a role in the perpetuation of the 
complaints. The symptoms of depression closely resemble the symptoms of an acute 
infection. Depression is as a rule often not recognized as such and the complaints 
accompanying the depression are easily attributed to physical causes [8, 19]. This process 
can be facilitated by the tendency of the patient to look for physical causes to explain his 
complaints. The depression is then not treated and functions as a complicating factor. 
Already in 1961 Imboden et al. established that patients with an elevated depression score 
recover from an infection more slowly than others [35]. The mechanism is not clear but it 
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is conceivable that the effect of a depression can be exerted via somatic and psychological 
mechanisms. Depression can in fact lead to immunological and endocrinological changes 
[23-25], but it is also known that depressed individuals are less active which would add an 
extra component to the avoidance of physical activity. 
Depression appears therefore to be related to CFS in a complex manner whereby both 
psychological and somatic factors can play a role. 
Attributions. Attributions are the ideas which someone has about the causal relationships 
between events. In CFS, attributions concerning the cause of the complaints are of specific 
interest. Patients with CFS attribute the complaints to somatic causes: they are convinced that 
the complaints have a physical cause and they exhibit a strong resistance to psychological 
interpretations of the complaints [3, 8, 11, 19]. 
Among patients with CFS there has as yet not been a specific investigation of the 
background of this somatic attribution. Possibly it is a result of the fact that - within the 
framework of the experience of the patient - the complaints of fatigue arose after the flu or 
some other physically orientated event such as the delivery of a child or surgery. Talking 
about ME (myalgic encephalomyelitis) might confirm such attributions because this term 
implies an organic disease. 
Attributions and the way the patient thinks about his complaints have received little 
attention in the literature but there are indications that attribution to a physical cause can have 
a direct influence on perpetuation of the CFS complaints. Thus, it appeared that among 
patients with chronic gastric complaints, attribution of the complaints to somatic factors was 
related to an unfavourable course [36]. Moreover, attributions can reinforce the avoidance 
of activity. Attributing the complaints to a somatic cause which cannot be found enhances 
the feeling of helplessness and thus the reaction of depression. These feelings can be 
accompanied by complaints of fatigue so that a vicious circle is established. 
Attribution of the complaints to physical factors can also lead to the denial of the 
influence of psychologic factors. The patient's own capacity to combat the complaints of 
fatigue and to learn how to cope with them is as a result hampered. 
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Treatment 
At the present time there is no effective treatment of CFS. The preceding considerations 
suggest, however, several methods of approach. Treatment could be directed toward 
increasing physical activity, decreasing the feelings of depression and influencing attributions. 
In general, one should realize that patients with CFS will receive a psychological 
interpretation of their complaints with scepticism. This is probably partly due to the fact that 
they have been told by professionals and by those in their immediate circle that there is 
'nothing wrong', that their complaints are 'only psychologic' or that they 'just' have ME. 
None of these attributions will satisfy the patient. The patient believes he is not being taken 
seriously. A serious attitude toward the patient and his complaints is therefore exceedingly 
important. Understanding the enormous influence which these complaints can have on daily 
life can help in this respect. It should be explained that the complaints are the consequence 
of an interaction between physical and psychological factors, although the nature of this 
interaction often can no longer be ascertained. No matter how the complaints developed, the 
patient must leam to cope with them. Within this framework, influencing the attribution to 
physical causes would seem to be an important first step since these attributions often have 
an inhibitory effect on every non-somatic treatment. 
Attention can subsequently be directed toward the degree to which physical activity is 
avoided. If necessary a training programme can be initiated in order to gradually increase the 
physical activity. The crux of this treatment is to interrupt the above-mentioned vicious circle 
by making sure that the occurrence of symptoms no longer functions as a signal that rest is 
needed [28]. Positive results with increased activity have already been reported [30], but 
controlled studies have not yet been performed. 
An eventual depression can be treated by means of psychological as well as medical 
intervention. Positive results with antidepressants have been reported [19, 37], but here too 
controlled studies have not been performed [29]. 
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Conclusion 
From the above, it is clear that psychological factors play a role, presumably in the 
development but definitely in the perpetuation of chronic fatigue. As far as is known at 
present, the nature of the attributions, avoidance of physical activity, and depression can play 
a role. The patient group is, however, heterogeneous and it is therefore feasible that the 
various somatological (see article by Swanink et al.) and psychological hypotheses do not 
apply to the group of patients with CFS as a whole but only to certain categories. 
Our observation that CFS is insufficiently explained by psychiatric disorders is important 
for application of the criteria of Holmes [38]. The presence of a psychiatric diagnosis is used 
here as an exclusion criterion: it is presumed that the presence of a psychiatric diagnosis 
would in itself be sufficient to explain the complaints of chronic fatigue. Such a premise 
would appear to us to be at the very least premature, partly in view of the hypothesis 
described in this article that depression can be a consequence of the complaints and (or) can 
play a role in the perpetuation of these complaints. 
At present, there are still multiple aspects of chronic fatigue to be investigated. As yet 
most of the studies have focused on either somatic or psychological factors. This dualism 
does not appear to be justified. In CFS there appears to be a complex interaction between 
somatic and psychologic factors. The study which our research team has just started in 
Nijmegen is focused on the influence of and the relationships between the two types of 
factors. 
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Dimensional assessment of CFS 
Abstract 
The absence of laboratory tests and clear criteria to identify homogeneous 
(sub)groups in patients presenting with unexplained fatigue, and to assess clinical status 
and disability in these patients, calls for further assessment methods. In the present study, 
a multi-dimensional approach to the assessment of chronic fatigue syndrome (CFS) is 
evaluated. Two-hundred and ninety-eight patients with CFS completed a set of postal 
questionnaires that assessed behavioural, emotional, social, and cognitive aspects of CFS. 
By means of statistical analyses nine relatively independent dimensions of CFS were 
identified along which CFS-assessment and CFS-research can be directed. These 
dimensions were named: psychological well-being, functional impairment in daily life, 
sleep disturbances, avoidance of physical activity, neuropsychological impairment, causal 
attributions related to the complaints, social functioning, self-efficacy expectations, and 
subjective experience of the personal situation. A description of the study sample on these 
dimensions is presented. 
Introduction 
The chronic fatigue syndrome (CFS) is characterized by severe disabling fatigue of 
unknown origin. Several operational definitions [1, 2] have proved to be unsatisfactory in 
identifying cases of CFS [3, 4]. A major problem with these criteria is that they are 
mainly symptom-based. Fatigue, the main symptom in CFS, is a nonspecific complaint as 
reported in the general population as such [5] and in a substantial number of patients seen 
in primary care settings [6, 7]. Moreover, fatigue is a prominent symptom in a variety of 
physical and psychiatric illnesses. Fatigue is not only nonspecific, but as a phenomenon it 
is also difficult to understand. Kennedy [8], reviewing the literature on fatigue, concluded 
that 'the status of fatigue as a physiological response, psychological perception, or 
symptom of physical and psychiatric diseases remains unclear'. To date, no clear 
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definition of fatigue exists, resulting in problems in measurement [9]. 
Not only fatigue is highly nonspecific, but so are other symptoms commonly 
observed in CFS. Patients with CFS show considerable overlap in symptoms with patients 
with clinical depression and those with chronic neuromuscular diseases [10] and chronic 
pain [11]. Thus symptoms alone seem to have little diagnostic value. Neither do 
laboratory tests contribute to the assessment of CFS [12-15]. 
The absence of laboratory tests and clear criteria to identify homogeneous 
(sub)groups in patients presenting with unexplained chronic fatigue and assessing clinical 
status and disability in these patients calls for other assessment methods [3]. In the present 
study, a multi-dimensional approach to the assessment of CFS will be used. Behavioural, 
emotional, social, and cognitive aspects of CFS are measured. The main aims of this 
study are to identify dimensions of CFS and to provide a description of patients 
presenting with unexplained chronic fatigue using these dimensions. 
Subjects and method 
Subjects. In the present study the following inclusion and exclusion criteria have been 
applied [4]: patients had to experience severe disabling fatigue, of definite onset, lasting 
for more than 1 year; other symptoms may be present. Patients with established medical 
conditions known to produce chronic fatigue, and patients with a diagnosis of 
schizophrenia, bipolar-disorder, psychotic depression, substance use disorder, eating 
disorder, or proven organic brain disease were excluded. 
Three-hundred and ninety-five self-referred patients were sent a postal questionnaire. 
Ninety per cent completed and returned the questionnaire (N = 357). Detailed 
information on present illness, specialist visits, and treatment was obtained. Based on this 
information, respondents with definite or suspected illnesses that could provide an 
explanation for the complaints were excluded (e.g. patients taking medication for heart 
problems). Patients who had not been examined by at least one specialist for their 
complaints (10 patients) also were excluded from analyses. These inclusion and exclusion 
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procedures resulted in a study sample of 298 subjects. 
Instruments 
Fatigue questionnaire. We participated in the development of the Checklist Individual 
Strength (CIS) by the University Hospital of Amsterdam and the University Hospital of 
Rotterdam. This 24-item questionnaire was designed to measure several aspects of 
fatigue. Each item is scored on a 7-point Likert scale. Principal components analyses 
yielded a four-factor solution. Four items that had a low loading on their primary factor 
or that loaded substantially on more than one factor were deleted. These factors were easy 
to interpret and were named: (1) subjective experience of fatigue (8 items); (2) 
concentration (5 items); (3) motivation (4 items); (4) physical activity level (3 items). The 
final subscales accounted for 67.7% of the variance. Psychometric properties were 
excellent: Cronbach's alpha reliability coefficient for the entire CIS was 0.90. Gutman 
split-half reliability coefficient was 0.92. Cronbach's alphas for the subscales were 0.88, 
0.92, 0.83, and 0.87 respectively. Data from two comparison groups are available. The 
first group consists of healthy subjects (N = 60; mean age = 32 yr). The second group 
are patients with functional bowel disorder (FBD) (N = 61; mean age = 41 yr). 
Self-reported complaints. Symptom assessment was based on spontaneous reports by 
the patient. Patients were asked to write down their complaints. Information concerning 
the course and duration of the complaints was also obtained. 
Psychological well-being. The Beck Depression Inventory (BDI) [16] is a 
standardized self-report questionnaire to measure depression. Four diagnostic categories 
are based on the total score: 0-9 = nondepressed; 10-15 = mildly depressed; 16-23 = 
moderately depressed; 24 or more = severely depressed. A score of 16 or more is 
indicative of a clinical depression. The Symptom Checklist (SCL-90) [17] is a 90-item 
indicator of psychopathology and screens for anxiety (SCL-ANX), agoraphobia (SCL-
AGO), depression (SCL-DEP), somatization (SCL-SOM), cognitive difficulties (SCL-IN), 
interpersonal sensitivity (SCL-SEN), hostility (SCL-HOS), and sleep disturbances (SCL-
SLP). A total score called the psychoneuroticism score (SCL-PSN) can be obtained. 
Comparison data are available for normal subjects (N = 1009; mean age = 43 yr), for a 
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mixed psychiatric out-patient group (N = 2118; mean age = 36 yr) [17], and for a group 
of patients with functional bowel disorder (FBD) (N = 103; mean age = 44 yr). 
Daily fiinctioning. The effect of the complaints on daily functioning was assessed by 
the Sickness Impact Profile (SIP) [18, 19], using the following eight subscales: home 
management (SIP-HM), mobility (SIP-MOB), alertness behaviour (SIP-AB), sleep/rest 
(SIP-SR), ambulation (SIP-A), social interactions (SIP-SI), work (SIP-W), and recreation 
and pastimes (SIP-RP). Comparison data are available for two groups of patients 
registered at five family practices situated in urban, suburban, and rural areas [19]. The 
first group (N = 450; mean age = 47 yr) reported physical complaints of minor severity 
or no physical complaints at all. The second group (N = 144; mean age = 49 yr) 
reported moderate to severe physical complaints (gastrointestinal, back pain, arthralgia, 
and cardiovascular complaints). 
In addition to the SIP, general questions regarding daily functioning were included: 
these assessed the patient's opinion concerning: (a) the extent to which their complaints 
interfered with daily activities (4-point scale); (b) problems in housekeeping activities and 
work (5-point scale); (c) satisfaction in housekeeping activities and work (5-point scale). 
Avoidance behaviour. Avoidance of physical activity is thought to play a role in the 
perpetuation of the complaints in CFS [20, 21]. Therefore, four questions were asked 
with respect to avoidance of physical activity as a way of coping with complaints (e.g. 
'avoiding complaints by nonactivity'). The level of physical activity is assessed by the 
CIS-Activity subscale (see the section Fatigue questionnaire). 
Cognitions and attributions. Cognitions were assessed by: (a) a specific 3-point scale 
question concerning self-efficacy expectations ('do you think you can influence your 
complaints?'); (b) causal attributions: patients were asked to write down their opinions 
regarding the causes of the complaints. These responses were coded into the dichotomous 
variables 'physical causes' and 'non-physical causes'; (c) the Multi-dimensional Health 
Locus of Control questionnaire (MHLC) [22, 23] which measures control beliefs with 
respect to health in general. The MHLC contains three subscales: internal attributions 
(MHLC-I: health is determined by own behaviour/capacities); external attributions 
(MHLC-E: health is determined by fate/chance); and powerful others (MHLC-P: health is 
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determined by partners/friends/doctors). MHLC-data of a comparison group of patients 
with FBD are available (N = 103; mean age = 44 yr). 
Social interactions. General questions were asked concerning: (a) satisfaction with 
social life (5-point scale); (b) problems in social relations (4-point scale); (c) the SIP 
contains a subscale assessing the effect of the complaints on social life (SIP-SI: see 
section Daily fimctioning). 
Sleep disturbances, (a) A general sleep disturbances-question, which is coded 'yes' or 
'no'; (b) a question with respect to the type of the sleep disturbance (problems falling 
asleep, restless sleep, and early awakening in the morning); (c) duration of sleep at night 
and during the day; (d) the SCL-90 contains a subscale on sleeping problems (SCL-SLP: 
see section Psychological well-being). 
In addition to the above mentioned instruments information on age, sex, marital 
status, occupation, and education was obtained. 
Statistical analyses 
Testing differences between groups has been performed by analyses of variance 
(ANOVA). When appropriate, covariates were included in the ANOVA. The 
identification of the dimensions of the CFS was a four-step procedure: (I) Principal 
components analyses on all subscales and the general questions. Variables that had low 
factor loadings or that loaded substantially on more than one factor were excluded; (II) 
Per factor the included variables were weighted in order to achieve approximately equal 
standard deviations; (III) Per factor reliability procedures were performed on the weighted 
variables (Cronbach's a). Variables that suppressed alpha were excluded. For each 
dimension a score was obtained by summing the scores of the variables belonging to the 
dimension; (IV) Stepwise multiple regression analyses were performed on the dimension 
scores in order to evaluate interrelations. 
In analyses in which more than 5% of cases were excluded because of missing 
values, these values were replaced by means of the linear trend at point method, which is 
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available in SPSS (release 6.0). For each variable, the existing series was regressed on an 
index variable, scaled 1 to n. Missing values were replaced with their predicted value. 
Results 
Descriptive 
Biographical. Mean age was 39 yr (range 18-73). There were 75 males and 223 
females. Fifty-five percent of patients were married or cohabiting, 34% were single, 8% 
were divorced, and 3% were widowed. Only 31% of patients reported being still at work, 
whereas 58% worked before the onset of the complaints. Of the patients presently 
working, 80% worked part-time because of the complaints. All patients had visited at 
least one specialist for their complaints (internist: 81%; neurologist: 59%; psychologist: 
35%; psychiatrist 32%; rheumatologist: 19%). 
Spontaneously reported complaints are presented in Table 1. Only complaints 
reported by at least 10% of patients are included in the table. The average number of 
complaints reported is 8 (SD = 3.8). Median duration for the complaints was 5 yr. 
Subjective feeling of fatigue (CIS-Subjective Fatigue). Data are presented in Table 2. 
Overall analyses of variance revealed group differences on CIS-Subjective Fatigue 
(p<0.001: age and sex were entered as covariates in the analyses). Patients with CFS 
reported more fatigue than healthy subjects and patients with FBD, FBD-patients reported 
more fatigue than healthy subjects. 
Psychological well-being. SCL-90 data of CFS-patients, psychiatric out-patients, 
FBD-patients, and healthy subjects are depicted in Table 3. As sex is related to SCL-90 
scores [17], this variable was entered as a covariate in analyses of variance. Overall 
analyses revealed group differences on all subscales (p<0.001). Significant differences 
between groups are displayed in Table 3. On the BDI, 32% of patients did not have 
depressed feelings at all. Using a score of 16 or more, 36% of patients could be 
considered as having a clinical depression. 
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Table 1. Spontaneously reported complaints by 298 CFS-patients. 
Complaint 
Myalgia 
Difficulty concentrating 
Gastrointestinal complaints 
Headache 
Dizziness 
Sleep disturbances 
Memory problems 
Muscle weakness 
Recurrent infections 
Irritability 
Depression 
Changes in body temperature 
Speech disturbances 
Visual disturbances 
Arthralgia 
Polyuria 
Excessive transpiration 
Coordination disturbances 
Emotional lability 
Sore throat 
Allergies 
% 
71 
51 
49 
46 
43 
43 
36 
35 
26 
24 
22 
21 
20 
19 
17 
16 
16 
15 
15 
13 
12 
(Λ0 
(210) 
(151) 
(145) 
(136) 
(127) 
(122) 
(106) 
(103) 
(77) 
(72) 
(66) 
(63) 
(59) 
(57) 
(52) 
(48) 
(48) 
(45) 
(44) 
(39) 
(36) 
Table 2. Mean CIS scores (SD) of 298 patients with chronic fatigue syndrome (CFS), 
61 patients with functional bowel disorder (FBD), and 60 healthy subjects. High 
scores indicate a high level of fatigue, a high level of concentration problems, low 
motivation, and a low level of physical activity. 
Subscales CFS FBD Healthy 
Subjective fatigue 6.1(1.0) 4.4(1.8) 2.4(1.4) 
Concentration 4.8(1.8) 3.6(1.7) 2.2(1.2) 
Motivation 4.0(1.7) 3.4(1.6) 2.0(1.0) 
Activity 5.0(1.7) 3.3(1.9) 2.0(1.3) 
On all subscales, CFS-patients scored significantly higher than FBD-patients and 
healthy controls (p<0.001), and FBD-patients scored significantly higher than healthy 
controls (p<0.001). 
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Tabic 3. Mean SCL-90 scores (SD) of 290 patients with chronic fatigue syndrome (CFS), 
103 patients with functional bowel disorder (FBD), 1009 healthy subjects, and 2118 
psychiatric out-patients. 
ANX 
AGO 
DEP 
SOM 
IN 
SEN 
HOS 
SLP 
PSN 
Healthy 
13.9 (5.2)** 
8.4 (2.9)** 
22.5 (7.9)** 
17.8 (6.6)** 
13.7 (4.9)** 
25.6 (8.0)** 
7.6 (2.4)** 
4.9 (2.7)** 
123.9 (33.3)** 
FBD 
17.0 (7.1) 
9.3 (4.3) 
26.9 (10.2)** 
23.7 (9.4)** 
17.7 (6.5)** 
27.2 (9.0) 
8.2 (2.4) 
6.5 (3.4) 
147.8 (45.2)** 
CFS 
17.9 (6.9) 
9.7 (4.4) 
31.2(11.3) 
30.6 (8.7) 
23.0 (7.3) 
27.9 (10.2) 
8.7 (3.4) 
7.5 (6.5) 
167.8 (48.7) 
Psychiatric 
26.0 (9.9)** 
13.9 (7.3)** 
42.2 (15.0)** 
26.6 (10.0)** 
21.7 (8.2)* 
39.1 (15.5)** 
11.6 (5.3)** 
7.8 (3.7) 
206.0 (65.6)** 
* Significantly different from CFS: ρ< 0.05. 
** Significantly different from CFS: p<0.001. 
ANX = anxiety; AGO = agoraphobia; DEP = depression; SOM = somatization; 
IN = cognitive difficulties; SEN = interpersonal sensitivity; HOS = hostility; SLP = sleep; 
PSN = psychoneuroticism. 
Daily functioning. Ninety-three per cent of patients reported that they experienced 
severe impairment in daily life because of their complaints, 7% reported moderate 
impairment. Sixty-two per cent reported marked problems in activities at home or at 
work, and 70% reported not being satisfied with respect to daily functioning. Data on the 
SIP are presented in Table 4. Overall analyses of variance showed group differences on 
all subscales (p<0.001). 
Avoidance behaviour. Only 4% of patients did not score on any of the four items 
measuring avoidance of physical activity, 11% scored on one item, 17% scored on two 
items, 26% scored on three items, and 43% scored on four items. Overall analyses of 
variance revealed group differences on CIS-Activity (p< 0.001). Age and sex were 
entered as covariates in the analyses. See Table 2 for mean scores, standard deviations, 
and group differences. 
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Table 4. Mean SIP-scores (SD) of 296 patients with CFS, comparison group 1 (450 family 
practice patients with physical complaints of minor severity or no physical complaints at all) 
and comparison group 2 (144 family practice patients with moderate to severe physical 
complaints). 
SR 
HM 
MOB 
SI 
A 
AB 
W 
RP 
Comparison group 1 
2.8 (6.2)* 
2.1 (8.4)* 
1.2 (5.8)* 
2.3 (6.3)* 
1.4 (5.2)* 
2.5 (9.0)* 
4.5 (15.0)* 
4.3 (10.3)* 
Comparison group 2 
10.7 (10.7)* 
13.4(16.1) 
6.2 (10.8)* 
9.2(11.4)* 
8.0(11.5) 
11.1 (18.2)* 
16.1 (28.4)* 
18.0(18.5) 
CFS 
16.6(11.7) 
15.7 (10.1) 
9.5 (9.5) 
14.9 (10.4) 
7.8 (8.1) 
30.7 (20.6) 
25.2 (16.9) 
20.0(10.1) 
* Significantly different from CFS: p<0.001. 
SR = sleep and rest; HM = activities at home; MOB = mobility; SI = social interaction; 
A = ambulation; AB = alertness behaviour; W = work; RP = recreation and pastimes. 
Cognitions. Eighty-six per cent of patients reported a physical explanation for their 
complaints (predominantly viral infection), whereas only 7% reported a psychological 
explanation. Thirty-nine per cent of the patients believed that they could influence their 
complaints (positive self-efficacy), 27% did not know, and 35% believed that this would 
not be possible (negative self-efficacy). Compared to FBD-patients, CFS-patients showed 
less internal attributions regarding health in general (MHLC-I; ρ<0.001) and had less 
confidence in powerful others (MHLC-P; ρ <0.001). There was no significant difference 
between these two groups with respect to external attributions (MHLC-E). 
Social interactions. Twenty-seven per cent of patients reported difficulties in social 
relations and 29% reported not being satisfied with social interactions. On the SIP-social 
functioning (SIP-SI) subscale, CFS-patients showed more problems in social interactions 
than patients with moderate to severe physical complaints (see Table 4). 
Sleep disturbances. Although 43% of patients reported to have sleep disturbances 
spontaneously (see Table 1), 61% of patients reported sleep disturbances when 
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specifically asked (of those patients, 56% had problems falling asleep, 67% had restless 
sleep, and 27% woke up early in the morning). Average duration of sleep at night was 8 
h (range 3-14) and during the day 2 h (range 1-11). For SCL-SLP results, see Table 3. 
Neuropsychological complaints. A total of 59% reported memory and/or 
concentration problems (see also Table 1). Neuropsychological problems are also 
expressed in high scores on CIS-concentration (Table 2) and SIP-alertness behaviour (SIP-
AB: Table 4). Overall analyses of variance revealed group differences in CIS-
concentration (p<0.001) and SIP-AB (p<0.001). For significant differences between 
groups for CIS-concentration see Table 2 and for SIP-AB see Table 4. 
Dimensions 
Principal components analysis yielded a 9-factor solution (see Table 5). The first 
eight factors were easily interpreted and were named: psychological well-being, functional 
impairment in daily life, sleep disturbances, avoidance behaviour, concentration problems, 
causal attributions related to the complaints, social functioning, and self-efficacy 
expectations. The ninth factor was somewhat difficult to interpret. It contains variables 
that would have been expected to be included in other dimensions. The general question 
'problems in housekeeping/work', for example, would have been expected to be included 
in the dimension functional impairment. What the variables in this factor have in 
common, in contrast with variables that are included in the other eight dimensions, is that 
they represent highly subjective general interpretations of the personal situation. On the 
SIP, for example, respondents mark a list of specific situations as either present or 
absent. Hence, less subjective interpretation is required than is the case in evaluating the 
extent to which complaints interfere with daily functioning in general. The variables in 
this dimension tap another mode of responding. This dimension could be named 
'subjective experience'. 
Reliability analyses resulted in Cronbach's alphas varying from 0.62 to 0.91 (see 
Table 5 for detailed information on variables finally included in each dimension and 
dimension reliability coefficients. Variables are ordered according to the magnitude of 
their primary factor loading). 
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Table 5. Dimensions of CFS, composing variables, and Cronbach alpha reliability coefficients 
of the dimensions. 
Dimension Variables Cronbach's 
alpha 
Psychological well-being 
Functional impairment 
Sleep disturbances 
Avoidance physical activity 
Neuropsychological functioning 
Social functioning 
Causal attributions 
Self-efficacy expectations 
Subjective experience 
SCL-ANX; SCL-AGO; SCL-DEP; 
SCL-SEN; SCL-IN; SCL-SOM; BDI 
SIP-HH; SIP-Α; SIP-MOB 
Sleep disturbances; SCL-SLP 
Avoidance of physical activity items 
SIP-AB; CIS-concentration 
Problems relations; 
Satisfaction social life; 
SIP-SI 
Physical attributions; 
Non-physical attributions 
Self-efficacy expectations; 
MHLC-intemal 
Problems in housekeeping/work; 
CIS-activity; 
Satisfaction in daily life; 
CIS-subjective fatigue 
0.91 
0.80 
0.78 
0.63 
0.84 
0.62 
0.71 
0.77 
0.75 
Stepwise multiple regression analyses were performed to evaluate interrelations 
between dimensions. Each of the nine dimensions served as the dependent variable 
consequetively with the remaining dimensions as the independent variables. As the 
subjective experience dimension represents another mode of responding, this dimension 
was excluded as an independent variable from all regression analyses. In these analyses 
the number of excluded cases exceeded 5%. Therefore, for all regression analyses 
missing values were replaced using the linear trend at point method. Results are displayed 
in Table 6 (variables are ordered according to the step number they were entered into the 
model). The analyses show that, although the dimensions are interrelated, the combined 
effect of related dimensions can explain only a minor to moderate part of variance. Also, 
regression analyses were performed with fatigue severity (CIS-subjective fatigue sub-
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Table 6. Stepwise multiple regression analyses with dimensions and fatigue severity. 
Independant Variables 
Dependent variable Dimensions in model R2 (% variance 
explained) 
Psychological well-being 
Functional impairment 
Sleep disturbances 
Avoidance physical activity 
Concentration 
Social functioning 
Self-efficacy 
Causal attributions 
Subjective experience 
Concentration 
Sleep disturbances 
Social functioning 
Causal attributions 
Functional impairment 
Social functioning 
Avoidance physical activity 
Psychological well-being 
Psychological well-being 
Functional impairment 
Psychological well-being 
Social functioning 
Functional impairment 
Causal attributions 
Concentration 
Psychological well-being 
Functional impairment 
Psychological well-being 
Psychological well-being 
Concentration 
Functional impairment 
Concentration 
Self-efficacy 
Social functioning 
Psychological well-being 
0.69 (47%) 
0.46 (22%) 
0.45 (20%) 
0.29 (8%) 
0.61 (38%) 
0.57 (33%) 
0.13 (2%) 
0.19 (3%) 
0.62 (39%) 
Fatigue severity (CIS subscale 
subjective fatigue 
Psychological well-being 
Functional impairment 
Self-efficacy 
0.53(28%) 
scale), being the principal complaint in CFS, as the dependent variable. Fatigue severity 
was predicted by the dimensions psychological well-being, functional impairment, and 
self-efficacy expectations (R2 = 0.51; variance explained: 27%). 
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Discussion 
In the present study a multi-dimensional approach to the assessment of CFS was 
developed. This study identified nine dimensions, measuring emotional, behavioural, 
cognitive, and social functioning. Multiple regression analyses showed that, although 
interrelations between the dimensions exist, the combined effect of related dimensions 
explained only a minor to moderate part of variance. Hence, each dimension provides a 
unique contribution to the assessment of CFS. Comprehensive assessment of CFS then 
implies measurement of different dimensions simultaneously. 
A recently developed multi-dimensional questionnaire is the Profile of Fatigue-
Related Symptoms (PFRS) [24, 25], which has four subscales: emotional distress, 
cognitive difficulty, fatigue and somatic symptoms. The PFRS was developed to provide a 
measure of severity and pattern of illness. The PFRS resembles the CIS used in this 
study, although the former only gives information on symptoms whereas the CIS also 
provides data on behaviour. The PFRS may be a suitable instrument for the assessment of 
symptoms, but comprehensive assessment of CFS goes further than symptoms. 
Eifert and Wilson [26] cautioned for methodological pitfalls in multi-dimensional 
assessment. Studies on the relationships between different dimensions can be confounded 
by the use of different methods of assessment across the dimensions. The surfacing of a 
set of variables that requires a higher degree of subjective interpretation as a separate 
dimension (subjective experience), in contrast to the standardized psychological 
instruments measuring the same concept, supports this notion. Since different modes of 
assessment may yield different results, it is appropriate to measure every dimension by 
different methods. We are currently carrying out studies in which, apart from self-report, 
other modes of assessment are also being used. These include standardized neuropsycho-
logical laboratory tests, the actometer (an apparatus to measure the level of physical 
activity), and self-monitoring. The use of multiple measures increases the complexity of 
the method, and results in rather a vast package of instruments. This is clearly a 
disadvantage in clinical practice. In research settings, however, multi-dimensional 
assessment in CFS has many advantages. This method provides a comprehensive 
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assessment of patients with CFS. Clinical status, disability, and other relevant processes 
are measured. Multi-dimensional assessment may fill the void that exists in methods to 
identify homogeneous (sub)groups in patients with unexplained chronic fatigue. Studies 
that evaluate the effects of therapeutic interventions should concentrate not only on a 
possible reduction in fatigue severity or other symptoms, but also on the effects of 
treatment on other aspects of the patients' functioning. Also, a multi-dimensional 
assessment might be useful in tailoring therapy to the individual patient. 
Some critical remarks with respect to the present study have to be made. The sample 
was self-referred. Generalizing results to other cohorts of patients with CFS might then be 
difficult. To test generalizability, the present study sample was compared with a recently 
tested group of 68 patients with unexplained fatigue who were referred to the General 
Internal Medicine out-patient clinic of our hospital by their family doctor or a specialist. 
There were no differences between groups with respect to socio-demographic data or any 
other measure we used, except that self-referred patients reported more complaints and 
had a longer duration of complaints. 
Information on physical abnormalities and treatment relied on self-report. This made 
the exclusion of patients with a medical condition known to produce fatigue difficult. To 
overcome this problem as far as possible, complaints had to have been present for more 
than 1 year. This minimalized the risk of including patients with delayed convalescence of 
a viral infection. Moreover, we excluded all patients who had not been investigated by at 
least one specialist. 
The dimensions we have found should not be considered as exhaustive in measuring 
all relevant aspects of CFS, nor is it said that the identified dimensions should be 
measured by the instruments used in the present study. But the main theme here is that, to 
get a comprehensive picture of CFS, a multi-dimensional approach should be applied. 
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Chronic fatigue syndrome 
Abstract 
Objective. To investigate the relation between severity of complaints, laboratory data and 
psychological parameters in patients with chronic fatigue syndrome (CFS). 
Subjects. Eighty-eight patients with CFS and 77 healthy controls matched for age, gender 
and geographical area. 
Methods. Patients and controls visited our outpatient clinic for a detailed medical history, 
physical examination and psychological tests: Checklist Individual Strength (CIS), Beck 
Depression Inventory (BDI) and Sickness Impact Profile (SIP). Venous blood was drawn 
for a complete blood cell count, serum chemistry panel, C-reactive protein and serological 
tests on a panel of infectious agents. 
Results. All patients fulfilled the criteria for CFS as described by Sharpe et al. (J R See 
Med 1991;84:118-21), only 18 patients (20.5%) fulfilled the CDC criteria. The outcome 
of serum chemistry tests and haematological tests were within the normal range. No 
significant differences were found in the outcome of serological tests. Compared to 
controls, significant differences were found in the results on the CIS, the BDI, and the 
SIP. These results varied with the number of complaints (CDC criteria). When the 
number of complaints was included as the covariate in the analysis, there were no 
significant differences on fatigue severity, depression, and functional impairment between 
patients who fulfilled the CDC criteria and patients who did not. 
Conclusion. It is concluded that the psychological parameters of fatigue severity, 
depression and functional impairment are related to the clinical severity of the illness. 
Because the extensive panel of laboratory tests applied in this study did not discriminate 
between patients and controls, it was not possible to investigate a relation between the 
outcomes of psychological and laboratory testing. 
Introduction 
Chronic Fatigue Syndrome (CFS) is characterized by severe disabling fatigue of 
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definite onset (not lifelong), lasting for more than 1 year, and for which no explanation 
can be found. The fatigue is often accompanied by a variety of non-specific symptoms 
and signs. The aetiology of CFS is not known. For research purposes, the Centres for 
Disease Control described a working case definition, which represented a consensus 
opinion rather than validated criteria [1]. Similar but less stringent case definitions were 
subsequently proposed in the United Kingdom [2] and in Australia [3]. In these case 
definitions, the fatigue has to be disabling, of definite onset, and lasting for at least 6 
months. Other symptoms, such as myalgia and neuropsychological problems, may be 
present but are not required. 
A number of somatic and psychological hypotheses have been proposed as possible 
explanations for the cause of CFS [4, 5]. One of these hypotheses is that a persistent viral 
infection leads to continuous immune activation with production of pro-inflammatory 
cytokines, which could explain a number of symptoms [6, 7, 8]. According to another 
hypothesis the primary defect is an immune dysfunction, that includes inadequate killing 
of virus-infected cells, thereby resulting in persistent infection [9, 10, 11]. Some 
researchers have proposed that CFS is an atypical manifestation of a depression [12, 13], 
whilst others think that the perpetuation of the complaints is the result of prolonged 
physical inactivity [14]. Recently, impaired activation of the hypothalamic-pituitary-
adrenal axis has been found in patients with CFS [15]. Altered reactivity of the 
hypothalamic-pituitary-adrenal axis has also been described for patients with the primary 
fibromyalgia syndrome, which is thought to be closely related to CFS [16]. 
Abnormalities observed in serological and immunological studies on patients with 
CFS are diverse, sometimes conflicting, and often minimal. In some studies, patients 
were selected on postviral fatigue, severe myalgia and muscle weakness [17-19], whereas 
in other studies, CFS patients were selected on increased antibody titres to EBV [11, 20]. 
As a consequence, these data cannot be extrapolated to CFS patients in general. The 
impact of the abnormalities in laboratory studies is not clear, because usually a correlation 
with clinical severity of the illness is not made. 
In the present study, laboratory data of patients with severe disabling fatigue lasting 
for more than 1 year have been compared with those of a well matched control group. 
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Our leading question was to investigate whether there would be a relation between 
severity of the complaints, laboratory data and the psychological parameters fatigue 
severity, depression and functional impairment. Furthermore, we investigated whether 
patients who fulfill the CDC criteria differ from patients who do not, clinically, in 
laboratory tests or in psychological tests. The study was approved by the ethical 
committee of our hospital. 
Material and methods 
Subjects. One-hundred patients were randomly chosen from a database of 298 patients 
with CFS. The latter patient group, which was self-referred, was described in detail by 
Vercoulen et al. [21]. In brief, all patients experienced severe disabling fatigue, of definite 
onset, lasting for more than 1 year; other symptoms may be present but are not required. 
Patients with established medical conditions known to produce chronic fatigue, and 
patients with a diagnosis of schizophrenia, bipolar disorder, psychotic depression, 
substance use disorder, eating disorder, or proven organic brain disease were excluded. 
The selected patients were invited to visit our outpatient clinic for a detailed medical 
history as well as a physical examination. All patients gave their informed consent. 
Blood samples were taken for complete blood cell counts, a serum chemistry panel 
which included sodium, potassium, calcium, bicarbonate, glucose, creatinine, creatinine 
Phosphokinase, liver function tests (lactic dehydrogenase, alkaline phosphatase, alanine 
aminotransferase, gamma-glutamyl transferase), and red blood cell magnesium (RBC-
Mg). Three patients dropped out during these investigations. 
In nine patients, medical history and physical examination revealed other diagnoses 
that might contribute to their complaints (chronic pancreatitis, diabetes mellitus, severe 
chronic obstructive pulmonary disease (COPD), cardiac arrhythmia, anorexia, colon 
carcinoma, cocaine abuse, manic depressive disorder, paranoia). These patients were 
excluded from the analyses. The remaining 88 patients were asked to visit our clinic again 
after 3 months and to bring a healthy, non-fatigued control subject with them, matched 
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for gender, age and geographical area. The use of healthy neighbourhood controls is 
necessary to control for recent local epidemics. Seventy-seven patients were able to find 
such a control. None of the controls were receiving medical treatment, and they all stated 
that they were not feeling fatigued. 
Clinical examination 
Questionnaire. Patients and controls were asked to complete a questionnaire. With 
this questionnaire, information was obtained on age, sex, marital status, education, 
occupation, duration of the symptoms, medication and treatment. Information on the 
number and presence of the complaints was obtained in two ways. One way was to ask 
both patients and controls to write down their complaints with a maximum of 16 
(spontaneously reported). The other way was to ask them whether they had a specific 
complaint or not (standardized questionnaire), and how often it was present using a 4-
point scale: 1 = never; 2 = several times per month; 3 = several times per week; 4 = 
every day. Because a score below 3 did not discriminate between patients and controls, a 
specific complaint was scored as being present when the score was 3 or 4. 
Physical examination. All patients had an extensive physical examination with special 
attention for swollen lymph nodes, pharyngitis, muscle atrophy, muscle strength, and 
tendon reflexes. Unless indicated by medical history, a physical examination of controls 
was not done. 
Laboratory tests 
Blood samples were taken for a complete blood cell count, differential count, C-
reactive protein and serological tests on a panel of infectious agents. Antibodies to viral 
capsid antigen and to early antigen of Epstein-Barr virus were detected by indirect 
immunofluorescence on HH514 cells. These cells are a subclone of P3HR1 and were 
kindly provided by Dr. G. Miller (Yale University School of Medicine, New Haven, CT, 
USA). Raji cells were used for the detection of antibodies against Epstein-Barr virus 
nuclear antigen. HSB-2/HHV-6GS cells (obtained from the AIDS Research and Reference 
Reagents Program of the NIH) were used for the detection of immunoglobulin G (IgG) 
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and IgM against human herpesvirus type 6. Before IgM was tested, serum samples were 
incubated with GuIlSORB (Gull Laboratories, UT, USA), to remove IgG and rheumatoid 
factor. ELISAs for antibodies against cytomegalovirus (CMV) and Toxoplasma gondii 
were performed as described by van Loon et al.[22]. Toxoplasma IgG was expressed in 
international units (IU) and CMV-IgG antibodies in arbitrary units (AU) using a standard 
curve of reference serum samples. Antibody capture ELISAs were used for the detection 
of IgM and IgA antibodies. For the detection of enteroviral IgG, IgM and IgA, antibody-
capture ELISAs were used as recently described [23]. For all ELISAs except Toxoplasma 
IgG and CMV-IgG a ratio was computed as follows: the extinction of each serum was 
divided by the extinction of a cut-off serum. When the ratio was >1.2 a serum was 
considered positive, when the ratio was < 1 a serum was considered negative. When the 
ratio was in between, this was considered indeterminate. 
Psychological tests 
Different aspects of fatigue, depression, and functional impairment were measured as 
described before [21]. The following tests were used: 
Fatigue questionnaire. The Checklist Individual Strength (CIS) is a reliable and 
validated questionnaire designed to measure four aspects of fatigue, namely subjective 
experience of fatigue (eight items), concentration (five items), motivation (four items), 
and physical activity (three items)[21]. Each subscale has a maximum score of 7. High 
scores indicate a high level of fatigue, a high level of concentration problems, low 
motivation, and a low level of physical activity. 
Depression. Depression was assessed by the Beck Depression Inventory (BDI) [24]. 
A score of 16 or more is indicative of a clinical depression. 
Functional impairment. The effect of the complaints on daily functioning was 
assessed by the Dutch version of the Sickness Impact Profile (SIP), which is 
psychometrically similar to the English version [25, 26]. Because of the virtual absence of 
sickness in the healthy control group, we used normative data, which are available of 
patients who reported to have complaints of minor severity or no physical complaints at 
all (n = 450; mean age, 47 years), and of patients who reported to have moderate to 
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severe physical complaints (л = 144; mean age, 49 years) [26]. 
Statistical analysis 
Differences between patients and controls were tested using Student's Mest for 
normal distributed variables. Non-parametric tests such as Mann-Whitney's 17-test and 
chi-squared tests were used when appropriate. Testing differences between three groups 
or more was performed by analysis of variance (ANOVA). When appropriate, covariates 
were included in ANOVA. 
Results 
Clinical data 
Questionnaire. The mean age of the 88 patients was 40 (SD 10.7; range 20-66) years. 
The male:female ratio was 1:3 (23 males and 65 females). Sixty-seven per cent were 
married or cohabited, 26% were single, 2% were divorced, and 5% widowed. Seventy-
seven patients were able to find a healthy control matched for age (mean age 41 years; 
SD 11.3), sex (male:female ratio, 1:3), and geographical area. There were no differences 
of socioeconomic and marital status between patients and controls. Thirty-one patients 
(35%) were on sick leave, and an additional 30 (34%) were not working at the time of 
our study. Only 25 patients (29%) reported to be at work, compared to 54 (71%) of the 
controls (chi-squared test, Ρ = 0.003). Sixty-seven per cent of the patients worked before 
the onset of the complaints. Of the patients still working, 12 (48%) worked part-time as a 
result of their complaints. 
All patients had visited one or more specialists for their complaints (predominantly 
internist, neurologist, psychologist, psychiatrist, rheumatologist). Sixty-five per cent of 
the patients were taking medication (mainly analgesics, vitamins, and homeopathic drugs) 
versus 16% of controls (mainly incidental use of analgesics). Sixty-six per cent of the 
patients reported an acute onset of symptoms after an infectious illness. This is different 
from the studies in the UK on post-viral fatigue syndrome, in which attribution to an 
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acute viral illness is a criterion, but similar to studies from the USA and Australia. In 
23% of the patients the onset of symptoms was gradual, 11% of the patients did not know 
how the symptoms had begun. The average duration of symptoms was 11 years, (median 
7 years; range 2-45 years). Complaints that were repeatedly present (more than once a 
week) during the past 3 months are presented in Table 1. It should be noted that the 
number of complaints was higher when specifically asked for, compared to spontaneously 
reported. When specifically asked for, the median number of complaints for patients was 
eight (range three to sixteen), for controls zero (range zero to four). Based on the 
standardized questionnaire, 18 patients (20.5%) fulfilled the CDC criteria. For all 
patients, the median number of minor CDC criteria was six. All patients fulfilled the 
criteria for CFS as described by Sharpe et al.[2]. 
Physical examination. Physical examination revealed no abnormalities, especially no 
swollen lymph nodes, no pharyngitis, no muscle atrophy and normal tendon reflexes. 
Table 1. Complaints of 88 patients with chronic fatigue. 
c
 . . Number (%) Number (%) 
" standardized* spontaneous* 
Fatigue 
Myalgia 
Gastro-intestinal complaints 
Concentration problems 
Allergies 
Muscle weakness 
Sleeping problems 
Memory problems 
Arthralgia 
Headache 
Irritability 
Dizziness 
Sore throat 
Polyuria 
Depressive feelings 
Recurrent infections 
Blurred vision 
Lymphadenopathy 
Slightly elevated body temperature 
* Obtained by standardized questionnaire. 
tt Spontaneously reported complaints. 
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88 (100) 
66(75) 
59 (67) 
57 (65) 
57 (65) 
53(60) 
42 (48) 
42 (48) 
39(44) 
34 (39) 
29 (33) 
27 (31) 
19 (22) 
15 (17) 
14 (16) 
14 (16) 
-
12 (14) 
7(8) 
88 (100) 
46 (55) 
42 (48) 
30 (34) 
-
24 (29) 
24 (29) 
17 (19) 
28 (32) 
41 (47) 
12 (14) 
21 (24) 
И (13) 
-
10(11) 
13 (15) 
12 (14) 
4(5) 
9(11) 
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Laboratory results 
The outcome of laboratory tests was similar for patients and controls. Serum chemis­
try tests and haematological tests were within the normal range (data not shown). Red 
blood cell magnesium was 143.7 μ% Mg/g RBC (SD 15.8) (normal 152 μg Mg/g RBC, 
SD 30.0). 
Results of serological tests are presented in Table 2. Again no significant differences 
were found between patients and controls. C-reactive protein, which is usually high in 
case of an infection, was low ( < 10 mg L"1) in both patients and controls. 
Table 2. Results of serological tests. 
Geometric mean titer (median titer) 
Serological test Patients Controls 
(n = 88) (л = 77) 
Treponema pallidum M HT 
Brucella abortus agglutination 
Brucella abortus CFT 
EB viral capsid antigen IgG 
EB viral capsid antigen IgM 
EB viral capsid antigen IgA 
EB early antigen IgG 
EB early antigen IgA 
EB nuclear antigen 
Herpesvirus 6 IgG 
Herpesvirus 6 IgM 
Borrelia IgG 
Borrelia IgM 
Enterovirus CFT 
Enterovirus IgG (ratio) 
Enterovirus IgM (ratio) 
Enterovirus IgA (ratio) 
Toxoplasma IgG (I.U.) 
Toxoplasma IgM (ratio) 
Cytomegalovirus IgG (AU) 
Cytomegalovirus IgM (ratio) 
Cytomegalovirus IgA (ratio) 
negative 
<10 
< 4 
39.5 (32) 
<10 
< 8 
10.3 (8) 
< 8 
32.1 (16) 
15.5 (10) 
<10 
5 positive* 
< 8 
36.3 (32) 
0.43 
0.68 
0.25 
175.6 
1.1 
23.4 
0.71 
1.0 
negative 
<10 
< 4 
38.0 (32) 
<10 
< 8 
7.4 (8) 
< 8 
40.2 (32) 
16.8 (10) 
<10 
4 positive 
< 8 
35.7 (32) 
0.51 
0.61 
0.37 
130.8 
0.97 
34.7 
0.61 
1.0 
* Number of positives. 
P, not significant for all serological tests. 
AU, arbitrary units; CFT, complement fixation test; EB, Epstein-Barr; IU, international units; 
MHT, micro haemagglutination test. 
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Table 3. Mean CIS scores of 88 patients and 77 controls 
Mean value (±SD) 
Subscales P-value 
Patients Controls 
Subjective fatigue 5.8(1.1) 1.8(0.9) <0.001 
Concentration 4.4(1.6) 2.3(1.2) < 0.001 
Motivation 3.2(1.7) 1.9(1.0) <0.001 
Activity 4.3(1.7) 1.9(1.2) <0.001 
Results of psychological tests 
Subjective feeling of fatigue. Scores of the fatigue questionnaire (CIS) are presented 
in Table 3. Patients were significantly more fatigued than controls as measured by the 
subscale subjective fatigue. Patients with CFS experienced significantly more 
concentration problems, had lower motivation, and showed less physical activity than 
healthy controls. 
Depression. Patients had significantly higher scores on the Beck Depression Inventory 
than controls. By using a score of 16 as the cut-off point, 18.3% of patients could be 
considered depressed versus 1.3% of controls (P<0.001). 
Functional impairment. Data on the inventory for functional impairment (SIP) are 
depicted in Fig. 1. Patients with CFS scored significantly higher when compared to 
reference group 1 (no physical complaints or physical complaints of minor severity) 
(P<0.001 for all subscales). When patients with CFS were compared to reference group 
2 (patients with moderate to severe physical complaints), patients with CFS scored 
significantly higher on alertness behaviour (P<0.001), and work (Ж0.001). There were 
no significant differences on the other subscales. 
Fulfilment of CDC-criteria 
There were no differences in fatigue severity (CIS-subjective fatigue) between 
patients who fulfilled the CDC criteria (CDC-CFS patients) and patients who did not (non 
CDC-CFS patients). No differences on any of the laboratory tests could be found when 
CDC-CFS patients were compared with non-CDC-CFS patients. When CDC-CFS patients 
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were compared with non-CDC-CFS patients, there was a significant difference in CIS 
concentration (P<0.05), CIS activity (Ж0.01), SIP sleep and rest (P<0.05), SIP 
ambulation (P<0.05), SIP alertness behaviour (P<0.05) and SIP recreation and pastimes 
(Ж0.01), which means that patients who have more complaints are significantly more 
impaired in daily functioning. When the number of complaints was included as covariate 
in the analysis, only a significant difference in recreation and pastimes remained 
(P<0.05). 
I CFS patients E Z I Reference group 2 ШШ Reference group 1 
Fig. 1. SIP-scores of 88 CFS patients (•) compared to reference group 1 ( 1 ) (physical 
complaints of minor severity or no physical complaints at all) and reference group 2 (D) 
(moderate to severe physical complaints). * = P< 0.001. 
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Discussion 
In this paper, clinical, laboratory and psychological findings of a cohort of patients 
with CFS are compared to those of a well matched control group. Most studies on CFS 
described in the literature have secondary or tertiary referred patients. To avoid this 
selection bias, we chose to include self-referred patients, which by nature could be 
expected to be more representative of the general problem. That these patients were 
severely fatigued and were considerably impaired by their complaints, is clear from our 
data on the fatigue questionnaire (CIS) and inventory for functional impairment (SIP). 
There was a remarkable discrepancy between spontaneously reported complaints and those 
acquired by a standardized questionnaire as is shown in Table 1. Using the standardized 
questionnaire, in which it is specifically asked whether a complaint is present, complaints 
were more frequently reported. This implies that the number of criteria that are scored 
depends on how data are collected. In this study, the number of CDC symptom criteria 
was based on the data from the standardized questionnaire. Although, only 18 patients of 
our study population (20.5%) fulfilled the CDC criteria, there were no differences in 
fatigue severity (CIS subjective fatigue) between patients who fulfilled the CDC criteria 
and patients who did not. When the number of complaints was included as covariate in 
the analysis, there were also no significant differences on depression and functional 
impairment. As there was no difference in any of the laboratory parameters, the sole 
effect of applying the CDC symptom criteria on our study group is separating patients 
with few symptoms from patients with many symptoms. For the group as a whole, the 
median number of minor CDC-criteria was six. It should be noted that the minor criteria 
that are obtained by physical examination, all focus on inflammation (or even infection), 
whilst an infectious aetiology forms only one of the possible explanations for CFS. 
Although 66% of the patients reported an acute onset of their complaints after an 
infectious illness, we did not find abnormalities on physical examination, and symptom 
criteria that focus on inflammation, such as sore throat, lymphadenopathy, and mild 
fever, scored relatively low (22, 14, and 8%, respectively). This might be related to the 
long duration of symptoms. Many patients reported that such symptoms had been present 
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during the first few months of their illness. However, this was not documented by a 
physician and may just reflect attribution to a 'viral' cause. 
With regard to laboratory findings, low magnesium concentrations in red blood cells 
(RBC-Mg) has been described by some researchers [27]. In our study, RBC-Mg was 
normal in CFS patients, and this is in accordance with the findings of others [28, 29]. 
We could not detect differences on the serological parameters when patients were 
compared with matched controls. By testing of paired sera, evidence was found for a 
recent Toxoplasma gondii infection in one patient, but there was no relation to the 
duration of the fatigue. Despite the fact that no differences were found between patients 
and controls in laboratory tests, we did find significant differences on the fatigue scale, 
the inventory for depression and functional impairment, when CFS patients were 
compared to controls. However, this does not imply that CFS is a psychiatric disease. 
Although depression scores were higher amongst patients than amongst controls, only 
18% of the patients could be considered depressed, whereas 59% of the patients did not 
have depressive feelings at all. 
Results on the inventory for functional impairment (SIP) indicate that CFS patients 
are considerably impaired by their complaints. Compared to patients with moderate to 
severe physical complaints (reference group 2), CFS patients stopped working more often 
(SIP work; Ж0.001), and are significantly more impaired by neuropsychological 
problems (expressed by SIP alertness behaviour; P<0.001). The measurement of these 
neuropsychological problems deserves more attention and is a subject for future research. 
We need to get a better idea of exactly how CFS patients and non-symptomatic, normal 
subjects differ in terms of attention and concentration, cognitive functioning, memory, 
various dimensions of mood and emotional functioning, in addition to quality of everyday-
life functioning. Neuropsychological problems may also be a symptom of dysregulation of 
the hypothalamic-hypopituitary-adrenal axis, which has been recently described by 
Demitrack et al.[15]. 
As the laboratory parameters that were used in this study were within the normal 
range, they could not be correlated with the severity of the illness, or to the CDC 
criteria. Therefore, it was not possible to investigate a relation between the outcome of 
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psychological and laboratory testing. The fatigue questionnaire (CIS), the depression 
inventory (BDI), and the inventory for functional impairment (SIP) correlated with 
clinical severity of the complaints and are valuable tools in the assessment of patients with 
CFS. Serological tests, however, are not helpful in assessing the presence or absence of 
CFS, because these tests did not discriminate between patients and controls. 
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Coxsackievirus Bl-based ELISA 
Abstract 
An antibody-capture enzyme-linked immunosorbent assay (ELISA) with coxsackie-
virus Bl as the antigen was evaluated for detection of immunoglobulin G (IgG), IgM, and 
IgA antibodies and showed broad specificity for enteroviruses. In total, 116 serum or 
cerebrospinal fluid samples from 62 patients were tested by ELISA and the complement 
fixation test (CFT). Additionally, 15 serum samples that contained poliovirus-specific IgM 
antibody were tested. Serum samples from 200 healthy blood donors were used for 
standardization of the assays. The sensitivity of the ELISA varied with time of serum 
sampling, with a relatively low sensitivity when serum was collected within 3 days after 
the onset of symptoms (23%; 5 of 22) but good sensitivity when serum was collected later 
(83%; 20 of 24). The sensitivity was better than that of the CFT. The ELIS As were 
broadly reactive as concluded from typing of virus isolates that were simultaneously 
obtained. The assay did, furthermore, detect antibody against poliovirus type 3. Sera that 
contained rheumatoid factor, antinuclear antibody, or cardiolipin antibody (by the 
Venereal Disease Research Laboratory test) did not react in this ELISA. Nonspecific 
reactivity did occur, however, in cases of infectious mononucleosis and in Mycoplasma 
pneumoniae infection. The enterovirus-specific ELISA is found to be simple to perform, 
more sensitive than the CFT, and far less laborious than the neutralization test. 
Introduction 
Enteroviruses are common pathogens that can cause a variety of symptoms ranging 
from mild respiratory infection to severe central nervous system disease. Enteroviruses 
may furthermore play a role in chronic diseases such as postviral fatigue syndrome [1-4], 
chronic myocarditis/dilated cardiomyopathy [5], polymyositis/dermatomyositis [6, 7], 
postpolio syndrome [8], and insulin-dependent diabetes mellitus [9-11]. The diagnosis of 
the acute infection is mainly based on virus isolation and serological tests such as virus 
neutralization or complement fixation (CF). Virus isolation is not successful in cases of 
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the chronic diseases mentioned above, and a relationship with enteroviruses can be 
investigated only by molecular techniques [12] or serology. Enteroviruses include 69 
serotypes. Hence, a neutralization test is laborious as long as the virus type is not known. 
CF tests (CFTs) are useful but of limited diagnostic value, particularly in a presumed 
persistent phase of infection. Enzyme-linked immunosorbent assays (ELISAs) for the 
diagnosis of enteroviral infections based on either antibody capture [13-15] or an indirect 
technique [16, 17] have been described previously. These tests made use of either a single 
serotype [16] or multiple serotypes [13, 17] as the antigen. Tests for immunoglobulin G 
(IgG) antibody were shown to be of limited value because of the presence of anamnestic 
antibody from earlier infections [16]. 
We describe an antibody-capture ELISA based on a heat-inactivated coxsackievirus 
Bl antigen for the detection of enterovirus-specific IgM, IgA, and IgG antibodies. We 
have deliberately chosen the antibody-capture ELISA because false reactions due to the 
interference with rheumatoid factors seldom occur and competition between antibodies of 
various isotypes is avoided. The antibody capture ELISAs are highly sensitive, with 
exception of the IgG-capture assay. A high level of nonspecific IgG in serum reduces the 
sensitivity of this assay to a relatively low level. The advantage of this low sensitivity is 
that the assay will not detect low concentrations of IgG class antibodies from past 
infections but only increased levels from recent infections or from persistent infections. 
The capture principle leads to an increased sensitivity (also for IgG antibody) when 
cerebrospinal fluid (CSF) is tested [18]. In this report, we describe the performance of 
this ELISA for the diagnosis of acute enterovirus infection with routine samples. 
Materials and methods 
Patients. Routine serum samples were collected during an 8-month period (May to 
December 1992) from patients with symptoms of respiratory infection, gastroenteritis, 
meningitis, pleuritis, and myocarditis. One hundred sixteen samples from 62 patients were 
tested for enteroviral antibodies by CFT and ELISA. A stool specimen, a throat swab, or 
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CSF was obtained from 35 of 62 patients for viral culture. For 14 patients, cultures 
remained negative for enterovirus; enterovirus was isolated from 21 patients. 
Enteroviruses were typed by the use of pools of neutralizing sera [19]. The types of 
enteroviruses that were isolated were coxsackievirus A9 (once), coxsackievirus BS (four 
times), echovirus 6 (once), echovirus 9 (twice), echovirus 11 (three times), echovirus 19 
(once), echovirus 30 (eight times), and poliovirus type 3 (once). Additionally, 15 serum 
samples that were obtained during a recent Dutch epidemic of poliomyelitis type 3 were 
kindly provided by the National Institute of Public Health and Environmental Protection. 
The latter sera were all taken from asymptomatic contacts of patients with poliomyelitis. 
All sera contained poliovirus type 3-specific IgM antibodies that were detected by a 
poliovirus type-specific ELISA [20-22]. 
Control sera. Sera collected in March 1991 from 200 healthy blood donors were used 
as controls. To investigate the specificity of the assay, rheumatoid factor IgM-positive 
serum samples (n = 20), serum samples with antinuclear antibodies (n = 21), syphilitic 
serum samples (positive by the Venereal Disease Research Laboratory test and the 
Treponema pallidum microhemagglutination test) (n = 20), serum samples with 
heterophile antibodies (Monospot; Ortho Diagnostic Systems, Raritan, N.J.) (л = 20), 
and Mycoplasma pneumoniae IgM- and IgA-positive serum samples (л = 15) were tested 
as well. Serum samples were kept at -20°C until analysis. 
Preparation of antigen. Coxsackievirus Bl was grown in buffalo green monkey cells. 
Buffalo green monkey cells were grown in 850-cm2 roller bottles (Coming Glass Works, 
Coming, N.Y.). Confluent monolayers were infected with coxsackievirus Bl (Tucson-
strain [23]) at a multiplicity of infection of 0.5. The cultures were maintained in 150 ml 
of minimal essential medium with 3% fetal bovine serum, 100 U of penicillin per ml, and 
50 μg of gentamicin per ml. The roller bottles were incubated at 36°C. Virus was 
harvested when complete cytopathic effect was observed, usually after 2 to 3 days. Cells 
were freeze-thawed three times and together with the culture medium firmly shaken with 
10% chloroform for 15 min and centrifuged at 2,000 χ g for 30 min [24]. The 
supernatant was centrifuged through a 30% (wt/wt) sucrose cushion at 150,000 χ g for 3 
h. The pellets were resuspended in a final volume of 6 ml of phosphate-buffered saline 
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(PBS) and heated at 56°C for 60 min in order to denature the virions and convert 
antigenicity from type specific (N antigen) to group specific (H antigen) [17, 25]. Control 
antigens were prepared in the same way by using noninfected cell cultures. The protein 
contents of the viral antigen and the control antigen preparations were determined as 
described by Lowry et al. [26]. The antigens were conjugated with horseradish peroxidase 
as described by Wilson and Nakane [27]. The conjugated viral and control antigens were 
suspended in PBS containing 0.005% mercurothiolate and 2% fetal bovine serum. The 
labelled antigens were stored in small aliquots at 4°C. 
Capture ELISA technique. The antibody-capture ELISAs for detection of enterovirus 
IgG, IgM, and IgA were carried out essentially as described previously [18, 28]. 
Polyethylene terephthalate glycol microtiter plates (96-well PETG assay plates, no. 6595; 
Costar Europe, Badhoevedorp, The Netherlands) were coated with 125 μ\ of goat 
antihuman IgG (Cappel Laboratories, Cochranville, Pa.), goat antihuman IgA (Cappel), 
or monoclonal antihuman IgM (kindly provided by J.P. Coutelier, Universite Catholique 
de Louvain and Institute of Cellular and Molecular Pathology, Brussels, Belgium) diluted 
in Trisbuffer (pH 9.0). The optimal dilutions were determined by checkerboard titration 
and were 1:500 for anti-IgG, and 1:1,000 for anti-IgM and anti-IgA antibodies. The 
plates were incubated overnight at 4°C, washed four times with wash buffer (0.01 M PBS 
[pH 7.2] with 0.05% Tween 20), and shaken dry. Next, 100 μΐ of patient serum diluted 
at 1:100 in PBS-Tween with 2% fetal bovine serum and 0.005% mercurothiolate (PFT-
M) was added and the plates were incubated at 37°C in a humidified atmosphere for 2 h. 
All sera were tested in duplicate. Plates were washed again four times and shaken dry, 
and 100 μ\ horseradish peroxidase conjugated antigen diluted in PFT-M was added. The 
optimal dilution of conjugated antigen was determined by block titration and was 1:1,000 
for the IgG assay and 1:1,500 for the IgM and IgA assay. After overnight incubation at 
4°C, the plates were washed again and 100 μ\ of substrate solution was added. The 
substrate solution was prepared immediately before use by dissolving 4 mg of ortho-
phenylenediamine per ml in 0.05 M citrate buffer (pH 5.2) and then adding 0.045% 
hydrogen peroxide (final concentration). The reaction was stopped after exactly 10 min by 
the addition of 100 μΐ of 3 M H2S04. The AA92 was read (Titertek Multiskan; Flow 
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Laboratories, Irvine, United Kingdom). The buffer control was used as a blank. A 
strongly positive serum sample, a cutoff serum sample, and a negative control serum 
sample were included in each test. The cutoff was chosen on the assumption that at most 
5% of the serum samples from healthy blood donors were reactive. A serum sample was 
considered positive when the absorbance was at least twice the absorbance of the cutoff 
serum for IgM and IgA or at least the same as cutoff value for IgG. The ELISA with the 
control antigen was performed in a similar way. 
CFT. The CFT was performed according to the microtiter technique described by 
Casey [29]. The enterovirus antigen in the CFT consisted of a mixture of antigens 
including coxsackieviruses Bl to B5 and A9 and echoviruses 4, 6, 9, 14, 24, and 30 
(Behringwerke AG, Marburg, Germany). The titer is expressed as the reciprocal of the 
highest dilution showing 50% hemolysis. The CFT was considered positive when a 
fourfold increase of antibodies between acute and convalescent sera was found or when 
the titer was > 128. 
Neutralization test. Sera from some of the patients were tested for neutralizing 
antibodies as described by Melnick et al. [30]. IgM was prepared by a fractionation-
concentration technique after gel chromatography as described by Inouye and Kono [31]. 
Because of the limited amount of serum, the IgM fraction was tested only against the 
virus strain against which the highest neutralizing antibody titer was found in 
unfractionated serum. 
Results 
Standardization of enterovirus-specific ELISA. Two hundred serum samples from 
healthy blood donors were tested for enterovirus IgG, IgM, and IgA antibodies. From the 
outcome, cutoff values were determined on the assumption that at most 5 % of the serum 
samples were reactive. This is illustrated for the IgG assay in Fig. 1. Serum with 
reactivity at the cutoff level as well as a strongly reactive serum sample and a negative 
serum sample were selected for standardization of the assays. The strongly positive serum 
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Frequency (%) 
35 
30 
26 
20 
15 
10 
5 
0 
0.06 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 0.55 0.6 >0.6 
Extinction 
Figure 1. Results of the IgG-capture assay with serum samples from 200 healthy blood 
donors. 
sample that was used was derived from a patient with culture-proven enteroviral infection 
who also had a high titer in the CFT (titer, >256). The A4g2 of this serum sample was 
greater than five times the absorbance of the cutoff serum sample for the IgM and IgA 
ELISA and greater than three times the absorbance of the cutoff serum sample for the 
IgG ELISA. To reveal any nonspecific reactions, all 200 donor serum samples were 
tested against the horseradish peroxidase-labelled control antigen made from uninfected 
cells. None of the sera reacted with the control antigen. 
Patients. One hundred sixteen serum samples from 62 patients were tested for 
enteroviral antibodies by CFT and ELISA. A stool specimen, a throat swab, or CSF was 
obtained from 35 patients for viral culture. For 14 patients, culture remained negative for 
enterovirus, and enterovirus was isolated from 21 patients. Data for these 21 patients are 
represented in Table 1. A recent enterovirus infection was diagnosed in 7 patients by CFT 
(33%) and in 14 patients by ELISA (67%;IgG 6 times, IgM 10 times, and IgA 6 times). 
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In seven patients, no enteroviral antibodies were detected by ELISA. In two of them 
(patients 5 and 14), such antibodies were detected by CFT. Two patients were eventually 
diagnosed as also having a bacterial infection at the time of blood sampling (patients 5 
and 6). Fifteen of the 21 patients presented with meningeal signs (Table 1, patients 7 to 
21). Enterovirus was isolated either from CSF (л = 9), from a throat swab (л = 2), or 
from a fecal sample (л = 4). In 5 of 15 patients, recent enteroviral infection was 
diagnosed by CFT (33%), and in 10 patients, it was diagnosed by ELISA (67%; IgG five 
times, IgM seven times, and Ig A four times). Five patients presented with meningeal 
signs during a small epidemic of echovirus 30 meningitis (patients 17 to 21). Sera from 
these patients were also tested for neutralizing antibodies against echovirus 30. All 
patients had a neutralizing antibody titer of >128. After fractionation of these serum 
samples, neutralizing antibodies of the IgM class could be detected in all samples as well. 
In 2 of the 14 patients whose cultures were negative for enterovirus, a recent enterovirus 
infection was diagnosed by serology. The clinical diagnosis for these two patients was 
Bornholm disease and myopericarditis (Table 2, patients 26 and 28). Among the 
remaining 12 of 14 culture-negative patients, other infections were documented for 6: 
parainfluenza virus (л = 2), herpes simplex virus (л = 1), varicella-zoster virus (л = 1), 
Ureaplasma infection (л = 1), and streptococcus infection (л = 1); in three cases no 
infection was documented, and in three cases a noninfectious cause was found. All serum 
samples from these patients were negative by ELISA and CFT. 
For 27 patients, no material for culture was available; thus, only serologic tests were 
performed. For 21 of these patients, enterovirus-specific serology was negative. In five of 
these patients there was serologic evidence for other viral infections, namely, by herpes 
simplex virus (л = 1), parainfluenza virus (л = 3), and respiratory syncytial virus (л = 
1). For six patients, serology indicated a past or recent enterovirus infection. Data for 
four of these patients are presented in Table 2 (patients 22, 24, 25, and 27). One patient 
presented with convulsions, and serologic results indicated a recent enterovirus infection: 
high titers were determined by CFT, and the patient was positive for both IgM and IgA 
antibodies. In one patient, IgM antibodies against enterovirus were detected. However, in 
this patient there were also IgM antibodies against cytomegalovirus, Epstein-Barr virus, 
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herpes simplex virus and varicella-zoster virus, which means that these antibody 
responses were probably nonspecific. 
Seven patients with cardiomyopathy, myocarditis/pericarditis, or pleuritis (Bornholm 
disease) as a clinical diagnosis are represented in Table 2. One patient died of cardio-
myopathy at birth (patient 23). The high titer in the CFT probably represents maternal 
antibodies. Among the remaining six patients, recent enteroviral infection was diagnosed 
in four by CFT (67%) and in all by ELISA (100%; IgG four times, IgM four times, and 
IgA four times). For three patients, serum was also tested for neutralizing antibodies 
against coxsackieviruses Bl, B2, B3, B4, and BS. Two patients had neutralizing 
antibodies against coxsackievirus B4, and one patient had neutralizing antibodies against 
coxsackievirus Bl. In these samples neutralizing antibodies of the IgM class could be 
detected, which indicates recent infection. 
Fifteen serum samples that were drawn from asymptomatic contacts of patients with 
poliomyelitis were tested by the coxsackievirus Bl-based antibody-capture ELISA and by 
CFT. All sera contained poliovirus type 3-specific IgM antibodies as determined at the 
National Institute of Public Health and Environmental Protection. The results are 
summarized in Table 3. All sera were positive by the IgM ELISA, 12 serum samples 
were positive by the IgA ELISA, and 9 serum samples were positive by the IgG-capture 
ELISA. Seven serum samples were positive by all three ELISAs. Nine serum samples 
were positive by CFT (titer, >256). 
Specificity of the assays. The results for the control sera with known antibody 
specificity are summarized in Table 4. Of the 20 serum samples with rheumatoid factors 
of the IgM type, only 1 was reactive in the IgM and IgA ELISA. Three of 21 serum 
samples with antinuclear antibodies reacted in the IgM ELISA, but none of them reacted 
in the IgA ELISA. One of 20 Venereal Disease Research Laboratory test-positive serum 
samples reacted with enteroviral antigen in the IgM ELISA as well as in the IgA ELISA. 
Unfortunately, reactivity to the enteroviral antigen was encountered in half (10 of 20) of 
the Monospot-positive sera and in the majority (10 of 15) of sera containing IgM and IgA 
antibodies against M. pneumoniae. All sera that reacted with the enteroviral antigen in the 
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Table 3. Sera taken during recent Dutch epidemic of poliomyelitis type 3. 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
Age 
9yr 
17 yr 
10 yr 
15 yr 
11 yr 
9yr 
18 yr 
23 yr 
5yr 
9yr 
17 yr 
3yr 
31 yr 
36 yr 
31 yr 
Poliovirus type-
specific IgM 
3 
3 
3 
3 
3 
3 
1,2,3 
1,2,3* 
3 
3 
3 
3 
1,2,3 
3 
1,2,3 
CFT 
titer 
>256 
4 
64 
>256 
8 
16 
>256 
64 
64 
>256 
>256 
>256 
>256 
>256 
>256 
IgG 
+ 
+ + 
+ + 
+ + 
-
-
+ + 
-
+ + 
+ + 
+ + 
+ + 
-
-
-
IgM 
+ 
+ + 
+ 
+ + 
+ 
+ + 
+ + 
+ 
+ 
+ + 
+ + 
+ + 
+ 
+ + 
+ 
IgA 
-
+ 
+ 
-
+ 
+ + 
+ + 
-
+ + 
+ + 
+ 
+ + 
+ + 
+ 
+ + 
Symbols: - = negative (IgG < the cutoff; IgM and IgA <2x the cutoff); + = positive (IgG, 
lx to 2x the cutoff; IgM and IgA, 2x to 5x the cutoff); ++ = strongly positive ( (IgG >2x 
the cutoff; IgM and IgA >5x the cutoff). 
# = vaccinated. 
ELISA were also tested with the control antigen and by CFT. None of the sera reacted 
with the control antigen in the IgG and IgA ELISA. In the IgM ELISA with the control 
antigen, some reactivity was found in the Monospot-positive sera and sera with antibodies 
against M. pneumoniae. However, reactivity with the control antigen was less prominent 
than reactivity with the enteroviral antigen. In 2 of 10 Monospot-positive serum samples 
and in 2 of 10 serum samples containing mycoplasmal antibodies, high titers were found 
by CFT, suggesting recent enterovirus infection or nonspecific reactivity occurring in 
CFT as well. All patient sera that were positive by ELISA with the enteroviral antigen 
were tested with the control antigen as well. None were reactive. 
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Table 4. Control sera with known antibodies 
No. of isolates positive/no. tested for: 
Known antibodies 
IgG IgM IgA 
Rheumatoid factor IgM 
Antinuclear antibodies 
VDRL" and TP-MHAb 
Heterophil antibodies 
Mycoplasma IgM and IgA 
0/20 
1/21 
0/20 
1/20 
0/15 
1/20 
3/21 
1/20 
10/20 
10/15 
1/20 
0/21 
1/20 
6/20 
2/15 
° VDRL = antibodes detected by the Venereal Disease Research Laboratory test. 
* TP-MHA = antibodies detected by the Treponema pallidum microhemagglutination test. 
Discussion 
The aim of this study was to evaluate the sensitivity and specificity of a 
coxsackievirus Bl-based antibody-capture ELISA as a simple test with broad reactivity for 
enteroviruses. It is known that cross-reactive epitopes are located on the empty capsids of 
enteroviruses. Heating to 56°C converts virions to empty capsids, thereby changing the 
antigenicity to group-specific reactivity [15, 17, 25]. The present study confirms this 
broad specificity. During the development of these ELISAs we have made conjugated 
antigens of the 10 enterovirus types with the highest incidence in The Netherlands. These 
conjugates have been tested either separately or as antigen mixtures. So far, infections by 
the following known serotypes have been recognized: echoviruses 6, 7, 9, 11, 14, 19, 25 
and 30; coxsackieviruses Bl, B2, B4 and B5; and poliovirus type 3. A combination of 
various serotypes pooled with an antigen mixture did not further broaden reactivity for 
enteroviruses, nor did the use of other serotypes as the antigen (data not shown). 
The cutoff values were arbitrarily chosen at the 95% confidence level of reactivity in 
a population of 200 healthy blood donors. In March (the time of collection of the donor 
sera), the incidence of acute enterovirus infections is low, but the exact prevalence was 
not known. This might have influenced the sensitivity and specificity of the tests. 
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Among the patients with culture-positive enterovirus infections, seven patients were 
missed by ELISA. In two of these patients (patients S and 6), there was also evidence of 
bacterial infection (Escherichia coli and Staphylococcus aureus). Therefore, the onset of 
enteroviral infection is not accurately known for these cases. It may be that the samples 
were drawn too early to find specific antibodies (patients 9 and 16). Unfortunately, there 
was no second sample. It may also be that the ELISA was falsely negative. Consistent 
with this possibility, enteroviral antibodies were detected in patients 5 and 14 by CFT but 
not by ELISA. Patient 8 suffered from neonatal meningitis and could have had a delayed 
antibody response, as seen more often with neonatal infections. Enteroviral antibodies 
were detected by ELISA in CSF from only two of eight patients. This is probably due to 
the time of sampling. CSF is usually taken at the onset of symptoms, when antibody 
production is just starting. Antibodies were indeed detected in two of three CSF samples 
that were taken more than 2 days after onset. Thus, ELISA with CSF may be useful when 
CSF is taken later than 2 days after onset, comparable to what is found with serum (see 
below). This has also been described by van Loon et al. [18], who did not detect 
antibodies against herpes simplex virus in CSF within 6 days after the onset of illness. In 
contrast, they found herpes simplex virus IgG and IgA in CSF from all patients with 
herpes simplex virus encephalitis more than 10 days after onset. 
In patients with cardiomyopathy, myocarditis/pericarditis, or pleuritis, cultures are 
usually not performed or are performed with a considerable delay. When clinical 
symptoms become clear, cultures are usually negative. In such patients, only serology 
may reveal a relationship with enteroviral infection. We have tested serum samples from 
seven of such patients by the coxsackievirus group В1-based ELISA and by CFT with the 
antigen mixture (Table 2). For one patient, serology was negative by ELISA. This patient 
(patient 23) was born with cardiomyopathy and died at birth. Polymerase chain reactions 
with heart biopsies from this patient, taken at autopsy, were negative for enterovirus. 
There is a discrepancy in IgM and IgA responses: nine patients had an IgM response 
but no IgA response, and three patients had an IgA response but no IgM response. This 
has been described before [32], but the reason for this discrepancy is not known. 
The sensitivity of the antibody-capture ELISA is good when the outcome of the IgG, 
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IgM and IgA assays are combined. The sensitivity ranges from 67% in cases of culture-
proven enteroviral infections and meningitis (14 of 21 and 10 of 15, respectively) to 86% 
(6 of 7) in cases of myocarditis, pericarditis, or pleuritis. The sensitivity in the case of 
poliovirus type 3-specific IgM-positive sera was 100% (15 of 15). The sensitivity is 
clearly related to the time when serum samples are taken. When serum samples are taken 
within 3 days after the onset of symptoms, the sensitivity is low (5 of 22 [23%]). When 
serum is drawn later than 3 days after onset, the sensitivity is good (20 of 24 [83%]). The 
CFT with the antigen mixture is less sensitive than the ELISA (44% versus 81%), 
especially when only one serum sample is available. When the ELISA and CFT were 
combined, the sensitivity was 88%. This ELISA was found to be as sensitive as an 
antibody-capture ELISA using different antigens [13, 14]. The sensitivity of the IgM 
ELISA alone is 58%. When IgM and IgA are combined, the sensitivity increases to 67%. 
The IgG-capture assay adds another 16% to the sensitivity. The relatively low sensitivity 
of the IgM and IgA ELISA may be due to the recurrent character of enterovirus 
infections. Recurrent enteroviral infection with different serotypes causes boosts in 
responses to common epitopes. This may result in diminished antibody responses of both 
IgM and IgA. For cytomegalovirus, as an example, it is known that IgM and IgA 
responses are less prominent or even absent in recurrent infection compared with the 
primary infection [28, 33]. 
Antibody-capture ELISAs have proven to perform excellently with CSF [18]. This is 
because of the low background levels of nonspecific Igs in CSF as long as the blood-brain 
barrier is not damaged. This is particularly so for the IgG-capture assay as is illustrated 
by patients 11 and 12 in our study. It can be envisaged that the IgG-capture ELISA will 
also perform well in case of high antibody levels (hyperimmunization), as has been 
reported to occur in persistent infection [4, 6, 9]. This has already been investigated by 
using poliovirus type-specific ELISAs for postpolio syndrome, with which we did not find 
evidence for viral persistence [20]. Similar studies are underway for postviral fatigue 
syndrome, dilated cardiomyopathy, and polymyositis [34]. 
As expected, there was no interference by rheumatoid factor. There was little cross-
reactivity in sera with antinuclear antibodies and none in sera with positive Venereal 
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Disease Research Laboratory test reactions. Unfortunately, there was significant cross-
reactivity with sera that contained heterophile antibodies or M. pneumoniae IgM and IgA 
antibodies. This is probably due to polyclonal B-cell activation, which is common in 
Epstein-Barr virus infection and mycoplasmal infection [35-37]. Cross-reactivity occurred 
mainly in the IgM ELISA and less in the IgA ELISA. 
Pitfalls in our assay seem to be similar to those reported by others [38]. The major 
disadvantage of this test is its cross-reactivity with Epstein-Barr virus and M. 
pneumoniae. However, the clinical symptoms of these infections are quite different from 
those of enteroviral infections, and therefore we do not think this will be a major problem 
in clinical practice. Perhaps the use of synthetic peptides, which has recently been 
described by Cello et al. [39], may reduce cross-reactivity. The great advantage of the 
test we described is that it is simple to perform, more sensitive than the CFT, and far less 
laborious than the neutralization test. 
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Enteroviruses and CFS 
Abstract 
The possible role of enteroviral persistence in the etiology of the chronic fatigue 
syndrome (CFS) was investigated by serological testing, VP-1 antigen testing, and 
polymerase chain reaction (PCR) analysis of stool specimens as well as by viral cultures 
of stool - both direct and after acid treatment. No differences between 76 patients with 
disabling unexplained fatigue and 76 matched controls were found by serological or 
antigen testing. Furthermore, no enteroviruses were isolated from any stool culture. 
Enterovirus was detected by PCR in one stool specimen of a patient with CFS but was 
not detectable in a second sample obtained from the same patient 3 months later. All stool 
specimens from controls were PCR-negative. These results argue against the hypothesis 
that enteroviruses persist in patients with CFS and that their persistence plays a role in the 
pathogenesis of this syndrome. 
Introduction 
The chronic fatigue syndrome (CFS) is characterized by excessive fatigue of at least 
6 months' duration. Usually this fatigue is accompanied by a variety of nonspecific 
symptoms, such as myalgia, impairment of memory, and difficulties in concentration. The 
disease leads to a diminution of physical and mental functioning. 
The etiology of CFS is not known. However, many patients with CFS believe that an 
infectious disease is the inciting event. Viruses that have been associated with CFS 
include Epstein-Barr virus, human herpesvirus 6, cytomegalovirus, retroviruses, and 
enteroviruses. Of the enteroviruses, the Coxsackie В viruses have been considered 
particularly likely to be involved in CFS because of their myotropic and neurotropic 
character. 
Support for an etiologic role of enteroviruses in CFS is derived from studies in the 
United Kingdom [1-5]. Several investigators have found enterovirus in stool (by culture) 
[1], in blood (by the VP-1 test)[l], and in muscle (by slot-blot hybridization and the 
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polymerase chain reaction [PCR]) [2-4]. In addition, one group reported high levels of 
neutralizing antibodies to Coxsackie В viruses [S]. On the basis of these results, it was 
suggested that the persistence of enteroviruses plays a role in CFS [1, 3-5]. Other studies, 
however, failed to confirm such a role [6-8]. In the latter studies, both antibodies to 
enteroviruses and VP-1 antigen were found with equal frequency in patients with CFS and 
in controls. 
Our aim in this study was to investigate the persistence of enteroviruses in a group of 
patients with CFS and in a well-matched control group. To this end, we performed 
enterovirus-specific serological testing and VP-1 antigen testing on serum samples, and 
we subjected stool samples to PCR and viral culture (both direct and after acid treatment 
for the dissociation of putative immune complexes). This study was part of a broader 
multidisciplinary investigation evaluating clinical, psychological and laboratory data from 
patients with CFS. 
Materials and methods 
Patients. Seventy-six patients and 76 healthy controls were examined. Patients were 
randomly chosen from a data base of 298 patients with CFS. (This group, which was self-
referred, has been described in detail by Vercoulen et al. [9].) All patients reported 
severe, unexplained, debilitating fatigue of at least 1 year's duration. The enrolled 
patients came to our outpatient clinic twice within a 3-month interval. On the second visit, 
each patient was accompanied by a neighbor of the same gender and within 2 years of the 
same age; this control was selected by the patient. Patients and controls visited our clinic 
between December 1991 and April 1992 - a period covering months during which the 
incidence of infections due to enteroviruses is usually low in the Netherlands. Samples of 
blood and stool were obtained from patients and controls. All patients underwent a 
physical examination and an extensive laboratory work-up and completed a questionnaire 
that solicited information on age, sex, and duration and nature of symptoms. 
Antibody-capture ELISA. A broadly reactive antibody-capture ELISA was used for the 
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detection of IgG, IgM, and IgA antibodies to enteroviruses [10]. A strongly positive 
serum sample, a "cutoff sample, and a negative control sample were included in each 
test. The cutoff value was based on the assumption that at most 5% of serum samples 
from 200 healthy blood donors would be reactive. Thus levels were scored as positive 
(greater than the cutoff value) only when they exceeded those in a healthy population. 
Serum samples from patients and controls were tested simultaneously in order to 
minimize the day-to-day variability of the assay. 
Complement-fixation test. The CF test was performed according to the microliter 
technique described by Casey [11]. The enteroviral antigen used in this test (Behring-
werke AG, Marburg, Germany) actually consisted of a mixture of antigens, including 
those of coxsackieviruses Bl through B5; coxsackievirus A9; and echovimses 4, 6, 9, 14, 
24 and 30. The CF titer was expressed as the reciprocal of the highest dilution showing 
50% hemolysis. Serum samples from patients and controls were tested simultaneously. 
VP-1 test. The VP-1 antigen test was performed at the laboratory of Dr. J.F. 
Mowbray (Department of Immunopathology, St.Mary's Hospital Medical School, 
London). The enterovirus group-reactive monoclonal antibody 5-D8/1 was used [12]. 
Serum samples from patients and controls were randomly numbered for blind testing. 
Isolation of virus from stool specimens. A 100-mL suspension of feces in PBS (20%, 
wt/vol) was prepared from every stool specimen. Chloroform (10%, vol/vol) was added, 
and the mixture was shaken vigorously for 20 minutes. Supematants were clarified by 
centrifugation at low speed (2,000 g). A 5-mL volume of supernatant was used to 
inoculate duplicate tubes containing human fetal lung fibroblasts (no. 2002; Flow 
Laboratories, Rockville, MD) and tertiary kidney cells from cynomolgus monkeys [13] 
(0.1 mL of supernatant and 0.25 mL of culture medium per tube). After absorption of the 
inoculum for 1 hour at 37°C, the inoculum was decanted and replaced by 1 mL of the 
following culture medium: minimal essential medium (MEM) with 3% fetal bovine serum 
(FBS), 20 nW HEPES (pH 7.5), 2 mM glutamine, 50 μg of gentamicin/mL, 100 μg of 
vancomycin/mL, and 1 /¿g of amphotericin B/mL. The tubes were incubated at 37°C and 
were examined for cytopathic effect (CPE) every 3 days for 2 weeks. A blind passage 
was undertaken after 1 week. 
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The remaining 95-mL volume of supernatant was centrifugea in two bottles at 
150,000 g for 3 hours. The supematants were removed. One pellet was resuspended in 
2.5 mL of MEM with 3% FBS and stored at -70°C for acid elution. The other pellet was 
stored directly at -70°C for PCR. 
Nested PCR. Primers were selected from the 5' nontranslated region, which is highly 
conserved among enteroviruses. The primers were 100% homologous to the known 
enteroviral RNA sequences. RNA was extracted from the concentrated fecal pellet by the 
acid guanidinium thiocyanate-phenol-chloroform procedure (RNAzol В method; Cinna/ 
Biotecx Laboratories, Houston, Texas), as described by Chomczynski and Sacchi [14]. 
Reverse transcription was performed essentially as described by Zoll et al. [15] with 
primer 4 as the reverse primer and primer 1 as the sense primer (see table 1). The 
amplified product had a length of 484 base pairs (bp). For nested PCR, a 10-μί volume 
of the first PCR reaction product was added to a new PCR mixture containing 50 pmol of 
nested primers 2 and 3 and was subjected to an additional 40 cycles of amplification. A 
positive amplification resulted in a product of 155 bp. Each test included five controls: a 
DNA control (cDNA of coxsackievirus Bl), an RNA control (RNA of coxsackievirus 
Bl), a negative control (diethyl pyrocarbonate [DEPC]-treated distilled water), and RNA 
isolated from stool specimens from two healthy controls. The reactions were analyzed by 
electrophoresis of 25 /xL of the PCR reaction product on a 1.5% agarose gel stained with 
ethidium bromide and subsequent Southern blot hybridization as described previously 
[15], with use of an end-labeled oligonucleotide probe (table 1). 
Table 1. Enteroviral primer sequences used for nested PCR. 
Primer Oligonucleotide sequence Location* 
1 5'-CAAGCACTTCTGTTTCCCCGG-3' 160-180 
2 5'-TCCTCCGGCCCCTGAATGCG-3' 445-464 
3 5*-ATTGTCACCATAAGCAGCCA-3' 580-599 
4 5'-CACCGGATGGCCAATCCA-3' 626-643 
Probe: S'-TGTGTCGTAACGGGCAACTCTGCAGCGGAA-S' 509-538 
* Positions refer to the coxsackievirus Bl sequence of Iizuka et al. [16]. 
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Isolation of virus after acid elution. Acid elution was performed as described by 
Yousef et al. [1] with slight modifications. In brief, a 1.5-mL volume of 0.1 M glycine/ 
HCl buffer (pH 2.4) was added to 2.5 mL of concentrated stool extract, and the pH was 
readjusted to 2.4 with 0.5 M HCl. The mixture was incubated at room temperature for 3 
hours and then centrifuged over a 30% sucrose cushion at pH 2.4 for 3 hours at 150,000 
g. The pellet was resuspended in 2 mL of MEM with 3% FBS, and the pH was adjusted 
to 7.0 by the addition of 0.5 M NaOH. The suspension was then inoculated in duplicate 
onto tertiary monkey kidney cells and human fetal lung fibroblasts (1 mL of concentrated 
stool extract plus 2.5 mL of culture medium) seeded in 25-cm2 flasks (no. 690160; 
Greiner GmbH, Frickenhausen, Germany). After absorption for 1 hour at room tempera­
ture, the inoculum was decanted, and a 5-mL volume of culture medium was added to the 
flasks, which were subsequently incubated at 37°C. The cultures were examined for CPE 
every 3 days for 6 weeks. Blind passages were done after 2 and 4 weeks. 
Results 
Demographic and clinical information. The mean age of the 76 patients was 40 years 
(median, 41 years; range, 20-66 years); the mean age of the 76 controls was 41 years 
(median, 42 years; range, 19-67 years). The male-to-female ratio for patients was 1:3. 
The majority of patients reported myalgia, muscular weakness, impairment of memory, 
and problems with concentration and sleeping. In 90% of cases, the criteria for CFS 
delineated by Sharpe et al. [17] were fulfilled. The average duration of symptoms was 11 
years (median, 7 years; range, 2-45 years). Sixty-six percent of patients reported an acute 
onset of the manifestations of CFS after an infectious illness. Patients were not part of a 
cluster but came from all parts of the Netherlands (both rural and urban areas). 
Serological results. The results of the antibody-capture ELISA for IgG, IgM, and IgA 
antibodies to enteroviruses were similar for patients and controls (P>.05, Wilcoxon rank 
sum test). Likewise, the CF test detected no significant difference between patients and 
controls (P=.69, χ 2 analysis). VP-1 antigen was detected in serum samples from 16 
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patients and 17 controls. There was no correlation between the presence of VP-1 antigen 
and the presence of enteroviral IgG, IgM, or IgA (figures 1-3); of the eight patients 
whose sera were positive for enteroviral IgG, IgM, and/or IgA (table 2), only one had 
serum positive for VP-1 antigen. Moreover, no correlation was found between the 
outcome of virological tests and the duration, nature, or acute onset of symptoms. 
Nested PCR. Nested PCR was used for the analysis of concentrated stool extracts 
from all 76 patients and all 76 controls. An amplification product was visualized by gel 
electrophoresis in one sample from a patient with CFS and in no samples from controls; 
the single positive result was confirmed by Southern blot hybridization (figure 4). The 
patient for whom this result was obtained had a negative result in the VP-1 antigen test 
and in serological tests. No enteroviral RNA was detected in a second stool specimen 
obtained from this patient 3 months later. 
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Lane 7 depicts diethyl pyrocarbonate-treated water; lane 8, coxsackievirus Bl RNA positive 
control; lane 9, coxsackievirus Bl cDNA positive control; and lane 10, size marker, pBR322 
digested with Hinñ. The larger fragments in lanes 1, 8 and 9 are the results of amplification 
with primers 1 and 4. Arrows indicate the 155-bp fragment specific for amplification of 
enterovirus. 
Isolation of virus from stool specimens. All direct cultures of stool for enteroviruses 
gave negative results. Acid elution with subsequent culture was undertaken for 23 patients 
and 22 controls who had either a high antibody titer (i.e., a titer higher than those of 95% 
of healthy blood donors), or a positive result in the VP-1 antigen test; for the patient with 
a positive PCR result; and for a randomly selected group of 22 of the remaining 52 
patients. The virological findings for these patients are presented in table 2. No virus was 
isolated. 
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Discussion 
To investigate the possible role of enteroviral persistence in CFS, we examined serum 
and stool specimens from 76 patients with CFS and 76 controls matched for gender, age, 
and neighborhood. (We used neighborhood controls to correct for the potential effects of 
local epidemics of infection due to enteroviruses.) We found no differences between 
patients and controls in either the prevalence or the titer of enteroviral antibodies, whether 
assayed by the CF test or by an antibody-capture ELISA broadly reactive with different 
serotypes [10]. These results are in agreement with those of Miller et al. [8], who found 
no difference between the IgM and IgG serum antibody titers of patients with CFS and 
those of controls. Like Lynch and Seth [6] and Halpin and Wessely [7], we failed to find 
differences in the prevalence of VP-1 antigen in serum samples from patients and 
controls. These results are in contrast to those obtained by Yousef et al. [1], who found 
VP-1 antigen in the serum of 44 of 87 patients with postviral fatigue syndrome (PVFS), 
but in no serum samples from controls. 
Enteroviral RNA was detected by PCR in a concentrated stool specimen from only 
one patient with CFS and in no such specimens from controls. A stool sample obtained 3 
months later from the patient with a positive result was negative for enteroviral RNA. 
Several research groups have shown that the limit of detection of enteroviruses in fecal 
samples by PCR is as low as 1 pfu [18, 19]. The sensitivity of the PCR technique 
described by our group [15] was found to be as low as 10 genome equivalents in a model 
system but was approximately 20 pfu in biological samples. Use of nested PCR increased 
the sensitivity to <1 pfu [20, 21]. However, we and other investigators [21, 22] have 
found that fecal samples may inhibit the reverse-transcription or the amplification step. 
Negative PCR results for fecal samples should therefore be interpreted with caution. 
After an acid dissociation step, Yousef et al. [1] isolated enteroviruses from stool 
specimens from 17 of 76 patients with PVFS; these patients' direct cultures had been 
negative. However, we isolated no enterovirus from stool specimens from 46 selected 
patients and 22 selected controls by the same technique. Even the patient with a positive 
PCR result had a negative culture after acid elution. Thus, either the enterovirus involved 
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in this infection is difficult to isolate in cell culture, or PCR is generally more sensitive 
than culture after acid elution. Consistent with a low incidence of enteroviral infections in 
the winter, all direct cultures were negative. 
Several investigators have found enteroviral RNA sequences in muscle-biopsy 
specimens from patients with PVFS [2-4]. In these studies PVFS was defined as severe 
fatigue starting after an acute episode of an apparently viral illness and lasting for > 1 
year [1-4] without laboratory evidence of an initial infection as required by the definition 
of Sharpe et al. [17]. In cooperation with Drs. J.W. Gow and P.O. Behan (Department of 
Neurology, Southern General Hospital, Glasgow, United Kingdom), we recently tested 
muscle-biopsy specimens from their patients with PVFS and from controls. We detected 
enteroviral RNA in several samples. However, the significance of such findings is 
difficult to interpret since not only patients but also a number of controls had positive 
results ([4] and authors' unpublished results). The discrepancy between the latter findings 
and those obtained in the study reported herein may be explained by epidemiological 
differences in viral incidence between the United Kingdom and the Netherlands. 
Alternatively, it may reflect differences in methods of patient selection and in case 
definition. 
We used the case definition of CFS on which consensus has been reached in the 
United Kingdom [17]; this definition is different from that of PVFS. Still, 66% of our 
patients reported an acute onset of their symptoms after an infectious illness and would 
qualify as having PVFS as defined by Yousef et al. [1] and Gow et al. [4]. The only 
difference between our patients and those in the studies from the United Kingdom is the 
longer average duration of illness in the former. It is unlikely that this difference accounts 
for the negative results obtained in our study, however, because there was a considerable 
overlap in the duration of illness documented in the three studies. There was no 
correlation between the duration of symptoms or the acute onset of symptoms and the 
outcome of virological tests in our study. Gow et al. found no correlation between the 
duration of PVFS and PCR positivity [4]. A similar discrepancy is apparent in the 
incidence of enteroviruses in association with the inflammatory myopathies polymyositis 
and dermatomyositis: investigators in the United Kingdom have reported the persistence 
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of enteroviruses in patients with these conditions [3, 23, 24], whereas researchers from 
other geographic areas (including our group in the Netherlands) have been unable to 
detect enteroviral RNA in muscle-biopsy specimens from these patients [25-27]. 
In summary, we conclude that persistence of enteroviruses is unlikely to play a role 
in the development of CFS. 
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EBV and the Chronic Fatigue Syndrome 
Abstract 
The etiology of chronic fatigue syndrome (CFS) is unknown. Some patients have high 
antibody titers to viral capsid antigen (VCA) and early antigen (EA) of Epstein-Barr virus 
(EBV), suggesting that reactivation of EBV is involved. We investigated virus load 
(spontaneous transformation) and immunological regression of EBV-induced trans-
formation in peripheral blood mononuclear cells (PBMCs) from 10 selected patients with 
CFS who had high antibody titers to VCA and EA. The outcome was compared with that 
for nine healthy controls and one patient with severe chronic active EBV infection 
(SCAEBV). There were no significant differences in viral load between patients and 
healthy controls. Immunological regression of in vitro-transformed PBMCs was also 
equally efficient in patients and controls. The SCAEBV-infected patient and two controls, 
who were all seronegative for EBV, showed impaired regression. In conclusion, we were 
unable to demonstrate a role for reactivation of EBV in CFS, even in selected patients 
with high titers of antibody to VCA and EA of EBV. 
Introduction 
Chronic fatigue syndrome (CFS) is claimed to be often precipitated by an acute 
infection. Research into the potential viral causes of CFS has concentrated on herpes-
viruses, enteroviruses, and retroviruses. Of the herpesviruses, Epstein-Barr virus (EBV) 
has received particular attention. Higher-than-expected IgG titers to the viral capsid 
antigen (VCA) and early antigen (EA) of EBV (EB-VC A and EB-EA), and low titers or 
absence of antibodies against the nuclear antigen of EBV (EB-NA) have been described 
[1, 2]. However, similar antibody profiles have occasionally been found for healthy adults 
[3-5], but this would still not rule out a role for EBV in a subgroup of patients with these 
antibody profiles. Persistent viral activity or reactivation may be the consequence of 
impaired cellular immunity, as has been reported in patients with CFS [6-9]; impairment 
of cellular immunity provides the opportunity for viral reactivation, boosting virus-
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specific responses. Sumaya [4] and Jones [5] have both noted that spontaneous EBV-
induced proliferation of peripheral blood mononuclear cells (PBMCs) occurs more readily 
in patients with chronic fatigue (27% and 30%, respectively) than in healthy controls (6% 
and 5%, respectively). This would indicate that suppression of circulating EBV-
transformed В cells may be diminished in patients with CFS. To further explore the 
potential role of EBV, we investigated the load of replicating EBV, and regression of 
EBV-transformed colonies in a selected group of patients with CFS who had high 
antibody titers to EB-VCA or EB-EA. 
Materials and methods 
Subjects. From a cohort of 88 patients with CFS and 76 controls matched for gender, 
age, and geographical area, we selected 10 patients with high titers of EB-VCA IgG 
( à 128) or EB-EA IgG (>32). Such titers were found for <5% of 200 healthy blood 
donors (figure 1) but for 12% of the CFS patients. All patients fulfilled the criteria for 
CFS described by Sharpe et al. [10]. Patients were compared with their matched controls. 
Characteristics of patients and controls are summarized in table 1. For comparison, a 23-
year-old woman with severe chronic active EBV infection (SCAEBV) was simultaneously 
tested. Her disease was in a stable phase (4 years after onset), and she was receiving 
maintenance treatment with acyclovir at a dose of 800 mg/day. This patient had 
persistently high antibody titers to EB-VCA and EB-EA (table 1). 
Immunofluorescence tests. Antibodies to EB-VCA and EB-EA were detected by 
indirect immunofluorescence on HH514 cells, a subclone of P3HR1, originating from Dr. 
G. Miller (Yale University School of Medicine, New Haven, CT). In our laboratory, 
HH514 cells are used for routine diagnostic tests on EBV-VCA and EB-EA, and we find 
that the results of immunofluorescence tests on these cells easy to interpret, although 
antibody titers are usually 10 times lower than those obtained by fluorescence on P3HR1 
cells. We tested serum samples of 200 healthy blood donors to obtain reference titers, 
which are depicted in figure 1. Raji cells were used for anti-complement immunofluores-
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cence determination of antibodies to ЕВ-NA as described before [3]. 
Spontaneous transformation. Venous heparinized blood (40 mL) was drawn from 
patients and controls, and peripheral blood mononuclear cells (PBMCs) were isolated by 
buoyant density centrifugation on Ficoll/Hypaque (Pharmacia, Uppsala, Sweden). The 
transformation assay was performed essentially as described by Rickinson et al. [11] with 
use of cyclosporin A to inhibit Τ cell function. Six repetitive wells of a 96-well flat-
bottommed microtest plate (Costar Europe, Cambridge, United Kingdom) were seeded 
with PBMCs at twofold dilutions ranging from 1 χ IO6 to 1.5 χ IO4 cells per well. Plates 
were incubated at 37°C in a humidified atmosphere containing 5% C0 2 . At weekly 
intervals, half of the medium was replaced by fresh culture medium and the cultures were 
observed for the occurrence of transformation. 
Regression assay. The regression assay was also performed as described by Rickinson 
et al. [11]. PBMCs were incubated with 2 mL of supernatant from B95-8 cells containing 
104 trans-forming units of EBV per milliliter. Cultures were maintained by regular 
refeeding during a 6-week period, and they were observed throughout that period for the 
incidence of virus-induced transformation and subsequent regression. The regression was 
expressed in terms of the minimum initial cell number required per well for a 50% 
incidence of regression, as calculated by the Reed and Muench formula [12]. 
Results and discussion 
Spontaneous transformation. The results of the transformation assay of samples from 
patients and controls are depicted in figure 2, A. In contrast to earlier reports in the 
English-language literature, PBMCs from patients with CFS did not show increased 
transformation compared with those of healthy controls (median, < 1 per 106 cells for 
both patients and controls). However, high numbers of transforming PBMCs were found 
in the patient with SCAEBV infection (1 per 3.6 χ IO4 cells). The inherent problem that 
leads to SCAEBV is unknown but the manifestations of this infection are suggestive of an 
abnormal vims-host interaction of a serious magnitude. The symptomatology is grossly 
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Figure \.A: Distribution of titers against viral capsid antigen of Epstein-Barr virus among 200 
healthy blood donors determined with use of indirect immuno-fluorescence on HH514 cells. 
B: Distribution of titers against early antigen of Epstein-Barr virus among 200 healthy blood 
donors determined with use of indirect immunofluorescence on HH514 cells. 
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Figure 2. Results of transformation and regression assays for patients with CFS and controls. 
A: Minimum cell number in which at least 50% of the cultures showed transformation. О = 
patient with severe chronic active Epstein-Barr virus infection. B: Minimum cell number 
needed for regression of EBV-transformed PBMCs in 50% of the cultures. О = patient with 
severe chronic active EBV infection. 
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different from that of CFS [13]. 
Regression assay. Regression of EBV-transformed cells was measured to estimate 
cell-mediated resistance to EBV. We found that PBMCs from patients with CFS and 
healthy controls showed an equal capacity to cause regression of EBV-transformed blasts 
in vitro, indicating normal cellular resistance to EBV in both groups (figure 2, B). Thus 
high antibody levels per se are not indicative of viral load or diminished immune 
surveillance to EBV. (We did not observe regression in two controls who were 
seronegative for EBV.) Regression started 3-4 weeks after the assay was started and was 
usually complete within 6 weeks. These findings differ from those of Borysiewicz et al. 
[14], who described four patients with persistent fatigue for whom reduced capacity in the 
regression assay was found. We did not observe regression of EBV-transformed В cells in 
the patient with SCAEBV infection, a finding consistent with impairment of cellular 
immunity towards EBV. 
This study provides further evidence that EBV does not play a causative role in CFS 
in the patients we studied. Although the possibility that EBV plays a role in a select group 
of patients with CFS cannot be excluded, we do not think that reactivation of EBV plays 
a causative role in the majority of cases of CFS. 
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Yersinia enterocolitica and CFS 
Abstract 
Chronic fatigue syndrome (CFS) is a clinically defined condition for which the 
etiology is unknown. One of the hypotheses is that CFS is the result of a persistent 
infection. Many patients report symptoms that can also be found in patients with 
persistent Yersinia infection. In this study, the potential role of Yersinia enterocolitica was 
investigated in patients with CFS compared to matched healthy controls, using an 
immunoblot technique. The prevalence of IgG and IgA antibodies to various Yersinia 
outer membrane proteins (YOPs) did not differ between patients with CFS and healthy 
controls. Although all patients with positive IgG and IgA reactions to two or more YOPs 
had symptoms that could point to persistent Yersinia infection, these symptoms were also 
found frequently in patients without antibodies to YOPs. We conclude that Y. entero-
colitica is unlikely to play a major role in the etiology of CFS. 
Introduction 
Chronic Fatigue Syndrome (CFS) is a clinically defined condition characterized by 
severe disabling fatigue of definite onset, lasting for more than 1 year, and for which no 
explanation has been found [1, 2]. The fatigue is often accompanied by a variety of 
nonspecific symptoms and signs. So far, the etiology of CFS is unknown. Because some 
of the symptoms resemble those caused by an infection, and many patients report that the 
onset of symptoms followed a "flu-like" episode, one of the hypotheses on the etiology of 
CFS is that CFS is the result of a persistent infection. Many pathogens have been 
implicated as the cause of CFS, but so far none have been proven to be the responsible 
agent [3-5]. Many patients with CFS report gastrointestinal complaints, arthralgia, 
lymphadenopathy and recurrent fever, symptoms that can also be found in patients with 
persistent yersinia infection. In this study we used a highly specific immunoblot technique 
[6, 7] to investigate a potential role of Yersinia enterocolitica in patients with CFS by 
comparison of the data in patients to those in healthy matched neighbourhood controls. To 
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our knowledge this is the first paper studying the possible relation of Yersinia enteroco-
litica infection and CFS. 
Materials and Methods 
Subjects. Eighty-eight patients with CFS and 77 healthy neighbourhood control 
subjects, matched for gender, and age, were included in the study. This patient group has 
been described in detail previously [3]. All patients met the criteria for CFS as delineated 
recently by Fukuda et al. [2]. All patients were invited to visit our outpatient clinic for a 
detailed medical history as well as a physical examination. Blood samples were taken for 
complete blood cell counts, a serum chemistry panel, and serological tests on a panel of 
infectious agents [3]. When no abnormalities were found, patients were asked to visit our 
clinic again after three months and to bring with them a healthy non-fatigued neighbour­
hood control, matched for gender and age. Seventy-seven patients were able to do so. 
Neighbourhood controls were used to correct for geographically determined variations in 
exposure. Venous blood was drawn from both patients and controls for a complete blood 
cell count, differential count, C-reactive protein and serological tests. The study was 
approved by the ethical committee of our hospital. Both patients and controls signed an 
informed consent. 
Immunoblot. Purified plasmid-encoded virulence-associated Yersinia outer membrane 
proteins (YOPs) of Y. enterocolitica serotype 08 (strain WA-314; Dr. С Pai, Montreal 
Canada) were used as antigens. Purification and Western blotting of YOPs have been 
described before [7]. The following antigens could be detected: the 25 kDa protein (YOP 
E), the 36 kDa protein (YOP D), the 38 kDa protein (V-antigen), the 46 kDa protein 
(YOP H) and the 58 kDa protein (YOP M) [8]. Serum samples were diluted 1:100 in 
phosphate buffered saline containing 0.5% Tween-20 and were incubated with antigen-
coated nitrocellulose strips overnight at room temperature. The IgG and IgA antibody-
antigen complexes were visualized using alkaline phosphatase conjugated anti-IgG and 
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Ig A respectively as previously described [9]. Serum taken from patients with culture 
positive Yersinia enterocolitica infection was used as a positive control in each test run. 
Positive reaction in immunoblotting with at least two antigens was judged significant. 
When only IgG antibodies were detected, this was considered to be based on contact with 
Yersinia enterocolitica in the past. When both IgG and IgA were present, this was 
considered compatible with a recent or persistent Yersinia infection. 
Results 
Subjects. All patients complained of severe debilitating fatigue of at least one year 
duration, for which no explanation was found in previous medical investigations. Median 
duration of symptoms was 7 years (range 2-45 years). Thirty-four patients (39%) 
complained of gastrointestinal problems (predominantly abdominal pain, abnormal stools), 
39 patients (44%) reported arthralgia, and 12 patients (14%) reported recurrent 
lymphadenopathy or fever. The mean age of the patients was 40 years (range 20-60 
years), the male-to-female ratio was 1:3. 
Physical examination revealed no abnormalities in patients or controls. No sign of 
arthritis was found in any of the patients. Temperature was normal in all patients and 
Table 1. Distribution of IgG and IgA antibodies to the different YOPs of Y. enterocolitica in 
patients with CFS and healthy controls. 
No. positive 
CFS patients 
IgA (л = 13) 
IgG (л = 24) 
Controls 
IgA (л = 17) 
IgG (n = 19) 
YOPE 
4 
11 
4 
8 
YOPE 
11 
22 
11 
14 
V-antigen 
4 
16 
8 
13 
YOPH 
6 
14 
10 
11 
YOPM 
5 
16 
8 
9 
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lymphadenopathy could not be objectivated. Orientating chemical, haematological and 
virological laboratory tests were not different between patients and controls and did not 
yield evidence for (chronic or active) infection [3-5]. 
Immunoblot. Twenty-four patients (27%) and nineteen controls (25%) had IgG 
antibodies to one or more YOPs (see table 1 for distribution of antibodies). Antibodies 
were most frequently directed to YOP D. Four patients and two controls had both serum 
IgG and IgA antibodies to at least two different YOPs, compatible with a recent or 
persistent infection (table 2). One of these patients (patient 2) seroconverted at time of the 
study: the first serum sample revealed no antibodies to Yersinia, whereas in the second 
serum sample IgG and IgA antibodies were found to all the YOPs tested. Unfortunately 
stool cultures from this patient were not available. In all patients with IgG and IgA class 
antibodies against two or more YOPs, symptoms that could point to persistent yersiniosis 
(arthralgia, abdominal pain, lymphadenopathy, and fever) were present. However, these 
symptoms were also frequently reported by patients without antibodies to YOPs (see table 
3). The two controls who had significant IgG and IgA antibodies to Yersinia were 
asymptomatic. 
Table 3. Relation of symptoms that can be found in persistent yersiniosis and IgG and IgA 
antibodies to YOPs in patients with CFS and healthy controls. 
Symptoms 
arthralgia 
abdominal pain 
lymphadenopathy 
fever 
CFS 
anti-YOPs 
2 
1 
2 
0 
patients (n =  88) 
no anti-Yops 
37 
33 
10 
7 
Controls (n=77) 
anti-YOPs 
0 
0 
0 
0 
no anti-YOPs 
4 
6 
0 
0 
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Discussion 
Yersinia enterocolitica usually causes a mesenteric adenitis, although extramesenteric 
manifestations such as reactive arthritis and erythema nodosum occur in 20-25% of 
patients with yersinia infection [10-12]. Y. enterocolitica is known to be able to persist in 
the gut associated lymphatic tissue (GALT) and to cause a variety of symptoms among 
which fever, malaise, abdominal pain, arthralgia, and recurrent lymphadenopathy [8, 10-
14]. In the chronic phase, stool cultures are usually negative [10-15]. The serum 
agglutination test is of limited value because of cross-reactions and false negative 
reactions [6, 11, 12, 15]. Diagnosis of persistent yersiniosis has become possible mainly 
through detection of specific IgG and IgA antibodies to Yersinia outer membrane proteins 
(YOPs). Demonstration of circulating IgG and IgA antibodies to YOPs have proven to be 
more sensitive and highly specific for Yersinia infections [6, 12, 14, 15]. Presence of IgG 
antibodies to YOPs alone suggest Yersinia infection occurring in the past. The presence of 
IgA (beside of IgG) antibodies to YOPs are indicative of recent or persistent Yersinia 
infection. In this study, the prevalence of IgG antibodies to YOPs did not differ between 
patients and controls (Mann-Whitney U: ρ>0.05) and was similar to the prevalence of 
IgG against YOPs in sera from healthy blood donors [16]. In previous reports IgG and 
IgA antibodies to YOP D and YOP Η were claimed to be associated with the chronic 
phase of the infection [12, 16, 17], whereas IgG and IgA antibodies to YOP E and YOP 
M (usually combined with antibodies to the YOP D and YOP H) are found in the acute 
phase of infection [12, 16]. We detected IgG and IgA antibodies directed to the YOP D 
and YOP H in serum from 2 patients with CFS and in serum from one healthy control 
(see table 2). In these patients IgG and IgA antibodies were detected in both serum 
samples that were taken with a 3 month interval, suggesting persistent infection. In one 
patient a seroconversion for Yersinia was noted. As this patient reported to have CFS 
since 15 years, the recent Yersinia infection was probably just coincidental. In one control 
subject antibodies to YOP D and YOP H were found, which could possibly indicate 
persistent infection. However, as we had only one serum sample from the control 
subjects, this could not be confirmed. 
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Symptoms that are frequently found in persistent yersiniosis, such as arthralgia and 
abdominal pain, were present in 44 and 39% of patients with CFS respectively, and in S 
and 8% of the control subjects respectively. Although all patients with positive IgG and 
IgA immunoblotting reactions to two or more YOPs had symptoms that could point to 
persistent yersiniosis, these symptoms were also frequently found in patients without 
antibodies to the YOPs. Thus, presence of these symptoms poorly correlated with 
antibodies to Yersinia enterocolitica. 
In conclusion, the presence of IgG and IgA antibodies to the various YOPs were not 
different between patients with CFS and healthy controls. Symptoms that are 
characteristic for yersiniosis correlate poorly with presence of antibodies to YOPs in 
patients with CFS. Although we found serological evidence for persistent yersiniosis in 
occasional CFS patients, Yersinia enterocolitica infection is unlikely to play a major role 
in the pathogenesis of CFS. 
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Lymphocyte subsets and cytokines in CFS 
Abstract 
Whether immunologic abnormalities correlate with fatigue severity and functional 
impairment in chronic fatigue syndrome (CFS) was investigated. Blood mononuclear cells 
were immunophenotyped and circulating and ex vivo-produced cytokines were measured 
in 76 CFS patients and 69 healthy matched controls. Expression of CDllb on CD8+ cells 
was significantly decreased in CFS patients. However, the previously reported increased 
expression of CD38 and HLA-DR was not confirmed. There was no obvious difference in 
apoptosis in leukocyte cultures, circulating cytokines, and ex vivo production of 
interleukin (IL)-la and IL-1 receptor antagonist. Endotoxin-stimulated ex vivo production 
of tumor necrosis factor-α and IL-Iß was significantly lower in CFS. The immunologic 
test results did not correlate with fatigue severity or psychologic well-being as measured 
by Checklist Individual Strength, Beck Depression Inventory, and Sickness Impact 
Profile. Thus, these immunologic tests cannot be used as diagnostic tools in individual 
CFS patients. 
Introduction 
Chronic fatigue syndrome (CFS) is characterized by severe disabling fatigue, lasting 
for >6 months, for which no explanation has been found. The fatigue is often 
accompanied by a variety of nonspecific symptoms and signs [1]. Although the etiology 
and pathogenesis of CFS are unknown, several studies have found a variety of 
immunologic abnormalities, including decreased NK cell cytotoxicity [2-4], reduced 
mitogenic response of lymphocytes [3, 5, 6], increased expression of activation markers 
[3, 4, 7], and altered cytokine production [3, 6, 8]. However, since most of the changes 
are rather subtle, the pathophysiologic significance and the relation with clinical 
symptoms or disease severity remain unclear. Reports in the literature show conflicting 
results, probably due to methodologie problems or patient selection. Of special concern is 
the selection of control groups. In many cases, these are laboratory controls and are often 
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not concurrently tested. Cytokine studies also lack standardization. Therefore, the data 
from the literature cannot easily be compared and interpreted. 
The present study analyzed immunophenotypes peripheral blood mononuclear cells 
(PBMC) from 76 patients with CFS and 69 simultaneously studied healthy controls 
matched for sex, age, and neighborhood. We also measured circulating cytokines and ex 
vivo production of proinflammatory cytokines by using a whole blood culture system that 
does not require isolation of PBMC and probably more closely resembles the in vivo 
situation [9]. The aim of this study was to investigate whether previously reported 
immunologic abnormalities could be found in a randomly chosen group of patients with 
CFS compared with well-matched controls. An additional goal was to correlate 
immunologic abnormalities with fatigue severity, functional impairment, and psychologic 
well-being. 
Materials and Methods 
Subjects. Seventy-six patients and 69 healthy controls matched for sex, age, and 
neighborhood, were included in the study. As described before, patients were randomly 
chosen from a data base of 298 patients with CFS using a table of random numbers [10]. 
This larger patient group, which was self-referred, is described in detail by Vercoulen et 
al. [11]. AU patients complained of severe debilitating fatigue lasting at least one year that 
impaired both physical and mental functioning and for which no explanation was found in 
previous medical investigations. All patients met the criteria for CFS delineated by Sharpe 
et al. [1]. The median duration of symptoms was 7 years (range, 2-45). The mean age of 
the patients was 40 years (range, 20-60), and the male-to-female ratio was 1:3. The 
selected patients were invited to visit our outpatient clinic for a detailed medical history 
and a physical examination. Fatigue, depression, and psychologic well-being were 
assessed by the Checklist Individual Strength (CIS), Beck Depression Inventory, and 
Sickness Impact Profile as previously described [11]. Blood samples were taken for com-
plete blood cell counts, a serum chemistry panel, and serologic tests [10]. When no 
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abnormalities were found, patients were asked to visit our clinic again after 3 months and 
to bring with them a healthy nonfatigued neighborhood control, matched for sex and age. 
Sixty-nine patients were able to do so. Neighborhood controls were not only used to 
control for age and sex but also for duration and stress of traveling and time of blood 
sampling. Both patients and controls were asked to stop all medication (especially 
analgesics) and were asked not to use alcohol for at least 48 h before testing. To avoid 
the possible confounding effect of diurnal and seasonal variation, venous blood samples 
were collected from patients and controls between 8:30 and 11:00 a.m. on the same day. 
Plasma Cortisol concentrations were measured in both patients and controls. The study 
was approved by the ethical committee of the hospital. Informed consent was obtained 
from all patients and healthy controls. 
Immunophenotyping and apoptosis. Venous blood (4 mL) was taken in an EDTA-
containing tube for white blood cell and differential counts. Heparinized blood was drawn 
for lymphocyte immunophenotyping by flow cytometry with dual-color direct and indirect 
immunofluorescence [7, 12]. Monoclonal antibodies (MAbs) were used to identify the 
following cell subsets: CD4, CD8, CD 19, CD8CD28, CD8CD56, CD8CDllb, 
CD8CD38, and CD8HLA-DR (Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Service and Becton Dickinson Immunocytometry Systems, San Jose, CA). 
Apoptosis experiments were done as described [13] and simultaneously with the other 
immunologic tests on 4 consecutive days in cultured cell samples from 9 patients with 
CFS and their matched controls. In brief, PBMC were isolated by ficoll-isopaque density 
centrifugation from heparinized blood and cultured in the absence and presence of CD3 
MAbs. Percentages of apoptotic cells were determined by in situ nick translation as 
described [13]. Positive controls included in these experiments were samples from human 
immunodeficiency virus-positive patients. 
Cytokine production. Blood samples for cytokine measurements were collected into 4-
mL endotoxin-free EDTA tubes (Vacutainer; Becton Dickinson, Rutherford, NJ). The 
plasma was immediately processed to avoid ex vivo cytokine production and release. 
151 
Chapter 9 
Cytokine production was measured using a whole blood culture system as described 
elsewhere [9]. Interleukin (IL)-la, IL-lß, IL-1 receptor antagonist (IL-1RA), and tumor 
necrosis factor-α (TNF-a) were measured with an RIA as described [9]. IL-la was also 
measured with an ELISA (provided by J.J. Castracane, Endogen, Boston). Transforming 
growth factor-B (TGF-ß) was measured with a bioassay as described [6] and with an 
immunoassay (Quantikine; R & D systems, Minneapolis). Active TGF-ß was measured in 
serum; then total TGF-ß was measured after addition of acetic acid and urea, which 
release latent TGF-ß from the latency-associated peptide. The sensitivities of the assays 
were as follows: IL-la, 5 pg/mL (RIA) and 13 pg/mL (ELISA); IL-lß, 20 pg/mL; IL-
1RA, 50 pg/mL; TNF-a, 40 pg/mL; TGF-ß, 200 pg/mL (bioassay), 300 pg/mL (total 
TGF-ß, immunoassay), and 125 pg/mL (active TGF-ß, immunoassay). In each assay, 
reference samples with known concentration of cytokines were tested concurrently. 
Patients and controls were tested simultaneously to correct for intertest variability. 
Statistical analysis. Since cytokines and cell-markers are known to have a non-
Gaussian distribution, we used the Wilcoxon signed rank test to evaluate differences 
among cytokine production and Τ cell subsets between patients and controls. We used 
Spearman's rho to test for correlation between cytokine production, immunophenotyping 
analysis, and clinical symptoms such as fatigue and depression. 
Results 
Immunophenotyping. Absolute lymphocyte counts were similar for patients with CFS 
(1685 ± 626/mL) and controls (1698 ± 464/mL). The total numbers of CD2+ (total T), 
CD4+ (helper/inducer), CD8+ (suppressor/cytotoxic), and CD19+ (total B) lymphocytes 
did not differ between CFS patients and controls. The proportion of CD8+ cells 
expressing CD lib (suppressor Τ cell) was significantly decreased in patients with CFS 
compared to controls (p < .05; figure 1). We did not find increased expression of 
activation markers CD38 and HLA-DR on CD8+ cells, nor did we find a significantly 
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Percent of lymphocytes 
CD11b CD28 CD38 CD56 
Figure 1. Expression of CDllb, CD28, CD38, CD56, and HLA-DR on CD8+ 
cells. Boxes show 25th and 75th percentiles with median; whiskers indicate 
range. *p < .05. 
altered expression of CD28 (p = .054). There was reduced expression of CD56 on 
CD8+ cells, but this was significant only after one-tailed testing (p < .05). Taken 
together, these findings indicate expansion of the cytotoxic Τ lymphocyte population with 
concomitant decrease of the suppressor Τ lymphocyte population. Percentages of apoptotic 
cells after overnight culture with or without stimulation with CD3 MAb were not different 
in patient and control samples (data not shown). 
Cytokine production. Circulating concentrations of IL-la, IL-lß, TNF-α and IL-1RA 
and unstimulated cytokine production did not differ between patients and controls (data 
not shown). As is shown in figure 2, TNF-α and IL-lß production after stimulation with 
lipopolysaccharide (LPS) was significantly lower in CFS patients than in their matched 
healthy controls (p < .01 and ρ < .05, respectively). Although this difference was 
statistically significant, there was a large overlap between patients and controls. No 
differences were found in circulating total TGF-fl as measured by immunoassay (1.25 ± 
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ng/mL 
25 
16 
10 
Ш • 
• CFs 
S Control 
IL-18 TNF-a IL-1RA IL-1a 
Figure 2. Cytokine production after lipopolysaccharide stimulation in whole 
blood culture at 24 h. Boxes show 25th and 75th percentiles with median; 
whiskers indicate range. IL = interleukin; TNF = tumor necrosis factor; RA = 
receptor antagonist. * ρ < .05; **p < .01. 
0.58 vs. 1.20 ± 0.64 ng/mL, patients vs. controls) or in TGF-ß as measured by bioassay. 
The concentration of active TGF-ß on immunoassay was below the detection limit for all 
patients and controls. Plasma Cortisol concentrations were similar for patients and controls 
(0.36 ± 0.22 vs. 0.30 ± 0.14 mg/mL, respectively). 
Circulating cytokine concentrations correlated well with concentrations found in 
unstimulated whole blood cultures: IL-la r = 0.96; IL-lß r = 0.69, TNF-α r = 0.45; 
IL-1RA r = 0.74 (p < .001 for all). This is explained by the presence of these cytokines 
in plasma and the virtual absence of ex vivo cytokine production in the absence of a 
stimulus such as LPS. There was a low correlation between LPS-induced production of 
IL-lß and IL-la (r = 0.47, ρ < .001), IL-lß and TNF-α (r = 0.26, ρ < .05), and IL-
lß and IL-1RA (r = 0.25, ρ < .05). No correlation was found between cytokine 
production and expression of activation markers. The average level of fatigue using the 
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CIS rating scale (range, 1-7) was 5.8 (1.1 SD) for CFS patients and 1.8 (0.9 SD) for 
healthy controls (p < .001). However, in patients with CFS, we found no correlation 
between CIS-subscale fatigue and LPS-stimulated production of cytokines. 
Discussion 
The data presented here are consistent with those of some previous reports [4, 7, 14] 
but contrast with others [6, 8, IS]. This may be due to patient selection, choice of control 
group, and differences in methods of assessment. We included self-referred patients in 
this study to avoid selection bias that is encountered when only patients referred to an 
infectious disease outpatient clinic are investigated. For the same reasons, we did not 
select by symptoms or previously detected laboratory abnormalities. For controls, we 
asked patients to bring a healthy nonfatigued neighborhood control, matched for sex and 
age. By doing this, we avoided confounding effects such as duration and stress of 
traveling and corrected for unknown effects (e.g., environmental pollution). Furthermore, 
we used a whole blood culture system to measure cytokine production. This was done for 
practical convenience, but in addition, the method may reflect the in vivo situation more 
closely since manipulation, prestimulation, and possible selection of PBMC are 
minimized, and the role of plasma factors is included. 
Previous studies have shown a good correlation between IL-lß, IL-1RA, and TNF-a 
production in whole blood cultures and in isolated mononuclear cell cultures [16, 17]. In 
contrast to the results of Chao et al. [6], we found significantly decreased IL-lß and 
TNF-o production after LPS stimulation of peripheral blood cells. However, they 
separated the cells and did not add autologous plasma. Taken together, it can be 
hypothesized that plasma factors that inhibit cytokine production occur in CFS. Several 
inhibitory factors could be responsible for this. An increased concentration of TGF-ß, as 
found by Chao et al. [6], could explain the results, as TGF-ß is known to inhibit 
production of proinflammatory cytokines [6]. However, our finding that serum TGF-ß 
concentrations were similar in patients with CFS and concomitant controls does not 
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support this view. As plasma Cortisol measurements were normal, it seems unlikely that 
glucocorticosteroids inhibited the production of proinflammatory cytokines. Inhibitory 
cytokines, such as IL-4 and IL-10, or mediators, such as prostaglandins, could play a 
role. Further studies are underway to elucidate this issue. In contrast to others [8, 14, 
IS], we did not find increased concentrations of circulating IL-la. 
We did find decreased expression of CDllb on CD8+ cells, probably indicative of in 
vivo activated CD8+ Τ cells. This was also reported by Landay et al. [7] and Barker et 
al. [4]. We could not, however, detect significant differences in the expression of CD38 
and HLA-DR, which have been reported to be elevated in patients with CFS [4, 7]. Since 
we did not find a correlation between high scores on the CIS fatigue questionnaire and 
CD8 cell subsets (CDllb', CD38, and HLA-DR), we doubt whether alterations in these 
subsets are indicative of having active CFS, as has been suggested [7]. We considered the 
possibility that in patients with CFS, a state of immune activation could lead to 
programmed cell death. In apoptosis experiments in 9 patients and their matched controls, 
there was no obvious difference in the percentages of cells dying due to programmed cell 
death (data not shown). Therefore, our data do not support the hypothesis that patients 
with CFS have a state of immune activation. 
Our results show that subtle immunologic abnormalities can be detected in a 
randomly selected group of patients with CFS compared with a matched control group. 
However, since there is a wide range in the outcome of the immunologic tests used in this 
study, and because we did not find a significant correlation between symptoms and the 
outcome of these tests, the meaning of these findings is still unclear. It is clear that 
immunophenotyping of lymphocytes or assessment of cytokine production can be used 
neither to confirm nor to reject the diagnosis of CFS in an individual patient, nor to 
assess severity of illness. 
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Summary and general discussion 
Summary 
Chronic fatigue syndrome (CFS) is characterized by severe disabling fatigue of at 
least 6 months' duration, that has led to considerable impairment in daily functioning, and 
for which no explanation has been found. Usually the fatigue is accompanied by a number 
of aspecific complaints such as myalgia, concentration problems, and impaired cognition. 
Physical examination and laboratory tests reveal no abnormalities. The etiology of CFS is 
unclear. The studies that are described in this thesis, were performed to obtain more 
insight in the clinical, microbiological and immunological aspects of CFS. 
In chapter 2, an overview of the somatic and psychological hypotheses is given that 
have been proposed in the literature as possible explanations for the etiology of CFS at 
the start of our studies. 
In chapter 3, we have tried to find an answer to the question which instruments can 
be used to measure different aspects of the subjective complaints of CFS. Postal 
questionnaires were sent to 298 patients with CFS. Statistical analysis identified nine 
dimensions that measure emotional, behavioural, cognitive, and social functioning. These 
dimensions are: psychological well-being, functional impairment in daily life, sleep 
disturbances, avoidance of physical activity, neuropsychological impairment, causal 
attributions related to the complaints, social functioning, self-efficacy expectations, and 
subjective experience of the personal situation. These dimensions proved to be relatively 
independent, which means that each dimension provides a unique contribution to the 
description of the patients. Several instruments were described that can be used in the 
assessment of these dimensions. The results of the various tests showed that patients with 
CFS are severely fatigued and considerably impaired by their complaints. We concluded 
that a multi-dimensional approach should be applied in the assessment of CFS. 
In chapter 4, we tried to correlate clinical symptoms with laboratory data and 
psychological parameters in patients with CFS. We noticed that there were no differences 
in the outcome of laboratory tests between patients and controls. Compared to controls, 
however, CFS patients dis show significant differences on the Checklist Individual 
Strength (CIS), Beck Depression Inventory (BDI), and Sickness Impact Profile (SIP). We 
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found that the psychological parameters of fatigue seventy (CIS), depression (BDI) and 
functional impairment (SIP) are related to the clinical severity of the complaints, and are 
valuable tools in the assessment of patients with CFS. In contrast, laboratory tests are not 
helpful in the assessment of CFS, because these tests did not discriminate between 
patients and controls. 
One of the somatic hypotheses is that CFS is the result of a persistent infection. 
Arguments in favour for this hypothesis are: the occurrence of outbreaks of CFS, the 
acute onset of symptoms after a flu-like illness. In addition, the presence of mild fever, 
nightsweats and lymphadenopathy (which is rarely if ever encountered according to our 
experience) should point to an infectious etiology. We have investigated the question 
whether there is evidence for a persistent infection in patients with CFS. The role of 
enteroviruses, Epstein-Barr virus, and Yersinia enterocolitica were studied in detail. First, 
an ELISA was developed for the detection of IgG, IgM, and IgA antibodies to 
enteroviruses (chapter 5). Serum samples from both patients and controls were tested for 
the presence of enteroviral antibodies and VP-1 antigen. In contrast to researchers from 
the United Kingdom [1], we found no differences between patients and controls in either 
presence or titer of enteroviral antibodies, and VP-1 antigen. Stool samples were 
scrutinized for the presence of enteroviruses by culture, both direct and after dissociation 
of putative immune complexes, and by PCR. We did not find evidence for persistence of 
enteroviruses in stools by culture or PCR (chapter 6). Therefore, we came to the 
conclusion that persistence of enteroviruses cannot be established in patients with CFS. 
This conclusion is further strengthened by recent work in cooperation with Dr. B. 
Evengärd (Huddinge Hospital, Stockholm). Muscle biopsy specimens from 27 Swedish 
patients with CFS were tested for the presence of enteroviral RNA by use of nested PCR. 
The biopsies were all negative for enteroviral RNA (manuscript in preparation). 
American investigators have suggested that reactivation of Epstein-Barr virus (EBV) 
could be involved in the etiology of CFS. This was based mainly on high antibody titers 
to the viral capsid antigen and early antigen of EBV, and low titers or absence of 
antibodies to the nuclear antigen of EBV [2-5]. However, similar antibody profiles have 
been described to occur occasionally in healthy adults [6-8]. In chapter 7, we investigated 
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virus load and immunologic regression of EBV-induced transformation in peripheral blood 
mononuclear cells from 10 selected patients with CFS who had high antibody titers to the 
viral capsid antigen or to the early antigen of EBV. The outcome was compared with that 
for nine healthy neighbourhood controls, matched for gender and age. There were no 
significant differences in viral load and immunologic regression between CFS patients and 
healthy controls. Thus, we could not demonstrate a role for EBV in CFS, even in selected 
patients with high antibody titers. 
As Yersinia enterocolitica is known to be able to persist in the gut associated 
lymphatic tissue (GALT) and to cause a variety of symptoms among which fever, 
malaise, abdominal pain, arthralgia, and recurrent lymphadenopathy [9-14], we 
investigated whether serological patterns compatible with persistent yersiniosis could be 
demonstrated in patients with CFS (chapter 8). We used an immunoblot technique to 
detect IgG and IgA antibodies to Yersinia outer membrane proteins (YOPs) [15, 16]. The 
prevalence of IgG antibodies to YOPs did not differ between patients and controls. In 4 
patients and in 2 controls we found serological evidence for a recent or persistent Yersinia 
infection. However, symptoms that are characteristic for persistent yersiniosis poorly 
correlated with presence of antibodies to YOPs in patients with CFS. We therefore 
concluded that Y. enterocolitica infection is unlikely to play a major role in the 
pathogenesis of CFS. 
Some researchers have put forward that an immune dysfunction results in chronically 
or intermittently active infection, that leads to an exaggerated or prolonged production of 
cytokines [17-23]. Cytokines may indeed be responsible for fatigue, fever, myalgia, sleep 
disorders, and cognitive dysfunction. In chapter 9, we investigated the hypothesis that 
CFS is caused by an immune dysfunction. We studied lymphocyte subsets, apoptosis, and 
cytokines in patients with CFS compared to their matched controls. We detected a 
significantly decreased expression of CDllb on CD8 + cells in CFS patients as compared 
to the matched neighbourhood controls. Endotoxin-stimulated ex vivo production of tumor 
necrosis factor-α and interleukin-lß was significantly lower in CFS patients. However, 
there was a wide overlap in the outcome of the immunological tests between patients and 
controls, and the immunologic test results did not correlate with fatigue severity, 
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psychological well-being, or functional impairment. Therefore, our findings do not 
support the view that CFS is an immune dysfunction syndrome. 
General discussion 
Do the studies in this thesis provide the answers to the questions that were raised in 
the introduction? I will try to go into these questions one by one. The first question about 
the assessment of CFS has been answered in chapter 3. A number of instruments has been 
described that enables us to measure the different aspects of fatigue reliably. This multi-
dimensional approach is important for studying the natural course of CFS [24], and in the 
evaluation of the effects of intervention studies. 
The question whether laboratory tests can be used as a diagnostic tool in CFS has to 
be answered with "no". Reviewing the literature, we found that the outcome of various 
laboratory studies were inconsistent (see reference 25 for overview). This may very well 
have been due to patient selection. Many of the previously reported studies were 
performed in patients that were referred to infectious disease clinics or even CFS clinics. 
This implies that these studies were probably performed in secondary, tertiary or even 
more frequently referred patients. With each referral another doctor will add his own 
(subjective) selection criteria, based on his or her cognitions about CFS (e.g. infectious 
cause). This may eventually result in a highly selected patient population. Therefore, the 
results of such studies cannot be applied to the general population of patients with CFS. 
We have tried to overcome the problem of patient selection by using self-referred 
patients, who could be expected to be more representative of the general problem. Apart 
from the selection bias due to patient referral, one can imagine that geographical and 
cultural differences may play a role too. It is striking that CFS seems to occur 
predominantly in the Caucasian population in developed countries. To our knowledge, 
there have been no reports of CFS in, for instance, black people living in Africa. This 
may be due to cultural differences (different appreciation of fatigue and illness), genetical 
differences, or it may just reflect the lack of interest in CFS or shortage of research 
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facilities in undeveloped countries. 
Additional methodological pitfalls can be found in the performance of laboratory 
tests. It is obvious that the statement 'seek and ye shall find' can be applied to a number 
of laboratory studies. When 100 laboratory tests are performed, using a 9596 confidence 
level, at least 5 tests can be expected to give a significant outcome on the basis of chance 
alone. When patients and controls are not carefully matched, there may be even more 
tests with a significant outcome. The same is true for the number of correlations being 
made. It must be stressed that concurrent sampling and testing of patient and control 
samples is as important as matching of patients and controls. We too have noted that the 
intertest variability of, for instance, immunofluorescence tests led to significant 
differences between patients and controls. After concurrent testing these differences 
disappeared. Furthermore, significant differences were found in the outcome of various 
serological and immunological tests when a healthy blood donor population was compared 
with the healthy neighbourhood controls, that were matched to the CFS patients. This 
may be due to differences in sample collection (seasonal differences, diurnal differences, 
hormonal differences), stress, travel, or even environmental differences. To avoid these 
confounding effects, we chose to ask the patients to bring with them a healthy 
neighbourhood control matched for age and gender. Patient and controls visited our 
outpatient clinic together, which enabled us to collect blood samples at the same time. 
Samples from patients and controls were tested concurrently to avoid intertest variability. 
Doing so, we were unable to reproduce the laboratory abnormalities that were previously 
described. Given the variety of infectious agents studied and the lack of evidence to 
reveal one of these agents as the causative agent, we conclude that infection alone is 
unlikely to cause or perpetuate CFS. However, infection might trigger the onset of CFS 
in addition to other factors such as psychological factors, in a susceptible host. This can 
only be studied in a prospective way. 
Dealing with the last question "Is CFS an immune dysfunction syndrome?", we have 
not been able to find arguments to support serious immune dysfunction. Although there 
were some significant differences between patients and controls, this was of no practical 
clinical importance. As there was a wide overlap between patients and controls, and the 
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outcome of the immunological tests did not correlate with the seventy of the complaints, 
none of the immunological tests can be used to identify patients with CFS. The 
abnormalities that are found in the various immunological studies on CFS in the literature 
are subtle, non-specific, and sometimes conflicting. This may be due to methodological 
problems such as selection bias and intertest variability. Usually there is a wide overlap 
between the outcome of patients with CFS and healthy controls. Furthermore, it is not 
known whether the abnormalities in immunological tests that are found in patients with 
CFS are the cause or the result of CFS. It might very well be that these subtle abnormal-
ities are secondary to chronic stress or to physical inactivity. 
So far, there is no diagnostic test for CFS. This does not imply that CFS is not a 
serious problem. That these patients are severely fatigued and considerably impaired by 
their complaints is clear from our studies (chapter 3 and 4). Given the conservative 
estimation of the prevalence of CFS in the Netherlands of 1.2 per 1000 [26], and the fact 
that CFS affects predominantly people in the age group of 20-55 years old, this means 
that CFS has a great economic impact. Recently, the Dutch Minister of Health (Dr. E. 
Borst-Eilers) acknowledged that CFS is a chronic, debilitating disease that deserves 
serious attention and that more research efforts are needed. The inclusion of benign 
myalgic encephalomyelitis as a synonym for postviral fatigue syndrome in the tenth 
revision of the International Classification of Diseases (ICD-10) illustrates that CFS has 
received international acknowledgement. However, the proposed name 'benign myalgic 
encephalomyelitis' is less appropriate since no sign of inflammation of the central nervous 
system has been found. The same holds true for the term postviral fatigue syndrome. As 
a viral cause cannot be established this term probably just reflects a somatic attribution. 
Recently an attempt has been made to establish new criteria for CFS for research 
purposes [27]. When these criteria are internationally applied to future studies, this may 
improve the comparability of the CFS patients in different countries. Future studies of our 
study group will be directed into the neuropsychological aspects of CFS, changing 
attributions and cognitions, improving coping with the complaints, gradually improving 
physical activity. 
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Conclusion 
What did we learn from the studies on CFS? From the studies described in this 
thesis, we conclude that research into CFS has to be multidimensional, multidisciplinary 
and carefully controlled. Despite extensive studies into the infectious etiology of CFS, we 
did not find evidence for any of the previously implicated infectious agents to play a role 
in the pathogenesis of CFS. The subtle immunological abnormalities were not correlated 
with fatigue severity, or functional impairment. So far, none of the proposed somatic 
hypotheses of the pathogenesis of CFS have proven to be right. Therefore, serological 
and immunological tests cannot be used to identify patients with CFS. 
What are the practical implications of the studies presented in this thesis? We still do 
not know what is the cause of CFS. However, we do know that chronic or persistent 
infection and severe immunologic dysfunction are not related to CFS. We therefore 
recommend that extensive laboratory tests are not applied to patients with CFS other than 
in research settings. 
One can only speculate about the future prospects of CFS? Despite efforts to reveal a 
stealth virus, there is no lead that supports the infectious etiology. The immunologic 
abnormalities are very subtle and predominantly unconfirmed in controlled studies. Thus, 
the search for the "immunomodulating factor" seems hopeless. Therapy directed to a viral 
cause is unwarranted, immunomodulating therapy is still premature. As several studies 
(including ours) indicate that psychological factors are associated with the perpetuation of 
the complaints [24], we are exploring the possible beneficial effect of cognitive 
behavioural therapy. 
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Samenvatting en discussie 
Samenvatting 
Het chronisch vermoeidheidssyndroom (CVS) is een aandoening die gekenmerkt 
wordt door ernstige vermoeidheid, die langer dan 6 maanden duurt, die heeft geleid tot 
ernstige beperkingen in het dagelijks functioneren en waarvoor geen verklaring kan 
worden gevonden. Gewoonlijk gaan de moeheidsklachten vergezeld van een aantal niet 
specifieke klachten waaronder spierpijn, geheugenstoornissen en concentratiestoomissen. 
Bij lichamelijk onderzoek en laboratoriumonderzoek worden doorgaans geen afwijkingen 
gevonden. De oorzaak van de moeheidsklachten is vooralsnog onduidelijk. Het onderzoek 
dat beschreven is in dit proefschrift werd uitgevoerd om meer inzicht te verkrijgen in de 
klinische, microbiologische en immunologische aspecten van CVS. Hierbij hebben we 
geprobeerd om een antwoord te krijgen op de volgende vraagstellingen: 
1] Welke instrumenten kunnen gebruikt worden om de verschillende aspecten van de 
subjectieve klachten van CWS te meten? 
2] Is er een correlatie tussen de resultaten van de verschillende laboratoriumtesten, 
klinische symptomen en psychologische parameters? Kunnen deze laboratoriumtesten 
gebruikt worden als diagnostische test voor CVS? 
3] Zijn er aanwijzingen voor een persisterende infectie bij patiënten met CVS? 
4] Zijn er bewijzen voor een activatie van het immuunsysteem of voor een dysfunctie 
van het immuunsysteem bij patiënten met CVS? 
In hoofdstuk 2 wordt een overzicht gegeven van de somatische en psychologische 
hypothesen die bij de aanvang van het onderzoek beschouwd werden als mogelijke 
verklaring voor het ontstaan van CVS. 
In hoofdstuk 3 wordt beschreven hoe we de verschillende aspecten van de 
subjectieve klachten van CVS gemeten hebben. Hiertoe werden vragenlijsten verstuurd 
naar 298 patiënten met CVS. Met behulp van statistische analyse konden 9 dimensies 
geïdentificeerd worden waarmee emoties, gedrag, cognities en sociaal functioneren 
gemeten kunnen worden. Deze dimensies zijn: psychologisch welbevinden, functionele 
beperkingen in het dagelijks leven, slaapstoornissen, vermijding van lichamelijke 
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activiteit, neuropsychologische beperkingen, causale attributies ten aanzien van de 
klachten (wat denkt men dat de oorzaak van de klachten is), sociaal functioneren, "sense 
of control" (het idee dat men zelf de klachten kan beïnvloeden), en subjectieve ervaring 
van de persoonlijke situatie. Deze dimensies bleken relatief onafhankelijk te zijn, hetgeen 
betekent dat iedere dimensie een unieke bijdrage levert aan de beschrijving van de 
patiënten. Verschillende instrumenten worden beschreven die gebruikt kunnen worden bij 
het meten van deze dimensies. De resultaten van de verschillende testen lieten zien dat 
patiënten met CVS ernstig vermoeid zijn en door hun klachten aanzienlijk belemmerd 
worden in hun functioneren. We concludeerden dat een multidimensionele aanpak 
toegepast dient te worden bij het onderzoek van CVS. 
In hoofdstuk 4 hebben we getracht klinische symptomen te correleren met 
laboratoriumgegevens en psychologische parameters. We vonden echter dat er geen 
verschillen waren tussen patiënten en controles in de resultaten van laboratorium-
onderzoek. Vergeleken met controles werden er wel significante verschillen gevonden op 
de Checklist Individual Strength (CIS), de Beck Depression Inventory (BDI), en de 
Sickness Impact Profile (SIP). We vonden dat de psychologische parameters met 
betrekking tot de emst van de moeheid (CIS), depressie (BDI) en functionele beperkingen 
(SIP) gerelateerd waren aan de klinische emst van de klachten, en waardevolle 
instrumenten zijn bij het onderzoek van patiënten met CVS. Serologische testen bleken 
echter niet zinvol te zijn in het onderzoek naar CVS, omdat deze testen geen onderscheid 
maken tussen patiënten en controlepersonen. 
Eén van de somatische hypothesen is dat CVS het gevolg is van een persisterende 
infectie. Argumenten voor deze hypothese zijn: het optreden van epidemieën van CVS, 
het acute ontstaan van symptomen na een griepachtig ziektebeeld. De aanwezigheid van 
subfebriele temperatuur, nachtzweten en pijnlijke lympheklieren (hetgeen in onze ervaring 
slechts zelden gevonden wordt), zou eveneens pleiten voor een infectieuze oorzaak. We 
hebben onderzocht of er bij CVS-patiënten aanwijzingen zijn voor een persisterende 
infectie. Dit werd met name onderzocht voor enterovirussen, Epstein-Barr virus, en 
Yersinia enterocolitica. Om te beginnen werd een test ontwikkeld voor het aantonen van 
immuunglobuline G (IgG), IgM en IgA antistoffen tegen enterovirussen (hoofdstuk 5). 
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Sera van patiënten en controles werden getest op de aanwezigheid van enterovirale 
antistoffen en VP-1 antigecn (een eiwit dat specifiek zou zijn voor enterovirussen). In 
tegenstelling tot onderzoekers uit Engeland vonden we geen verschillen tussen patiënten 
en controles, noch in de aanwezigheid of titer van enterovirale antistoffen, noch van VP-1 
antigeen. Ontlasting werd nauwkeurig nagekeken op de aanwezigheid van enterovirussen 
door middel van kweek, zowel direct als na vrijmaken van het virus uit 
immuuncomplexen, en met behulp van de polymerase ketting reactie (PCR). We vonden 
geen aanwijzingen voor persistentie van enterovirussen in ontlasting met behulp van 
kweek of PCR (hoofdstuk 6). We hebben dus geen enkele aanwijzing voor persistentie 
van enterovirussen bij CVS-patiënten. Deze conclusie wordt nog versterkt door recent 
onderzoek in samenwerking met Dr. B. Evengârd (Huddinge Hospital, Stockholm). 
Hierbij werden spierbiopten van 27 Zweedse patiënten met CVS getest op de 
aanwezigheid van enteroviraal RNA met de PCR. De biopten waren allemaal negatief. 
In hoofdstuk 7 hebben we onderzocht of een chronisch actieve Epstein-Barr virus 
(EBV) infectie de verklaring is voor CVS. We onderzochten virus load en 
immunologische regressie van door EBV getransformeerde mononucléaire cellen uit bloed 
van 10 geselecteerde patiënten met CVS, die hoge titers hadden tegen het virale capside 
antigeen of het early antigen. De resultaten werden vergeleken met die van 9 gezonde 
controles van dezelfde leeftijd, hetzelfde geslacht en uit dezelfde woonplaats. Er was geen 
verschil in virus load en immunologische regressie tussen CVS-patiënten en gezonde 
controles. We vonden dus geen aanwijzingen dat EBV een belangrijke rol speelt in CVS, 
zelfs niet bij geselecteerde patiënten met hoge antistof titers. 
Omdat Yersinia enterocolitica in staat is te persisteren in het lymfatisch weefsel van 
de darm, en symptomen kan veroorzaken zoals koorts, malaise, buikpijn, gewrichtspijn, 
en klierzwellingen, hebben we onderzocht of er in CVS-patiënten serologische patronen 
gevonden worden, die passen bij een persisterende Yersinia infectie (hoofdstuk 8). We 
gebruikten hiervoor een immunoblot techniek voor het aantonen van IgG en IgA 
antistoffen tegen Yersinia outer membrane proteins (YOPs). De prevalentie van IgG 
antistoffen tegen de YOPs bij patiënten en controles kwam overeen. Bij 4 patiënten en 2 
controles vonden we serologisch aanwijzingen voor een recente of persisterende Yersinia 
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infectie. Er was echter een geringe correlatie tussen symptomen die karakteristiek zijn 
voor een persisterende Yersinia infectie en de aanwezigheid van antistoffen tegen YOPs 
bij CVS-patiënten. Het is daarom onwaarschijnlijk dat CVS veroorzaakt wordt door een 
persisterende Yersinia infectie. 
Sommige onderzoekers hebben naar voren gebracht dat bij CVS-patiënten een 
dysfunctie van het immuunsysteem resulteert in een chronische of intermitterende actieve 
infectie, die leidt tot een te hoge of langdurige produktie van cytokinen. Cytokinen 
kunnen inderdaad symptomen veroorzaken als moeheid, koorts, spierpijn, cognitieve 
stoornissen en slaapstoornissen. In hoofdstuk 9 hebben we de hypothese dat CVS 
veroorzaakt wordt door een immuundysfunctie onderzocht. We hebben lymfocyten 
subpopulaties bepaald, apoptosis experimenten gedaan, en cytokinen gemeten bij patiënten 
met CVS en de resultaten vergeleken met de bepalingen bij controles van dezelfde 
leeftijd, hetzelfde geslacht en afkomstig uit dezelfde woonplaats. We vonden een 
significant verminderde expressie van CDllb op CD8 + cellen bij CVS-patiënten 
vergeleken met hun controles. De door endotoxine gestimuleerde ex vivo produktie van 
tu.nor necrose factor a en interleukine Iß was significant lager bij CVS-patiënten. Er was 
echter een grote overlap in de resultaten van de immunologische testen tussen patiënten en 
controles, en de uitkomst van de immunologische testen correleerde niet met de ernst van 
de vermoeidheid, psychologisch welbevinden, of functionele beperkingen. Hieruit kunnen 
we concluderen dat immunologische testen niet geschikt zijn voor de diagnostiek van 
CVS. We hebben bij ons onderzoek geen aanwijzingen gevonden die de hypothese dat 
CVS veroorzaakt wordt door een dysfunctie van het immuunsysteem ondersteunen. 
Discussie 
Geven de studies in dit proefschrift antwoord op de vragen die gesteld werden in de 
introductie? Ik zal proberen om een voor een op deze vragen in te gaan. De eerste vraag 
over het meten van CVS is beantwoord in hoofdstuk 3. Een aantal instrumenten zijn 
beschreven die ons in staat stellen om de verschillende aspecten van vermoeidheid 
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betrouwbaar te meten. Deze multidimensionele aanpak is belangrijk bij de bestudering van 
het natuurlijk beloop van CVS en bij de evaluatie van interventiestudies. 
De vraag of laboratoriumtesten gebruikt kunnen worden als diagnostisch instrument 
voor CVS moet met "nee" beantwoord worden. Bij de bestudering van de literatuur bleek 
dat de resultaten van verschillende op laboratoriumtesten georiënteerde studies 
inconsistent waren. Dit zou goed het gevolg kunnen zijn van patiëntenselectie. Veel van 
de eerder gerapporteerde studies zijn uitgevoerd onder patiënten die verwezen zijn naar 
een polikliniek infectieziekten of zelfs naar een CVS-kliniek. Dit suggereert dat deze 
studies waarschijnlijk zijn uitgevoerd bij patiënten met een secundaire, tertiaire of nog 
frequentere verwijzing. Met elke verwijzing zal de dokter zijn eigen (subjectieve) 
selectiecriteria toevoegen, die gebaseerd zijn op zijn of haar kennis van CVS. Dit zal 
uiteindelijk resulteren in een sterk geselecteerde patiëntenpopulatie. De resultaten kunnen 
daarom niet doorgetrokken worden naar de CVS-patiënt in het algemeen. We hebben 
geprobeerd om het probleem van patiëntenselectie te voorkomen door patiënten te nemen 
die zich op eigen initiatief aangemeld hebben voor ons onderzoek en waarvan verwacht 
kan worden dat ze representatief zijn voor de CVS-patiënt in het algemeen. Naast 
selectiebias door verwijzing, kan men zich voorstellen dat ook geographische en culturele 
verschillen een rol spelen. Het is opvallend dat CVS vooral lijkt voor te komen onder de 
blanke bevolking in ontwikkelde landen. Voor zover ons bekend is, zijn er geen 
publikaties over CVS onder bijvoorbeeld de zwarte bevolking in Afrika. Dit zou het 
gevolg kunnen zijn van culturele verschillen, genetische verschillen, of het zou slechts het 
gebrek aan interesse voor CVS kunnen weerspiegelen of het gebrek aan onderzoeks-
faciliteiten in deze landen. 
Andere methodologische valkuilen liggen in de uitvoering van de laboratoriumtesten. 
Het is duidelijk dat de stelling 'zoek en gij zult vinden' van toepassing is op een aantal 
laboratoriumstudies. Wanneer 100 laboratoriumtesten uitgevoerd worden met een 95% 
betrouwbaarheidsinterval, zullen ten minste 5 testen een significante uitkomst geven op 
basis van toeval alleen. Wanneer patiënten en controles niet zorgvuldig gematcht worden, 
kunnen er zelfs meer testen zijn met een significant resultaat. Hetzelfde is van toepassing 
op het aantal correlaties dat berekend wordt. Het moet benadrukt worden dat het 
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tegelijkertijd afnemen en testen van monsters van patiënten en controles even belangrijk is 
als het matchen van patiënten en controles. Ook wij hebben bemerkt dat de intertest 
variabiliteit van bijvoorbeeld immunofluorescentie testen kunnen leiden tot significante 
verschillen tussen patiënten en controles. Na gelijktijdig testen verdwenen deze 
verschillen. Verder werden significante verschillen gevonden in de uitkomst van een 
aantal serologische en immunologische testen in serum van een gezonde bloeddonor 
populatie vergeleken met gezonde controles, die gematcht waren met de CVS-patiënten. 
Dit zou het gevolg kunnen zijn van verschil in monsterverzameling (ander seizoen, ander 
moment van de dag, verschil in hormonale status), stress, reisafstand, of 
omgevingsfactoren. Om deze verstorende effecten te vermijden, hebben we ervoor 
gekozen om de patiënten te vragen zelf een gezonde controlepersoon mee te brengen uit 
dezelfde woonplaats, van hetzelfde geslacht en van ongeveer dezelfde leeftijd. Patiënten 
en controles bezochten samen onze polikliniek, zodat bloed monsters op hetzelfde moment 
afgenomen konden worden. De sera van patiënten en controles werden in één test ingezet 
om intertest variabiliteit te vermijden. Op deze manier waren we niet in staat de eerder 
beschreven laboratoriumafwijkingen te reproduceren. Gezien het aantal verschillende 
micro-organismen dat bestudeerd is en het gebrek aan bewijs om één van deze micro-
organismen als verwekker te bestempelen, concluderen we dat infectie op zichzelf 
waarschijnlijk niet de oorzaak is van CVS. Echter, infectie kan mogelijk wel de trigger 
zijn voor het ontstaan van CVS tezamen met andere factoren zoals psychologische 
factoren, bij een hiervoor gevoelige gastheer. Dit kan echter alleen op een prospectieve 
manier uitgezocht worden. 
Wat betreft de laatste vraag "Is CVS een immuundysfunctie syndroom?", kunnen we 
concluderen dat we geen argumenten hebben gevonden die deze hypothese (CVS is 
immuundysfunctie) ondersteunen. Alhoewel er enkele significante verschillen gevonden 
werden tussen patiënten en controlepersonen, had dit klinisch praktisch gezien geen 
betekenis. Aangezien er een grote overlap bestond in de resultaten van de immunologische 
testen tussen patiënten en controles, en de uitkomst van deze immunologische testen niet 
gecorreleerd was met de ernst van de klachten, kan geen van de immunologische testen 
gebruikt worden om CVS-patiënten te identificeren. De afwijkingen die gevonden worden 
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in de verschillende immunologische studies bij CVS in de literatuur zijn subtiel, niet 
specifiek, en soms tegenstrijdig. Dit is mogelijk het gevolg van de eerder genoemde 
methodologische problemen. Meestal is er een grote overlap tussen de resultaten bij 
patiënten met CVS en bij gezonde controles. Verder is het onbekend of de subtiele 
afwijkingen in de immunologische testen die gevonden zijn bij CVS-patiënten de oorzaak 
of het gevolg zijn van CVS. Het zou best kunnen dat deze afwijkingen secundair zijn aan 
stress of physieke inactiviteit. 
Tot dusverre is er geen diagnostische test voor CVS. Dit betekent echter niet dat 
CVS geen belangrijk probleem is. Dat CVS-patiënten ernstig vermoeid zijn en aanzienlijk 
belemmerd worden door hun klachten is duidelijk uit ons onderzoek (hoofdstuk 3 en 4). 
Uitgaande van de conservatieve schatting van de prevalentie van CVS in Nederland van 
1.2 per 1000, en uitgaande van het feit dat CVS voornamelijk mensen in de leeftijdsgroep 
van 20-55 jaar treft, betekent dit ook een groot economisch probleem. Onlangs heeft de 
Nederlandse minister van Volksgezondheid (Dr. E. Borst-Eilers) erkend dat CVS een 
ernstige chronische ziekte is, die meer aandacht verdient en waarvoor meer onderzoek 
nodig is. De inclusie van benigne invalgisene encephalo-myelitis als een synoniem voor 
postviraal vermoeidheidsyndroom in de tiende revisie van de Internationale Classificatie 
van Ziekten (ICD-10) illustreert dat CVS internationaal erkenning heeft gekregen. De 
voorgestelde naam "benigne myalgische encephalo-myelitis" is echter minder geschikt, 
omdat er geen tekenen van ontsteking van het centrale zenuwstelsel worden gevonden. 
Hetzelfde geldt voor de naam postviraal vermoeidheidsyndroom. Omdat een virale 
oorzaak niet aangetoond is, weerspiegelt deze term waarschijnlijk een somatische 
attributie. 
Recent is er een poging ondernomen om nieuwe criteria voor CVS vast te stellen 
voor onderzoeksdoeleinden. Wanneer deze criteria internationaal worden toegepast in 
toekomstige studies, zal dat de vergelijkbaarheid van de CVS-patiënten in de verschillende 
landen ten goede komen. Toekomstige studies van onze onderzoeksgroep zullen gericht 
zijn op de neuropsychologische aspecten van CVS, het veranderen van attributies en 
cognities, het verbeteren van het omgaan met de klachten, en het geleidelijk aan toenemen 
van de physieke activiteit. 
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Wat hebben we nu geleerd van de studies over CVS? Uit de studies die beschreven 
zijn in dit proefschrift kunnen we concluderen dat onderzoek naar CVS multi-
dimensioneel, multidisciplinair en zorgvuldig gecontroleerd dient te zijn. Ondanks 
uitgebreide studies naar een infectieuze oorzaak van CVS, vonden we geen aanwijzingen 
dat één van de eerder aangewezen micro-organismen een rol speelt in de Pathogenese van 
CVS. Immunologische afwijkingen waren gering en bleken niet gecorreleerd te zijn met 
ernst van de vermoeidheid of functionele beperkingen. Tot dusverre is geen van de 
voorgestelde somatische hypothesen omtrent de Pathogenese van CVS juist gebleken. 
Serologische en immunologische testen kunnen niet gebruikt worden om patiënten met 
CVS te identificeren. 
Wat zijn nu de praktische implicaties van de studies uit dit proefschrift? We weten 
nog steeds niet wat nu de oorzaak is van CVS. Wat we wel weten is dat chronische of 
persisterende infecties en immunologische afwijkingen geen belangrijke rol spelen in 
CVS. We komen daarom tot de aanbeveling om uitgebreide laboratoriumtesten niet toe te 
passen op CVS patiënten behalve in een onderzoeksopzet. 
Over de vooruitzichten van CVS kunnen we alleen speculeren. Ondanks pogingen om 
een verborgen virus te ontdekken hebben we eigenlijk geen aanknopingspunten in de 
richting van een infectieuze oorzaak. Immunologische afwijkingen zijn subtiel en worden 
in gecontroleerde studies meestal niet bevestigd. Het zoeken naar de immunomodulerende 
factor lijkt dan ook zinloos. Therapie gericht op een virale verwekker is niet zinvol en 
immunomodulerende therapie is prematuur. Omdat meerdere studies (waaronder onze 
eigen studie) laten zien dat psychologische factoren een rol spelen bij het onderhouden 
van de symptomen, onderzoeken we nu of cognitieve gedragstherapie een gunstig effect 
heeft op de klachten. 
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Dankwoord 
Veel mensen hebben een bijdrage geleverd aan het tot stand komen van dit 
proefschrift. Zonder iemand tekort te willen doen wil ik een aantal personen toch met 
name noemen. Natuurlijk zou dit onderzoek nooit uitgevoerd zijn zonder de medewerking 
van de CVS-patiënten en de gezonde vrijwilligers, die soms uren onderweg waren naar 
Nijmegen. 
Professor A. van 't Laar was degene die mij zeer kort na het behalen van mijn buil 
voorstelde om onderzoek te gaan doen. Dankzij hem kwam ik in contact met prof. J. van 
der Meer, die mij in een eenvoudig schema uitlegde wat de onderzoeksopzet zou kunnen 
zijn. Jos van der Meer was de grote drijfveer achter het onderzoek. Samen met Joep 
Galama was je degene bij wie ik terecht kon voor (zeker in de beginfase) vrijwel dagelijks 
overleg en advies. Joep Galama was de grote stimulans achter het microbiologische 
gedeelte van dit proefschrift. Joep, jij wist mij ervan te overtuigen dat onze negatieve 
bevindingen zeker zo belangrijk waren als de positieve bevindingen in de literatuur. Je 
stimuleerde mij om nieuwe testen op te zetten en geschikt te maken voor de routine. 
De CVS-groep dank ik voor de prettige samenwerking en nuttige discussies. Hierdoor 
werd duidelijk dat vakjargon niet altijd vermeden kan worden, maar vaak wel velhelderd 
kan worden. Jan Vercoulen, bij jou kon ik altijd terecht voor statistische problemen, maar 
ook om zo nu en dan even stoom af te blazen. 
De medewerkers van de research virologie wil ik bedanken voor de gezellige tijd. 
Willem, Frank, Jan, Esther, Diana, Wil, Patrick, bedankt voor jullie steun en de gezellige 
rikuurtjes tijdens de pauze. 
Mijn dank gaat ook uit naar de mensen die verantwoordelijk zijn voor een groot deel 
van het analytisch werk; in het bijzonder naar Liane Veenstra, die alle immuun-
fluorescenties en ELISA's verrichtte, en Johanna van der Ven-Jongekrijg, die het 
leeuwedeel van de cytokinebepalingen op zich nam. Yvonne Poort dank ik voor haar 
flexibiliteit en aanpassingsvermogen. Over letterlijk alles kon gepraat worden. 
Tot slot wil ik mijn familie en vrienden bedanken voor hun geduld en hun begrip 
voor het feit dat ik soms geen tijd voor ze had. 
Mario, zonder jouw steun was het nooit gelukt. 
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Chronic Fatigue Syndrome: 
clinical, microbiological and immunological aspects 
Nijmegen, 21 maart 1996 
C.M.A.Swanink 
Stellingen 
1. Dat er bij patiënten met het chronisch vermoeidheidssyndroom (CVS) doorgaans geen 
afwijkende bevindingen zijn, wil niet zeggen dat deze patiënten geen ernstige klachten 
hebben (dit proefschrifi). 
2. Onderzoek naar CVS dient multi-dimensioneel en multidisciplinair aangepakt te 
worden (hoofdstuk 3). 
3. Serologische en immunologische testen kunnen niet gebruikt worden om de diagnose 
CVS te stellen, hooguit om deze te verwerpen (hoofdstuk 4 en 9). 
4. Het is onaannemelijk dat CVS veroorzaakt wordt door een persisterende infectie 
(hoofdstuk 6, 7 en 8). 
5. Bij onderzoek naar CVS valt of staat het onderzoek met de keuze van de controles 
(dit proefschrifi). 
6. Hoe meer laboratoriumtesten uitgevoerd worden des te groter is de kans dat één van 
deze testen een afwijkende bevinding zal geven. Bij de interpretatie van de gegevens 
dient dan ook gecorrigeerd te worden voor het aantal testen. 
7. Er is een fundamentele onrechtvaardigheid in de arbeidsongeschiktheidsuitkering 
waarbij voor een aandoening als CVS een aantoonbare ziekte of gebrek wordt 
gevraagd terwijl dit voor psychiatrische aandoeningen niet wordt gevraagd. 
8. De stelling "Baat het niet dan schaadt het niet" zou bij de behandeling van CVS 
vervangen moeten worden door de stelling "Werkt het niet, stop er dan mee". Dit 
zou patiënten en verzekeraars aanzienlijke sommen geld kunnen besparen. 
9. Het publiceren van negatieve bevindingen is tenminste even belangrijk als het 
publiceren van positieve bevindingen en dient daarom gelijkwaardig beoordeeld te 
worden. 
Stellingen 
10. Het lijkt wel of promovendi over een soort promotiegen beschikken dat door de 
inspanningen van (co)promotores tot expressie wordt gebracht. 
Esther-Schoondermark-van de Ven 
11. Uit de botsing der meningen zal een splinter der waarheid springen. 
Seneca 
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